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With an increasing number of infectious agents resistant to one or more existing 
antibiotics, there is a global requirement for new therapeutics. One possible method 
for treatment of infectious diseases proposed in this study is the adaptation of a 
technique developed for cancer treatment, targeted radionuclide therapy, with 
particular interest in Auger electron radiation.  Auger electrons are short range and 
low energy particles emitted from a range of radioactive isotopes. 
As a targeting agent, the antimicrobial peptide fragment UBI 29-41 was used. 
Antimicrobial peptides have a broad range of target microorganisms, ideal for 
toxicological studies of Auger electrons.  Here, the baseline toxicity of UBI 29-41 was 
established in a range of model organisms. This enabled the analysis of the toxic 
effect of Auger electron emitting radio-nuclides using the isotope125I. Although no 
direct toxic effect was observed with this particular isotope, the labelling allows easy 
replacement with more potent isotopes. 
To further develop the targeting agent a lipoarabinomannan (LAM) specific single-
chain variable fragment (scFv) was developed. LAM is a glycolipid and virulence 
factor associated with M. tuberculosis, the primary cause of tuberculosis in humans. 
By isolating the variable domains of a LAM specific monoclonal antibody, linked via 
a poly-glycine linker, the scFv was assembled in silico. The nucleotide sequence 
was optimised for and transfected into a Pichia pink expression system. Expression 
was successful with a ~27kDa product being secreted.  
The novel anti-LAM scFv generated in this study combined with the potential toxic 
effects of Auger electrons could provide a new avenue for the treatment and 
diagnosis of tuberculosis. 
 
 





1.1 Infectious diseases 
Despite the massive efforts that have been put into the fight against infectious 
disease, it is estimated that they still are accountable for approximately 25% of all 
deaths worldwide with increasing globalisation and mass gatherings posing further 
challenges (Abubakar et al., 2012; Fauci and Morens, 2012). 
Infectious diseases have several characteristics that distinguish them from other 
non-communicable human diseases (Fauci and Morens, 2012): 
 
 They have the potential for unpredictable global impact  
 Following infection the host commonly acquires stable and potent immunity 
against re-infection 
 They are transmissible 
 They only require a single agent to cause disease 
 They can be preventable 
 They have the potential to be eradicated 
 They are highly adaptive and have an edge on human evolution due to 
replicative and mutational capacities 
 They have a close dependence on nature and are highly reliant on human 
behaviour 
 They are frequently derived from or coevolved in other animals 
 




The human body has several defence mechanisms to prevent infection. These 
include the primary barriers such as skin, and commensal bacteria on the skin and 
in the gut. If the microorganisms overcome these barriers they are initially met by a 
complex innate immune defence system comprising the complement system, 
phagocytic cells and antimicrobial peptides. If the infection persists an adaptive 
immune response is mounted in extension of the innate defence system. Most 
infections are prevented from being established by either of these barriers. However, 
in some cases where the individual is immuno-compromised, the immune system is 
overwhelmed, or the barriers for other reasons are incapable of preventing the 
continual infection of the body, alternate means are required for the elimination of 
the infection (Janeway, 2005). 
 
1.1.1 Current diagnosis and treatment 
For most cases, infectious diseases are fairly easily diagnosed as they generally 
display unique alterations in the human physiology. However, this is not always the 
case. Some microorganisms are capable of being internalised into human cells and 
lie dormant for years and in some cases stay completely unnoticed by the human 
immune defence systems. The most common diagnostic methods are currently 
primarily culture isolation and identification, microscopic evaluation, immunoassays 
and PCR analysis, which are all fairly time-consuming (Madigan et al., 2003). 
Antibiotics today primarily comprise chemical components that either interfere with 
the integrity of the microorganisms or inhibit the intracellular machinery (Table 1) 
(Madigan et al., 2003).  
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Primarily used against gram positive bacterial 
infections and some gram negative bacterial 
infections in the respiratory tract and soft 
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Primarily used to treat acne and urinary tract 
infections but is also used in cases where 
other antibiotics have proven unsuccessful 
Table 1 Overview of the most common antibiotic chemicals (Krause, 1998; Madigan et al., 
2003). 
 
As can be seen in table 1 all the chemicals commonly used to combat infectious 
diseases require not only internalisation into the microorganisms in order to execute 
their function, but are also commonly quite specific in their mode of function. This 
opens up a myriad of possibilities for the microorganisms to adapt to the new 
chemicals. There are several mechanisms that microorganisms have developed to 
counter the antibiotics including reduced cell uptake, active efflux and modifications 
of the target to reduce binding efficiency to name a few (Krause, 1998).   
The great ability of microorganisms to adapt to chemicals has led to an increasing 
number of them today being resistant to either one or numerous antibiotic 
compounds, increasing the difficulty of treatment (Fox, 2011). 
There are several reasons that are hypothesised to be the primary ones for the 
emergence of resistant strains (Pechѐre, 2001; Fox, 2011): 
1) The increased low-dose routine use of antibiotics in livestock fodder 
2) The indiscriminate prescription of antibiotics by doctors often pressured by 
patients 




3) The failure of patients to complete an entire course of antibiotic treatment 
As microorganisms are capable of horizontal gene transfer via conjugation, 
transduction and transformation this allows the spread of resistance genes rapidly 
especially in environments with high density of varied bacterial strains such as 
hospitals. For this reason, more research than ever is focusing on novel ways not 
only to fight the problematic multi resistant strains, but also to produce new ways to 
combat infections efficiently and with minimised possibility of generating resistance. 
One infectious disease that currently is being thoroughly researched for new ways 
of both diagnosis and treatment is M. tuberculosis. 
 
1.2 Tuberculosis 
Tuberculosis (TB) remains a major cause of death and loss of life quality in the world 
today. It is estimated that it infects approximately one third of the world’s population 
and is the second leading cause of death in the world caused by an infectious 
disease. Approximately 1.2 million lives are lost to the disease each year and it is 
estimated that there are 9 million new cases each year, most of which are reactivated 
dormant infections (Gegenbacher and Kaufmann, 2012; WHO Global Tuberculosis 
Report 2012). Even with the great efforts currently being put into tuberculosis control, 
the emergence of a growing number of increasingly resistant strains and the further 
complications added by the HIV pandemic raises the need for research into new 
ways of managing the disease.  
 





The primary causative agent of tuberculosis in humans, Mycobacterium 
tuberculosis, is an aerobic rod shaped bacterium. Furthermore, it is a very slowly 
dividing bacterium, that even under optimal conditions, only divides every 18-24 
hours making it harder to not only diagnosis but to eradicate as well (Gegenbacher 
and Kaufmann, 2012).  
 
1.2.2 Genomic structure 
The genome size of the various strains of Mycobacteria fluctuates considerably as 
illustrated by the size difference between strains of Mycobacterium leprea and M. 
tuberculosis. Where M. leprea has a genome size of 3.27 Mb and ~1600 open 
reading frames (ORF) M. tuberculosis is much larger with 4.41 Mb genome and 
approximately 4000 ORFs (Cole et al., 2001; Cosma et al., 2003; Gegenbacher and 
Kaufmann, 2012). The genome size is also associated with virulence. Three regions 
in particular have been identified that are all present in both M. tuberculosis and M. 
bovis but absent in Bacillus Calmette–Guérin (BCG) referred to as “Regions of 
Difference” (RD) 1-3. Especially RD1 has been shown to have great impact on 
mycobacterial virulence and is the only region present in all tested virulent strains of 
the mycobacterial complex (Figure 1) (Mahairas et al., 1996; Berthet et al., 1998; 
Pym et al., 2002; Lewis et al., 2003; Guinn et al., 2004; Kurenuma et al., 2009; Ernst, 
2012). 





RD1 is a 9.5 kb gene segment comprising 9 genes including ESAT-6 (Early Secreted 
Antigenic Target 6), CFP-10 (Culture Filtrate Protein 10) and CFP-21 (Culture 
Filtrate Protein 21). These are important T-cell antigens and have been hypothesised 
to be the reason for the poor induction of an immune response and thereby 
generation of protective immunity by the BCG vaccine (Mahairas et al., 1996; Rai et 
al., 2012). A combination of secretory proteins of the RD1 region, ESX-1, has been 
indicated to be important in the transport of the abovementioned antigens and 
therefore in the functionality. 
 
1.2.3 M. tuberculosis cell wall 
Although it lacks an outer lipid bilayer, M. tuberculosis is not considered a typical 
gram positive bacterium due to its heavily glycosylated and waxy surface, which 
makes traditional gram staining very difficult. For this reason, the general 
visualisation of the bacteria is done using Ziehl-Neelsen acid-fast staining 
(Gegenbacher and Kaufmann, 2012). 
 
Figure 1 Overview of the Region of difference 1 (RD1) 
RD1 from M. tuberculosis including flanking regions. Arrows indicate transcriptional direction (Rai 
et al., 2012) 
 




The cell wall of M. tuberculosis is one of the most striking features of the bacteria 
and is associated not only with its unique survival pattern, but also with the virulence 
of the bacteria (Figure 2). The complexity of the cell wall has also been indicated to 
have a function as a protective barrier against the acidic environment of the 
phagosomes in which they primarily reside, as will be elaborated below 
(Gegenbacher and Kaufmann, 2012).  
 
The structure of the mycobacterial cell wall is generally divided into two segments: 
the upper and the lower segment, with the lower also defined as the cell wall core, 
or the mycolyl arabinogalactan-peptidoglycan (mAGP) complex (Chatterjee and 
Khoo, 1998; Brennan, 2003).  
 
Figure 2 Schematic representation of M. tuberculosis cell wall 
The core comprises peptidoglycan covalently attached to arabinogalactan which is further bound 
to mycolic acids. The upper layer is composed of cell wall proteins, phosphatidylinositol 
mannosides, phticerol containing lipids as well as lipomannan and lipoarabinomannan. It is only 
the upper layer that gets solubilised upon disruption (web 1; Brennan, 2003). 
 




The core is situated just above the cell membrane and is a complex matrix composed 
of peptidoglycan (PG), which is covalently attached to arabinogalactan (AG) and 
hereafter further attached in the ends to mycolic acids in an esterified fashion. The 
mycolic acids comprise long meromycolate and short α-chains.  
The upper layer is also interspersed with cell wall proteins, as well as 
phosphatidylinositol mannosides (PIMs), phthicerol containing lipids, lipomannan 
(LM) and lipoarabinomannan (LAM). 
If the cell wall is disrupted somehow it is only the upper layer that is solubilised. This 
indicates that the upper layer is primarily composed of signalling and effector 
molecules, whereas the lower layer is primarily associated with viability of the 
bacteria (Brennan, 2003). Of special interest is lipoarabinomannan (LAM), which has 
also been shown to be not only associated with M. tuberculosis survival, but also 
virulence of the pathogen and is the target of the scFv designed in this project. 
 
1.2.3.1 Lipoarabinomannan (LAM) 
LAM is an important heterogeneous glycolipid of the Mycobacterial cell wall. The 
size was found to differ greatly in size and branching pattern as well as acylation and 
phosphorylation on both the arabinan and mannose portions of the molecule. In the 
native state however, LAM of M. tuberculosis has an average size of 17.3 kDa 
(Chatterjee and Khoo, 1998).  
It is both important for survival as well as a virulence factor of M. tuberculosis 
(Knutson et al., 1998; Rademacher et al., 2007; Minion et al., 2011). The importance 
is indirectly reflected in the abundance of the molecule which can account for up to 




1.5% of the total bacterial weight (Hunter et al., 1986; Chan et al., 1991; Minion et 
al., 2011).  
LAM from M. tuberculosis is capped by short mannose-containing caps, which 
enable it to bind to mannose receptors on the surface of macrophages allowing 
phagocytosis (Chatterjee and Khoo, 1998). Although this structural motif is absent 
from Mycobacterium smegmatis LAM it is present on virtually all other strains of 
mycobacteria, including attenuated strains, indicating that the cap is not a virulence 
factor as first hypothesised (Chatterjee and Khoo, 1998; Brennan, 2003).  
Furthermore, LAM is capable of binding to Toll receptors as well as physically 
introducing itself into the host membranes.  
LAM is primarily involved in the survival of M. tuberculosis via causing the 
deactivation of macrophages; it causes this by impairing Ca2+ concentration rise in 
infected macrophages and hence inhibits phagosome maturation (Chan et al., 1991; 
Chatterjee and Khoo, 1998; Poirier and Av-Gay, 2012). This has a myriad of 
downstream effects:  
 
1) Impaired antigen presentation   
2) Restricted activation of IFN-γ inducible genes 
3) Decreased production of cytokines 
4) Inhibition of protein kinase C 
5) Lower levels of oxidative and nitrogen free radicals  
6) Inhibition of host cell apoptosis 
 




Studies have further indicated that LAM may have an indirect ability to reduce T-cell 
proliferation by inhibiting the transcriptional activation of MHC-II molecules. This 
significantly reduces the presentation of antigens on the surface of macrophages 
which thereby results in less T-cell activation and proliferation (Chan et al., 1991). 
Furthermore, LAM appears to have an impact on the maturation, MHC expression 
and antigen presentation of dendritic cells by binding to the DC-SIGN receptor, 
hence having a great impact on the establishment of the adaptive immune response 
(Doherty, 2012). 
Interestingly, it has been found that LAM is released from metabolically active, as 
well as degrading bacterial cells which has enabled the potential diagnostic 
approach of urine analysis for the presence of LAM, which also eases the diagnosis 
of children, where sputum tests are harder to perform (Minion et al., 2011). 
 
1.2.4 Pathology 
There are several ways in which M. tuberculosis can cause disease in humans; the 
most common of which in adults is pulmonary tuberculosis. However, other extra 
pulmonary forms of TB exist, which are found more often in immuno suppressed 
individuals and young children. These include tuberculous meningitis (central 
nervous system), tuberculous pleurisy (pleura), scrofula (lymphatic system), 
urogenital tuberculosis (genitourinary system) and Pott’s disease (bones and joints) 
(Krause, 1998). Finally, there is the more serious version referred to as miliary 
tuberculosis where M. tuberculosis spread systemically to other organs via either the 




blood or lymphatic system. Due to the septic nature of miliary TB it is considered 
much more serious than pulmonary TB.  
 
1.2.4.1 Primary infection 
The route of infection of M. tuberculosis is primarily via the pulmonary system by 
inhalation of droplets containing tuberculosis bacteria. The likelihood of infection 
transmission is dependent on a variety of variables including exposure duration, 
exposure intensity, virulence characteristics of the tuberculosis strain among others 
(Dheda et al., 2010). As the bacteria are inhaled into the lower levels of the lungs, 
they are taken up by alveolar macrophages, where they start replicating and form 
the initial lesions (Davis and Ramakrishnan, 2009).  Some infected phagocytic cells 
travel to the hilar lymph nodes and together with the initial lesions in the lungs, 
referred to as the Ghon focus, comprise the primary complex.  
Normally, as microorganisms are phagocytised, the resulting phagosome contains 
hydrolytic enzymes, reactive oxygen and nitrogen species (ROS and RNS, 
respectively) and antimicrobial peptides, all involved in the breakdown of the 
ingested microorganisms (Figure 3) (Gegenbacher and Kaufmann, 2012).  
M. tuberculosis, however, is capable of inhibiting this (Poirier and Av-Gay, 2012). 
Apart from aiding in immediate survival, this inhibits antigen presentation and the 
establishment of an adaptive immune response. However, eventually some of the 
bacteria will be broken down by the phagolysosome pathway and bacterial antigens 
will be mounted into major histocompatibility complex II (MHCII) allowing recruitment 
of CD4+ TH1 cells (Doherty, 2012). 





Following the establishment of the primary complex, an immune response by the 
host is triggered, recruiting the first line of defence including more immature 
macrophages, neutrophils, monocytes and dendritic cells to the site of infection. 
However, as these cells are also the primary host cells, this only recruits more cells 
for M. tuberculosis to spread to. As the macrophages cannot eradicate the infection 
the number of cells only continues to increase and this results in the formation of 
solid granulomas, the initial evidence of infection (Dheda et al., 2010; Ernst, 2012; 
Gegenbacher and Kaufmann, 2012). 
The primary route for the establishment of protective immunity against M. 
tuberculosis is primarily mediated by CD4+ TH1 cells and CD8+ T cells. 
Although it has not been completely established how the phagocytic cells are 
capable of mounting a CD8+ T cell response,  some indications have been made 
 
Figure 3 Schematic overview of mycobacterial inhibition of phagolysosome formation 
A simplified overview of the inhibitory effect of macrophages on the generation of the 
phagolysosome. A) Shows the normal progression of phagolysosomal generation. Following 
entry, the pH of the phagosome decreases followed by the fusion with a lysosome. The lysosome 
contains enzymes that are activated by the low pH thereby accelerating the degradation of the 
phagocytised material B) Shows the inhibited step in phagosome and lysosome fusion. The 
gradient bar indicates the decreasing pH as the phagosome is increasingly internalised and finally 
fused with the lysosome 1) Early phagosome 2) Phagosome 3) Lysosome 4) Phagolysosome. 
 




that M. Tuberculosis, after a couple of days of phagosome compartmentalisation, is 
capable of escaping the phagosome into the cytosol of the host cell (Van der Wel, 
2007).  In the cytosol, the bacteria will be able to be degraded by host cell enzymes, 
internalised into the endoplasmic reticulum (ER) and mounted into an MHC class I 
for cell surface presentation and CD8+ T-cell recruitment (Janeway et al., 2005; Van 
der Wel, 2007). Interestingly, there seems to be a clear connection between the 
virulence of the bacteria and the capacity to enter the cytosol, which may have great 
implications for the development of vaccines. 
CD4+ TH1 cells, upon activation, generate large amounts of cytokines such as 
interferon gamma (IFN-γ) and tumour necrosis factor alpha (TNF-α), both of which 
result in the activation of the macrophages, further inducing bactericidal activity, 
phagosome-lysosome fusion and result in the recruitment of more phagocytic cells 
(Pearl et al., 2001).  
As the CD4+ TH1 cells normally function by activating the macrophages and facilitate 
the fusion of phagosomes with endosomes, the recruitment is to a large extent 
redundant and only increases the size of the granulomas. So where normal 
pathogens are inhibited or even eradicated by the recruited TH1 cells, macrophages 
and dendritic cells, M. Tuberculosis has found a way of turning it into an advantage 
as it now has more cells to infect. Furthermore, in many granulomas it has been 
found that the macrophages have fused with one another forming massive multi 
nucleated giant cells. This further enables M. tuberculosis to infect new cells without 
being exposed to the extracellular space.  




To help promote its pathogenesis, M. tuberculosis has developed multiple means to 
inhibit host cell apoptosis and favour necrosis. This not only gives the bacteria 
prolonged survival, but also ensures a longer timeframe for multiplication before the 
rupture of the cells, thus enabling the bacteria to infect more cells upon release, not 
only by the increased number of bacteria released, but also thereby allowing more 
phagocytic cells to be recruited to the site of infection (Davis and Ramakrishnan, 
2009; Ernst, 2012). Necrosis is normally something that is found at the centre of the 
secondary state of granulomas and as time progresses the necrotic centre will cause 
the granuloma to become perforated forming the third state of granulomas, caseous 
granulomas. This allows the escape of M. tuberculosis to the surrounding tissue and 
airways and it is at this stage that TB becomes infectious (Gegenbacher and 
Kaufmann, 2012). 
With the maturation of the granulomas there is an increased deposition of both fibrin 
and calcium around the site of infection. Due to this, the tissue damage caused by 
tuberculosis infection is irreversible making it even more important to be diagnosed 
at an early stage (Cosma et al., 2003).  
Even if M. tuberculosis seems like an invincible organism, in most cases, i.e. , 
individuals with a fully functioning immune system, the primary disease will be 
contained and enter into a latent stage that is only ever activated in 5-10% of all 
infected individuals (Doherty, 2012).  
 




1.2.4.2 Latent infection 
Following the initial M. tuberculosis infection and immune system activation, M. 
tuberculosis can revert to a dormant state, often held in place by the complex 
mounted immune response. In 90-95% of cases the immune system is capable of 
retaining the mycobacterial infection in a compartmentalised fashion with a constant 
replacement of CD4+ T cells with expression of IFN-γ and TFN-α production and 
nitric oxide formation (Lazarevic et al., 2005). This state is characterised by low 
metabolic activity and more importantly increased drug resistance (Gegenbacher 
and Kaufmann, 2012).  
At the onset of the adaptive immune response most individuals initially show 
temporary signs of infection such as fever and skin rashes. However, as soon as the 
infection enters the latent stage, the disease becomes asymptomatic. The onset of 
the adaptive immune response also disrupts the exponential bacterial growth and 
the bacterial load in mouse models seem to level out at approximately 106 bacteria. 
The bacterial load in human latent TB infection has not yet been established (Ernst, 
2012).  
Although the adaptive immune response towards M. tuberculosis is able to stop the 
progressive growth it seems incapable of eradicating the infection altogether. The 
primary reasons for their limitation is the decreased MHC class II-mediated antigen 
presentation and antigen processing mediated by a 19 kDa lipoprotein. This induces 
the production of the anti-inflammatory protein lipoxin, inflammatory restriction by 
regulatory T-cells, down regulation of mycobacterial antigen expression leading to a 
failure in inducing CD4+ T cell response and finally an inhibition of the macrophage-




activating effects of IFN-γ (Noss et al., 2001; Scott-Browne et al., 2007; Divangahi 
et al., 2010; Bold et al., 2011; Ernst, 2012).  
Interestingly, some evidence has indicated that there might not necessarily be a 
complete distinction between latent and active phase of tuberculosis infection, but 
more a gradient so that in the latent phase there exists a small population of active 
M. tuberculosis bacilli and vice versa. This has great implications for treatment of 
tuberculosis (Lewis, 2010; Gegenbacher and Kaufmann, 2012).  
 
1.2.5 Tuberculosis control 
Both diagnostic tools and modes of treatment of TB is associated with many 
uncertainties although several are present.  
 
1.2.5.1 Diagnosis 
Diagnosis of TB today comprises most commonly a sputum test of patients with 
active TB, chest X-ray imaging and the Mantoux tuberculin skin test (Jassal and 
Bishai, 2009).  
The sputum test is only an effective diagnostic tool in the case of active TB as it 
requires the presence of bacilli in great enough numbers to be detectable under a 
microscope 
A major issue with M. tuberculosis culture growth is the long generation time. Even 
under optimal growth conditions it takes up to 6 weeks to get analysable colonies. 
Furthermore, it is quite often necessary to repeat the diagnosis making this a very 
time-consuming endeavour. However, culture growth allows the establishment of 




chemotherapeutic susceptibility of the tested organism, thereby more accurately set 
up the correct course of antibiotics for the individual (Jassal and Bishai, 2009). 
The problem associated with chest X-ray imaging is that it is practically impossible 
to detect the infection at the early stages as tissue alterations, due to granuloma 
formation, are required for recognition. This means that the disease will already be 
at an evolved stage making it harder to treat and more importantly the patient will at 
this point already have suffered irreversible damage to the lungs. 
In the case of latent infections of TB the gold standard is still the Mantoux tuberculin 
skin test. However false-positives do occur in individuals that have received the 
Bacillus Calmette-Guerin (BCG) vaccine. The skin test is also associated with false-
negatives, in particular in immune-compromised individuals (Ducati et al., 2006; 
Jassal and Bishai, 2009).  
A new alternative to the Mantoux skin test has been developed and relies on the 
detection of IFN-γ release in blood samples exposed to an array of M. tuberculosis 
specific antigens. As the antigens are specific to M. tuberculosis, previous 
vaccination with the BCG vaccine does not interfere with the result (Jassal and 
Bishai, 2009; Dheda et al., 2010). Furthermore, there are DNA based diagnostic 
tools that allow rapid amplification of tuberculosis specific genes. However, staff 
training and laboratory facilities in many regions worldwide which have limited 
resources, has limited the application of these diagnostic tools (Jassal and Bishai, 
2009). 
 





Although TB in most cases in the developed parts of the world is to a large extent 
curable, for the chemotherapy susceptible strains, it still takes administration of 3-4 
antibiotics over the course of >6 months. These antibiotics normally comprise 
isoniazid and rifampicin for 6 months with an addition of pyrazinamide and 
ethambutol for the first 2 months (Table 2) (Ducati et al., 2006; WHO Global 
Tuberculosis Report 2012).  
 






 Aminosalicylic acid 
Table 2 First- and second line drugs used in tuberculosis treatment. 
 
Although treatment with first-line antibiotics is inexpensive, the length of the 
treatment results in many patients failing to complete the course of antibiotics. This 
has resulted in the emergence of an increasing number of increasingly resistant 
strains, which will be addressed below. Treatment of resistant strains is not only 
more costly but also commonly takes longer and more importantly, has a lower 
success rate (Doherty, 2012). 




As both diagnosis and treatment primarily performed after symptoms of infection 
have been established, the infected individual already is at an infectious state 
meaning that treatment is primarily a type of disease control that has little effect on 
the actual spreading of the disease (Doherty, 2012). To counter this diagnosis, 
treatment has to either be done on all individuals regardless of symptoms or a proper 
vaccine has to be developed. 
 
1.2.5.3 BCG and vaccine development 
Currently only one vaccine exists for commercial use. The BCG vaccine is an 
attenuated strain of M. bovis and it is most commonly distributed to children as it has 
proven most effective in preventing tuberculous meningitis and miliary TB. However, 
the vaccine has a very varied efficiency in preventing pulmonary TB, which is the 
most prevalent form of TB in adults (Leung et al., 2001; Rodrigues et al., 2005, Ducati 
et al., 2006; Doherty, 2012). 
A lot of research is being put into the development of new vaccines. One avenue 
that has been investigated is increasing the efficiency of the existing BCG vaccine 
by introduction of specific parts of the RD1 domain (Pym et al., 2003; Skeiky and 
Sadoff, 2006). Another approach is the generation of a new attenuated tuberculosis 
strain by deleting specific virulence genes to render the bacteria non-pathogenic, but 
still capable of mounting a potent immune response (Skeiky and Sadoff, 2006). 
Finally, some groups have worked on the incorporation of specific M. tuberculosis 
antigen sequences into viral vectors, which are then introduced to mount a controlled 
immune response towards the produced antigen.  




However, the creation of a new vaccine is a lengthy process and as time passes the 
number and complexity of resistant tuberculosis strains increases. 
 
1.2.5.4 Resistant strains and incidence 
It is estimated that today approximately 50 million individuals are infected with 
multidrug-resistant TB (MDR-TB) and of these around half a million develop active 
TB each year (Gegenbacher and Kaufmann, 2012; WHO Global Tuberculosis 
Report 2012). 
MDR-TB is defined as a strain resistant to more than one antibiotic. Especially 
troublesome is the increased number of extensively drug-resistant (XDR-TB) strains, 
resistant to rifampicin, isoniazid, fluoroquinolone and to any of the injectable 
antibiotics capreomycin, kanamycin and amikacin (Jassal and Bishai, 2008). Of 
particular concern is the emergence of totally drug-resistant (TDR-TB) strains which 
have recently been described that are also resistant to all second-line drugs (Velayati 
et al., 2009; Udwadia et al., 2012).  
Compared to the normal >6 month treatment regimen, the WHO has recommended 
that patients with MDR-TB receive intensive treatment for 8 months and then 
continue treatment for a total duration of 20 months (WHO Global Tuberculosis 
Report 2012). Furthermore, resistant strains require a more individualised treatment 
than susceptible individuals’ further complicating infections with resistant strains, 
especially in resource limited regions (Jassal and Bishai, 2009). 
The requirement for new efficient and low-cost diagnostic tools and 
chemotherapeutics is desperately needed if the WHO goals of eliminating TB as a 




global health issue by 2050 are going to be fully realised (WHO Global Tuberculosis 
Report 2012). 
As most anti-tuberculosis treatments require the internalisation of the drug in order 
to be functional, a new approach to anti-tuberculosis treatment could be the 
implementation of non-internalising sterilisation techniques, for example targeted 
radionuclide therapy, which has already proven efficient in cancer treatment. Apart 
from helping in sterilising already resistant strains it could potentially also aid in the 
prevention of the establishment of new ones, while also having potential for 
diagnosis.  




1.3 Targeted radio nuclide therapy and imaging 
1.3.1 Types of radiation and applications 
There are three types of radioactive emissions important for radio nuclide therapy, 
α-, β- and Auger electron radiation, and two central for imaging: γ- and β+ radiation 
(Dearling and Pedley, 2007).  
α-radiation is the result of nuclear decay, which results in the release of a double 
positively charged helium nucleus consisting of two neutrons and two protons. Due 
to the relatively large mass compared to other types of radiation and its charge, it 
has a very low tissue penetration rate and thereby short range. As a consequence 
of this the linear energy transfer (LET) is generally very large, in the range of 80 
keV/μm making it a suitable candidate for therapy (Kassis and Adelstein, 2005; 
Sadeghi et al., 2010). LET is a term associated with particular emissions. The unit 
for LET is most commonly keV/μm or MeV/cm and as a consequence a denotation 
of the amount of energy on average deposited along a pathlength by an emitted 
particle. It is in some cases referred to as the “stopping power” (ICRU report 16, 
1970). LET is dependent on 3 factors: velocity, charge and mass of the emitted 
particle. Although the value of LET technically varies along the trajectory it is for most 
intents and purposes considered as an average distribution. However, an important 
general feature of LET is the shorter the pathlength of the emitted particle, the higher 
the LET. Upon emission the particles will have a certain intrinsic energy and as they 
interact along a path with other atoms this energy will be deposited in fractions until 
the energy is so low that an interaction will make the particle come to a halt or be 
absorbed. As photons do not have mass they interact differently with their 




surroundings. LET is therefore generally not associated with γ-radiation (ICRU report 
16, 1970). γ photons have 3 ways of losing energy, largely depending of the initial 
energy of the photon: 1) all energy can be absorbed by an orbital electron via the 
photoelectric effect, causing the ejection of the recipient electron; 2) Compton 
scattering in which part of the energy of the photon is transferred to an orbital 
electron thereby decreasing the energy of the photon and increasing the wavelength; 
and 3) the photon result in pair production in which the photon is converted to mass 
and kinetic energy of an electron-positron pair. This is generally for high energy 
photons as this requires nuclear interactions (ICRU report 16, 1970). To designate 
LET to γ-radiation is therefore practically meaningless. 
Another term important with relation to radiation is the inverse square law. Although 
the inverse square law is applicable to many domains in physics from gravity to 
magnetic fields etc., it also relates to the distribution of radiation of ionising radiation 
from a source. In essence it states that intensity, or dose, is inversely correlated to 





This is not only important in health and safety considerations when working with 
radiation, but has implications for the use of ionising radiation, particularly in 
therapeutic settings. It should not be confused with LET although they seem very 
similar. The inverse square law is particularly important for both α particles and 
Auger electrons as they have very short path lengths meaning that they deposit a 
very large dose in a very confined area.  




β- radiation consists of emitted electrons, the result of the internal conversion (IC) of 
a neutron into a proton resulting in the release of a small charged particle and an 
anti-neutrino. Due to the smaller mass and less charge of the β-particle it has a 
longer range and a generally lower LET compared to α-particles. The benefits of 
using this β-radiation over α-radiation would be the lower degree of tissue damage, 
however as the range is larger this damage would be spread over a larger area. 
Furthermore, due to the lower energy, generally larger doses are needed in the 
targeted tissue in order to elicit a response (Sadeghi et al., 2010). Despite the 
disadvantages, β- emitters are the main isotopes utilised for radiation therapies in 
cancer (Kassis and Adelstein, 2005; Buchegger et al., 2006; Sadeghi et al., 2010).  
β+ particles are created by the internal conversion of a proton into a neutron. These 
particles are primarily used for imaging purposes and will not be elaborated further. 
γ-radiation is, as mentioned previously, an emitted photon and thereby has no mass. 
It can be generated via several pathways including nuclear fission, nuclear fusion, in 
concert with either α- or β- emissions or simply when an atom returns from an excited 
state. As γ-radiation is composed of photons it has a very high tissue penetration 
rate compared to α- and β- radiation (Table 3).Consequently γ-radiation is a poor 
candidate for therapeutic purposes but is optimal for imaging, for which it is primarily 
used. However, many isotopes that emit γ-radiation also release so-called Auger 
electrons, which shows potential in therapeutic settings and will be addressed later. 
 
 








E(min)-E(max) Linear Energy 
Transfer (LET) 
Application 
γ-photon - ~ 100 keV  Imaging 





0.2 keV/μm Therapy 
Auger electron 2-500 nm eV- keV 4-26 keV/μm Therapy 
Table 3 An overview of the various types of radiations, their range, average LET, examples of 
isotopes with that emission and typical applications (Kassis and Adelstein, 2005; Buchegger 
et al., 2006). 
 
1.3.2 Radioactive isotopes 
The different properties of the various existing types of nuclear radiation means that 
each type of radiation has very specialised use in medical settings, which opts for 
careful consideration when choosing the isotopes to be used in each particular 
situation (Table 4). 
Several factors need to be evaluated: the physical and chemical properties of the 
candidate isotope including half-life and the LET of the isotope (Table 4), the 
methodology of the labelling and the behaviour in biological settings, with particular 
interest in the potential dissociation of radionuclide from the targeting agent, or 
effects on the bio distribution of the targeting agent (Sadeghi et al., 2010). 
 
 






Type of radiation Energy Range T1/2 Application 
99mTc γ 
+ Auger electrons 
140 keV + 0.9 
keV 
-*  
+ several nm† 
6 hrs Imaging/(therapy) 
111In γ 
+ Auger electrons 
173, 247 keV + 
0.9 MeV 
-*  
+ several nm† 
2.8 d Imaging/(therapy) 
125I γ  
+ Auger electrons 
35 keV + 0.179 
MeV 
-*  
+ several nm† 
60.1 d Imaging/(therapy) 
123I γ 
+ Auger electrons 
159 keV + 1.2 
MeV 
-*  
+ several nm† 
13.2 hrs Imaging/(therapy) 
213Bi α 8.3 MeV 60-85 μm 0.8 hrs Therapy 
211At α 6.8 MeV 61 μm 7.2 hrs Therapy 
225Ac α 6.8 MeV 50-80 μm 10.0 d Therapy 
188Re β- 2.1 MeV 10.4 mm 0.7 d Therapy 
90Y β- 2.3 MeV 11.3 mm 2.7 d Therapy 
131I β- 0.6 MeV 2.3 mm 8.0 d Therapy 
67Cu β- 0.6 MeV 2.1 mm 2.6 d Therapy 
177Lu β- 0.5 MeV 1.8 mm 6.7 d Therapy 
Table 4 Overview of some commonly used radio nuclides in radio pharmacy 
*= γ-photons have virtually unlimited range †= Auger electrons have shown to have very short range 
in biological material and the range varies with the energy of the emitted electrons (O'Donoghue and 
Wheldon,  1996) (Becker and Meller, 2001; Häfeli et al, 2001; Anderson et al., 2003; Milenic et al, 
2004; Martinez et al, 2006; Dearling and Pedley, 2007; Bryan et al, 2008; Sadeghi et al., 2010; 
Sharkey and Goldenberg, 2011; Jurcic, 2013)  
 




Interestingly, it has been shown that the various radio nuclides demonstrate 
considerable differences in bio-distribution. It was shown that an anti-
glucouronoxylomannan murine antibody labelled with either 188Re or 111In revealed 
that although their uptake in lung tissue was comparable, their blood clearance rate 
varied, where the 188Re labelled fragment was cleared approximately 5 times faster.  
Furthermore, their uptake in liver was also significantly varied with a much higher 
degree of accumulation in the liver of the 111In-labeled fragment (Dadachova et al., 
2007). This particular case could be explained by the accumulation of 111In mAb 
catabolites in the liver, whereas the 188Re nuclide is attached to the mAb via SH 
groups. Upon mAb catabolism this is converted into a perrhenate anion (ReO4-), 
which is rapidly cleared through the kidneys (Dadachova et al., 2007). Thus, it is not 
only the targeting moiety that is important in the design of the pharmaceutical; the 
radio labelling may affect the distribution as well as the kinetics of the targeting 
moiety and potential catabolites (Blok et al, 1999; Staud et al, 1999).  
Furthermore, the stability of the labelling technique itself is an important factor to 
consider. A study showing antibodies chelate-labelled with various radio nuclides, 
as well as using various chelating agents displayed varied degrees of stability in 
serum and biodistribution (Cole et al., 1987; Arano et al., 1995). This may have an 
effect on the applicability of the construct in both imaging and therapeutic scenarios. 
 
1.3.2.1 Imaging isotopes 
Isotopes chosen for imaging have generally short half-lives and are generally γ and 
β+emitters. 




The most commonly used radionuclide for pharmaceutical imaging purposes is 
99mTc, a metastable decay product of molybdenum-99 (Table 1) (Urch and Welch, 
2006). Several advantages are associated with 99mTc, including low cost and a 
relatively short half-life. In addition, the energy emitted by 99mTc photons is optimal 
for scintigraphic detection with a gamma detector thus resulting in high quality data 
(Brouwer et al., 2008). Additionally, 99mTc has been shown to also emit Auger 
electrons, which may have therapeutic value at increased dose rates and will be 
explored later (Donoghue and Wheldon, 1996). However, this does mean that 
potential damaging effects on the targeted tissue has to be taken into consideration. 
Recently however, there has been a decreased production of 99mMo production, the 
precursor to 99mTc due to the shutdown of old nuclear reactors. This has researchers 
and medical staff either try other isotopes, decrease the dose of 99mTc and/or 
increase the sensitivity of the imaging equipment (Thomas and Maddahi, 2010). 
Another γ-emitter is 111In, which also emits Auger electrons, and is also primarily 
utilized for imaging (Khaw et al., 1980).  
 
1.3.3 Radio imaging 
Due to the tissue penetration ability of in particular γ-radiation and the fairly easily 
detectable nature, radio imaging is a very attractive means to detect the localisation 
of not only cancers but recently it is also being used to visualise the location of 
infections, specifically targeting bacteria and furthermore being able to distinguish 
between infections and sterile inflammation as well as between bacterial and fungal 




infections (Welling, 2002; Meléndez-Alafort et al., 2004; Lupetti et al., 2003; 
Dadachova and Casadevall, 2009). 
This is of particular interest in immuno-compromised individuals as localisation of 
infections can be more problematic as an immune response is not mounted thereby 
potentially masking infections. Furthermore, it could be particularly useful to not only 
localise but also visualise the spread of an infectious agent and help determine the 
efficiency of the utilised antimicrobial treatment.  
As opposed to the available techniques such as ultrasonography, CT and MRI, radio 
imaging offers a more specific detection of infection (Walker et al., 2007). Whereas 
CT and MRI rely on alterations in the tissue, radio imaging is potentially able to 
visualize infection at a much smaller scale, and allows whole body imaging at once 
as opposed to CT and MRI where the focus primarily is on parts of the body. This 
can help in elucidating localisation of infections in patients with fevers of otherwise 
unknown source (Becker and Meller, 2001; Akhtar et al., 2005; Walker et al., 2007; 
Brouwer et al., 2008). 
One of the most important aspects for in vivo imaging is contrast, or signal-to-noise-
ratio. Greater contrast can be achieved by lowering the circulation time of the 
imaging agent, thereby increasing target to non-target ratios, and by enhancing the 
binding specificity (Blok et al, 1999; Weisser and Hall, 2009). For this reason a lot of 
research has been put into developing targeting agents that have low circulation 
time. This not only increases the contrast of the imaging, as imaging will to a larger 
extent be based on binding affinity to the target and not blurred by retention of 
imaging agent in circulation, but also decreases the timeframe the patients are 




subjected to radiation (Müller and Schibli, 2013). Other important aspects include 
excellent tissue penetration, high affinity to the target, high specific uptake and 
retention in the target tissue, stability in vivo, easy preparation and safe in human 
settings (Müller and Schibli, 2013). Some promising agents include single chain 
variable fragment (scFvs), which will be discussed later. However, a low circulation 
time could prevent the imaging agent from reaching detectable levels at the site of 
interest. 
Another aspect that has garnered attention in the field of imaging is the pre-targeting 
of unlabelled targeting agents. This has proven very efficient in reducing non-target 
organ localisation. This increases localisation of labelled targeting agents in target 
tissues due to the reduced non-specific binding (Schoffelen et al., 2010; Sharkey 
and Goldenberg, 2011).  
In 2003 the existing radiopharmaceuticals included 67Ga, 111In, or 99mTc-labeled 
polyclonal antibodies as well as 111In-oxine or 99mTc-hexamethylenepropyleneamine 
labelled white blood cells. These were, however, unable to distinguish between 
infection and sterile inflammation (Becker and Meller, 2001; Welling et al., 2001; 
Lupetti et al., 2003; Akhtar et al., 2005; Walker et al., 2007; Goldsmith and 
Vallabhajosula, 2009). Furthermore, there were several drawbacks associated with 
the use of leukocytes including difficult protocols and time-consuming procedures 
with the risk of transferring blood-borne infections such as Hepatitis C and HIV 
(Akhtar et al., 2005; Walker et al., 2007; Goldsmith and Vallabhajosula, 2009). Even 
considering these drawbacks, radio-labelled leukocytes remain the most utilized 
agent for infection imaging (Goldsmith and Vallabhajosula, 2009). 




In one clinical trial researchers were able to distinguish between infection and sterile 
inflammation by using a truncated mouse antimicrobial agent, UBI 29-41, labelled 
with 99mTc (Akhtar et al., 2005). Sterile inflammation was induced by injection of 
bacterial lipopolysaccharides. 99mTc-labelled ubiquicidine 29-41 was shown to be 
able to detect both bacterial as well as fungal infections and more importantly able 
to distinguish between infection and sterile inflammation (Welling et al., 2002). A 
study by Akhtar et al. (2005) showed that optimum in imaging was obtained only 30 
minutes following injection (Akhtar et al., 2005; Walker et al., 2007). Although the 
prospects are good, more investigation is needed within the field of radio imaging.  
By exchanging the radionuclide upon the targeting agent with one emitting a different 
type of radiation, it may be that a targeting agent utilized for imaging could be used 
in radiotherapy.  
 
1.3.4 Radio nuclide therapy 
The structural integrity of DNA is of vital importance to all organisms. For this reason 
a considerable amount of research has been put into the controlled utilisation of radio 
nuclides for the destruction of, most commonly, unwanted cancerous cells. Recently, 
research has been put into expanding the repertoire of radiation therapy to infectious 
diseases as well, which will be detailed below. 
The most basic type of radiotherapy is the irradiation of a specific area of the body 
with external photonic radiation sources. By utilising several sources a focal point is 
created where the absorbed dose is much higher than the surrounding tissue. This 
method is very often utilised in concert with chemotherapy (Web 2). 




Although in theory it is only the focal point that experiences high enough doses for 
cell death, many patients experience damage to the surrounding tissue making 
wound healing, among others, a major issue (Haubner et al., 2012). Furthermore, a 
big problem with cancer therapy is the common establishment of secondary cancers 
(Trott, 2009; Tubiana, 2009). Generally, the side-effects of radiation therapy are 
grouped into early and late side effects. The early side effects of radiation therapy 
include erythema, dry desquamation, hyperpigmentation and hair loss where the late 
side effects comprise skin atrophy, telangiectasia, dyschormia, dyspigmentation, 
fibrosis and ulcers (Haubner et al., 2012). For this reason, much research has been 
put into targeted radio therapy (Adelstein et al., 2003; Dadachova et al., 2004; 
Buchegger et al., 2006; Dadachova et al., 2007; Dearling and Pedley, 2007; Sharkey 
and Goldenberg, 2011; Jurcic, 2013). By targeting the radiation source to where it is 
needed it is not only possible to increase the absorbed dose of the cells of interest, 
but also decrease the adverse effects to the healthy surrounding tissue. 
Furthermore, problematic metastases can potentially be more easily targeted. 
Most research into the field of radiotherapy has been performed with cancer in mind, 
however the disadvantage of cancerous cell lines is their often indistinguishable 
antigenic properties compared to healthy cells. As the surface antigens of infectious 
agents are comparably considerably different to human cells, research has been put 
into investigating whether targeted radiotherapy can be used for infectious diseases 
as well. 
 




1.3.4.1 Radiotherapy of infectious diseases 
Most research of radiotherapy has been in the field of cancer therapy. However, 
recently there has been a lot of interest in targeting infectious diseases as well due 
to not only the emergence of multi resistant strains but also due to the increased 
number of immuno-compromised individuals. Finally, there is an increased use of 
incorporated medical devices such as catheters, pacemakers and prosthetic joints, 
which often is complicated by the development of bio films towards which 
radiotherapy has proven effective. (Martinez et al., 2006; Dadachova and 
Casadevall, 2009). Martinez et al. (2006) found that monoclonal antibody 18B7, 
specific for capsular polysaccharides on the surface of Cryptococcus neoformans, 
labelled with the α-emitting isotope 213Bi was able to penetrate a biofilm composed 
of C. neoformans. In contrast unlabelled, nonspecific 213Bi labelled antibodies as well 
as β- and γ- radiation had no effect.  
It seems that the general effect of radio therapy upon microorganisms is primarily 
“direct-hit”, in which cells are killed by radiation from a source directly attached to the 
cell, however, the “crossfire” effect, where cells are killed by radiation from a source 
attached to neighbour or distant cells, also appear to be important (Dadachova et 
al., 2004; Dadachova and Casadevall, 2009). The type of radiation used has an 
impact on whether the primary mode of function is down to “direct-hit” or “cross-fire”. 
Not surprisingly, α-radiation is primarily responsible to “direct-hit” induced cell death, 
whereas β-radiation primarily worked through “cross-fire” effects (Nosanchuk and 
Dadachova, 2012).  




Several studies showed that targeted radio-immunotherapy towards two fungal 
infections with either α- or β-emitters were 100-1000 fold more efficient than gamma 
radiation in sterilising the infections (Dadachova and Casadevall, 2009). 
Interestingly, it appears that the various types of radiation induce different types of 
cell death in fungi. Experiments made on C. neoformans showed that gamma 
radiation primarily induced cell death by membrane disruption, whereas α-radiation 
significantly reduced the metabolic activity (Bryan et al., 2008; Nosanchuk and 
Dadachova, 2012). 
There are several advantages to the use of ionising radiation to combat infectious 
diseases. One of the advantages of targeting infectious disease over cancerous cell 
lines is the obvious difference in surface antigens, which minimises the chance of 
cross-reactivity. However, it has to be stressed that some microorganisms may 
release certain antigens. This could lead to a more systemic distribution of the radio 
therapeutic agent. Although it has been hypothesised that in the case of analysed 
capsular polysaccharide released by C. neoformans, the antibodies are thought to 
have greater affinity to the bound than soluble form. However, it is an issue that has 
to be considered for each targeted antigen (Dadachova et al., 2003; Nosanchuk and 
Dadachova, 2012). 
Another advantage of the use of radiation therapy to combat infectious diseases, 
over the traditional chemical approach, is that microorganisms are less likely to 
generate resistance towards ionising radiation compared to the traditional chemical 
antibiotics as it does not interfere with specific pathways within the cell (Nosanchuk 
and Dadachova, 2012). However, microorganisms have shown great adaptability 




and have been shown to survive very high doses of radiation, such as Deinococcus 
radiodurans surviving doses of 5.000 Gy of γ radiation without effect on viability due 
to a very efficient DNA repair system (Battista, 1997). So the same considerations 
for chemotherapeutic agents apply to radio nuclear therapy that treatments must 
ensure eradication of all infectious agents. Another advantage is that radiotherapy 
is very unlikely to interfere with any other potential drugs administered. With many 
complicated infections a cocktail of drugs is administered each of which may have 
adverse effects when co-administered with other pharmaceutical compounds.  
One of the problematic aspects considered from radiotherapy are the potential 
adverse effects on the host physiology. This was addressed by analysing both 
platelet counts as well as the generation of fibrous connective tissue in the lungs of 
treated model mice. Fibrosis, an abnormal generation of fibrous connective tissue at 
site of injury, had previously been observed in patients irradiated with external 
radiation sources. Several doses were analysed and no notable difference in platelet 
count was observed, and as opposed to external beam radiation therapy of the 
lungs, no fibrous connective tissue was encountered indicating that targeting of radio 
therapeutic isotopes is much less destructive than the traditional radio therapeutic 
methods. Most of this can be attributed to the targeting of the radiation (Dadachova 
et al., 2004; Dadachova and Casadevall, 2009). 
Interestingly, some groups have shown that radio therapy can not only be used to 
combat bacterial and fungal diseases but also some viral diseases as well. 
Considerable success has been found when eradicating mammalian cells infected 
with Human Immunodeficiency Virus (HIV) and Human Papilloma Virus (HPV) and 




it has been hypothesised that radio immunotherapy in combination with traditional 
antiviral drug therapy may be the key to eradicate a HIV infection (Casadevall et al., 
2007; Wang et al., 2007; Phaeton et al., 2010; Nosanchuk and Dadachova, 2012).  
However, as mentioned above a key aspect in radio nuclide therapy is choosing the 
most suitable isotope. 
 
1.3.4.2 Therapeutic isotopes 
When dealing with therapeutic isotopes, here meaning radioactive isotopes that 
have significant DNA damaging abilities, different aspects of the bio-distribution have 
to be considered. The most important feature for imaging is the contrast and for this 
reason the clearance rate of the radio imaging conjugate is of great importance. The 
same is not necessarily optimal for a therapeutic isotope. If clearance is too fast the 
therapeutic isotope may not have time enough to inflict the necessary damage to 
cause cell death. It was found that a conjugate consisting of a therapeutic isotope, 
131I, labelled to an anti-CD20 antibody was very quickly cleared. By pre-dosing with 
unlabelled anti-CD20 antibody to saturate the antibody conjugate “sink”. In this 
particular case the sink was the spleen and by saturating non-specific antigenic sites 
a more favourable bio distribution was achieved due to the competition between 
labelled and unlabelled antibodies. This was evidenced by multiple tumour sites 
became detectable following the pre-dose of anti-CD20 indicating a better access of 
the radio labelled antibody to the site of interest. (Kaminski et al., 1993; Sharkey and 
Goldenberg, 2011). Another problem with targeted therapeutic isotopes is that if the 
targeting agent used is less than 50 kDa, the primary route of clearance is through 




the kidneys increasing the possibility of renal toxicity (Sharkey and Goldenberg, 
2011) 
When choosing the radionuclide for a specific situation it is of interest what the 
retention time of the targeting agent is. Utilising an isotope with a much longer half-
life than the retention time of the targeting agent is not beneficial and neither is using 
an isotope with a much shorter half-life than the circulation time of the targeting 
agent. 
Radiation sources frequently used in therapeutic settings include 213Bi, which emits 
a high LET α-particle and 188Re, an energy-rich -emitter (Dadachova et al., 2004; 
Milenic et al., 2004; Bryan, 2008). Both isotopes have very short half-lives, 0.8 hours 
and 0.7 days, respectively. 
As mentioned previously, one of the advantages of an α-emitter over a β-emitter is 
that the former has a much shorter path-length as opposed to β-emitter making α-
emitters much more focused thus reducing the chances of toxicity in adjacent tissue 
(Milenic et al., 2004). However, cross-fire effects can be beneficial when larger areas 
need to be affected. Furthermore, logistics also has to be considered. As 213Bi has 
a half-life of only 0.8 hours, this makes it problematic to not only to manufacture but 
also administer within a very short time-frame. Hence this makes 188Re a potential 
more realistic therapeutic isotope, despite its disadvantages (Sharkey and 
Goldenberg, 2011). However a study by Rivera et al. showed that 213Bi was had a 
greater bactericidal effect than 188Re against Bacillus anthracis (Rivera et al., 2009)  
Other isotopes with value in therapeutic settings include the -emitting isotopes211At 
and 225Ac and the -emitting 131I, 90Y, 177Lu and 67Cu (Sharkey and Goldenberg, 




2011).However, -emitting isotopes as 123I, 125I, 99mTc and 111In have recently 
garnered increased attention as therapeutic isotopes as they emit another type of 
radiation in therapeutic settings, Auger electrons. 
 
1.3.5 Auger electrons 
In 1925 Pierre Victor Auger discovered that by irradiating a cloud chamber with low 
energy X-rays multiple electron tracts were generated. These were later dubbed 
Auger electrons (Kassis, 2004; Kassis, 2011).  
Auger electrons are generated by the excitation loss of an inner shell electron. This 
can happen by several routes: either by the excitation of an inner shell electron, 
causing it to be emitted (IC), by the uptake of an inner shell electron by a proton (EC) 
or by photoelectric interactions with outer shell electrons (Adelstein, 2003; 
Balagurumoorthy et al., 2012). In both cases this leaves an unfilled space, most 
commonly in the innermost electron shell, the K-shell, which is then filled by an 
electron from one of the outer shells (Kassis and Adelstein, 2005). This transfer 
releases energy, which can be emitted either as X-ray photons or transferred to 
another outer shell electron. Upon the reception of this additional energy the electron 
is emitted as an Auger electron (Kassis, 2004). Depending on the location of the 
electrons in relation to each other and the shells in which they reside, the emitted 
electrons are referred to as Auger, Coster-Kronig or super Coster-Kronig 
monoenergistic electrons (Figure 4). They are all however, collectively termed Auger 
electrons, which will also be the term used henceforth (Kassis and Adelstein, 2005).  





In general, there are generated anywhere between 5-50 Auger electrons per decay, 
depending on the isotope (Kassis and Adelstein, 2005; Kassis, 2011). As this is an 
average number of electrons generated by decay, this effectively means that in some 
cases the atom is left in a 50+ state. This would result in an immediate filling of the 
orbitals by stealing electrons from the immediate environment, causing this event to 
be devastating to everything in close proximity to the decay site. 
 
Figure 4 Simplified overview of the process of generating Auger electrons. 
In the Initial state, an inner shell is excited by either an incident electron or a photon causing it to 
be ejected as a photoelectron. This process leaves the atom in an intermediate excited state with 
an inner shell lacking an electron. Due to the unfavourable conditions of this state an outer shell 
electron will jump in to fill the place and upon doing so will release energy. This energy can be 
emitted as either photons or be transferred to another outer shell electron, which upon the 
reception will become excited and be emitted as an Auger electron. This leaves the atom in the 
most favourable energetic state (web 3) 
 




The energy of the individual Auger electrons, however, is very small when compared 
to the classical radiation types. Furthermore, the range of Auger electrons is equally 
very short, varying from a few nanometres up to ~0.5 μm (Figure 5). Due the inverse 
square law, mentioned 
previously, this eventually 
results in a relatively high LET 
comparable to that of both α-
particles and β-particles   
(Kassis et al., 1982; Buchegger 
et al., 2006; Reilly and Kassis, 
2010). Furthermore, as Auger 
electrons have a very small 
focal point compared to both - 
and - particles this means that 
it is more likely that the target cell, with an equal dose, is overwhelmed by the DNA 
damage (Kassis and Adelstein, 2005). It has been estimated that the majority of 
electrons are deposited within a sphere of a few nm of the decaying atom and in 
general deposit in the range of 106-109 rad/decay within this field (Figure 6) (Kassis 
and Adelstein, 2005).  
 
Figure 5 An overview of the LET of Auger electrons 
in relation to the emitted energy 
As indicated the range of the electrons is for the majority 
inversely related to the LET (Kassis, 2011). 
 
 




The energy of the Auger electrons ranges from a few eV up to approximately 1 keV 
and the higher the energy 
the longer the range 
(Kassis and Adelstein, 
2005). However, as 
mentioned previously, 
the range of Auger 
electrons is very limited 
and they are therefore 
very reliant on the 
inverse square law. 
Interestingly this means 
that the lower the energy 
of the electrons, the higher the LET. But again, due to the short range, there is a 
point where the range of the electrons is so short that any target is out of reach. This 
is a particular disadvantage of the Auger electrons as they generally require very 
close proximity to their target to induce damage. This dependence on close proximity 
to the target was further investigated by Balagurumoorthy et al. (2012). By labelling 
minor groove binding components of varying length with 125I it was found that the 
smallest molecules resulted in direct DSB whereas in molecules where the 125I was 
positioned >12 Å from the DNA helix resulted in DSB caused by indirect 
mechanisms. 
 
Figure 6 Overview of the difference in therapeutic effects on 
DNA of α-, β- and Auger radiation 
Due to the close proximity of the Auger emitting isotope a large 
dose is transferred in the immediate vicinity of the decay site as 
opposed to both α- and β- emissions (Sadeghi et al., 2010). 
 




Auger emitters have been for a while considered a candidate for cancer therapy, and 
several groups have shown indications that Auger electrons indeed can be used for 
the destruction of cancerous cell lines despite the size of mammalian cells 
(Buchegger et al., 2006). To circumvent this problem many groups have enabled 
internalisation of the Auger emitters and localisation of the emitters to the nucleus of 
the cell, by targeting the conjugate to high turn-over receptors which thereby allows 
rapid internalisation and increased proximity to the target DNA (Narra et al., 1992; 
Michel et al., 2003; Sharkey and Goldenberg, 2011; Balagurumoorthy et al., 2012). 
Because of their short range they are particular interesting in treating cancers, 
particularly in radiosensitive organs such as the bone marrow (Sharkey and 
Goldenberg, 2011). However, the positive effects of the highly targeted nature of 
Auger induced toxicity is also one of the drawbacks. Whereas α- and β- radiation 
has a range of μm-mm in tissue, they can rely on cross-fire effects meaning that not 
all target cells require targeting to be affected. With Auger electrons, the little cross-
fire effects results in a high dependence on efficient targeting (Adelstein et al., 2003). 
The effects of Auger electrons have been analysed in both mammalian and bacterial 
systems, however the effects analysed were based on incorporation of 125I- labelled 
deoxyuridine into the genome (Krisch and Ley, 1974; Feinendegen, 1975; Adelstein 
et al., 2003; Balagurumoorthy et al., 2012). However, this is not a particularly 
practical approach to a therapeutic agent. Furthermore as the effects do not appear 
to require direct incorporation into target DNA to induce DSB, but still close proximity, 
it was interesting to analyse whether the toxic effect could be accomplished by 




simple attachment of the radionuclide to the surface of microbial cells due to the 
small size compared to mammalian cells (Balagurumoorthy et al., 2012). 
  




1.4 Targeting Agents 
In the previous section radioactive isotopes were evaluated as damaging agents for 
fighting infectious diseases. However, due to the destructive and non-specific 
nature, targeting is very desirable to prevent substantial damage to non-target host 
tissue. 
There are several ways of introducing targeting to a damaging component including 
selecting an agent, which has a natural bio-distribution in the desired target tissue. 
An example is radioactive iodine that naturally accumulates in the thyroid gland and 
for this reason is a well suited agent for treating various thyroid maladies such as 
thyroid cancer (Keating et al., 1949; Beierwaltes, 1978). However, most agents do 
have an undesirable bio-distribution and accumulate in tissues with high blood flow 
as the spleen, kidneys, bone marrow and liver. Especially problematic is the bone 
marrow that is very radiosensitive (Benua et al., 1962).  
Many types of targeting agents have been evaluated, but the most commonly 
analysed are antibodies and antibody derivatives such as single chain variable 
fragments (scFvs), which will be evaluated later. 
Most recently, antimicrobial peptides have garnered considerable attention for their 
non-specific microbial targeting capacity.  
 
1.4.1 Antimicrobial peptides 
Several hundreds of both non-ribosomally and ribosomally synthesised antimicrobial 
peptides have been identified (Hancock and Chapples, 1999). The former are 
primarily synthesised by bacteria and form the basis for many antibiotics, whereas 




the latter are generated by everything from viruses to mammals and will be the focus 
in this section (Hancock and Chappels, 1999).  
 
1.4.1.1 Synthesis and structure 
Although there are few cases of homology there are some shared general 
characteristics. They are generally between 50-60 amino acids (aa), they have a 
generally positive net charge (cationic), facilitated by arginine and lysine, and they 
are generally amphipathic and membrane active (Blok et al., 1999; Hancock and 
Chappels, 1999; Lupetti et al., 2003; Brouwer et al., 2008). Furthermore, the majority 
consists of approximately 50% hydrophobic amino acids and generally have a low 
proportion of both negatively charged and neutral polar amino acids (Hancock and 
Chappels, 1999). 
Despite their limited size they do generally form some secondary structures. 
Generally, the antimicrobial peptides fall into 4 categories based on their secondary 
structures (Brouwer et al., 2008): Peptides that contain  
1. Amphipathic -helices 
2. Two or more disulphide bridges 
3. Intermolecular disulphide bridges and also contain a loop/hairpin like 
structures and 
4. Linear peptides lacking cysteine but rich in amino acids such as tryptophan 
(Indolicidin) or proline and arginine (PR39) 
The structure seems to be more important for antimicrobial peptides than size. Many 
form -helices and have disulphide bonds, however due to the low degree of 




conservation and sequence homology they can adopt most secondary structural 
motifs. One feature many antimicrobial peptides have in common is the lack of 
secondary structures in water, when no disulphide bridges are present, and only 
form the structures when in a membranous or hydrophobic environment or if they 
self-aggregate (Bello et al., 1982; Falla et al., 1996; Hancock and Chappels, 1999). 
Although there is little sequence homology to be found between the various 
antimicrobial peptides, even within closely related species, there have been some 
indications of homology in the preproregion of the precursor molecules indicating 
that there is some limitation to the variation of the sequence involved in translation, 
secretion or intracellular trafficking (Simmaco et al., 1998; Zanetti et al., 2000; 
Zasloff, 2002). 
Due to the low degree of sequence homology between antimicrobial peptides and 
the considerable pharmaceutical potential, some research has also been put into the 
design of new synthetic peptides, however presently they are primarily alterations 
made to already existing antimicrobial peptides to modify characteristics such as 
specificity, stability and toxicity (Hancock and Chappels, 1999). 
Antimicrobial peptides are primarily produced by epithelial, endothelial and 
phagocytic cells during inflammation and they play an important role in both the 
innate as well as the adaptive immune responses and possibly in linking the two 
(Figure 7A) (Hancock and Chappels, 1999; Lupetti et al., 2003). However, 
antimicrobial peptides have been found to also come from the degradation product 
of cationic proteins as for example lactorferricin from lactoferrin and buforin II from 
histone 2A (Hancock and Chappels, 1999; Zasloff, 2002).  





The initiation of production of antimicrobial peptides is thought to be induced by 
contact of antimicrobial peptide producing cell lines with microorganisms, microbial 
products such as lipopolysaccharide (LPS) or pro-inflammatory cytokines (Brouwer 
et al., 2008). 
All antimicrobial peptides are derived from larger precursors, which also include a 
signal sequence. These undergo proteolytic cleavage and in some cases post-
translational modifications which include glycosylation, carboxy-terminal amidation 
and amino acid isomerisation as well as halogenation (Zasloff, 2002). 
Due to their relatively small size and very versatile structures the mode of function 
of antimicrobial peptides is very simple but efficient. 
 
 A            B 
 
Figure 7 Overview of the effects and mode of action of antimicrobial peptides 
A) shows a schematic representation of the complex network of the innate immune defence system 
where antimicrobial peptides are produced and exert their multi-facetted mode of function. LPS= 
Lipopolysaccharide (Lupetti et al., 2003). B) Shows the electrostatic and hydrophobic interactions 
with a microbial membrane. This is shown in contrast to a mammalian plasma membrane upon 
which antimicrobial peptides have no effect. The negatively charged acidic phospholipids are 
situated in both inner and outer leaflet in bacteria as opposed to only the inner leaflet in mammalian 








1.4.1.2 Antimicrobial effects 
Antimicrobial peptides have been found to affect the survival of many desirable 
targets, including gram positive and -negative bacteria, fungi, parasites, enveloped 
viruses and tumour cells (Brouwer et al., 2008). Their mode of function ranges from 
toxin neutralization to membrane destabilization, perforation, inhibition of metabolic 
processes and bacteriolysis (Brouwer et al., 2008).  
Apart from having antimicrobial activities, antimicrobial peptides are thought to have 
anti-tumour activity, aid in bone repair and play a role in angiogenesis (Figure 7A) 
(Cornish et al., 2004; Otvos, 2005; Steinstraesser et al., 2006; Brouwer et al., 2008). 
It is thought that the Shai-Matsuzaki-Huang (SMH) model primarily explains their 
general mode of function. The model proposes that the antimicrobial peptides form 
initial contact with the target microorganisms by electrostatic interactions. Where 
microorganisms are generally negatively charged on the surface, both due to the cell 
wall but also due to the existence of negatively charged lipids in the outer membrane 
leaflet, mammalian and plant cells only contain negatively charged lipids in the 
cytoplasmic leaflet and do not have a cell wall (Figure 7B) (Yang et al., 2000; Zasloff, 
2002). Thereby, due to their cationic nature antimicrobial peptides are attracted to 
the negatively charged surface of microorganisms (Brouwer et al., 2008). 
Following binding they exert a number of actions including displacement of lipids, 
alteration of the membrane structure and integrity and in some cases the 
antimicrobial peptides are internalised into the microorganism enabling interactions 
and neutralisation of important effector molecules within the cell (Yang et al., 2000; 
Zasloff, 2002). So the lethal effects on the membrane are thought to be caused by 




depolarisation of the microbial membrane, perforation of the membrane leading to 
cellular contents leaking out, membrane potential being disrupted as well as normal 
membrane functions being affected and induction of hydrolases that degrade the cell 
wall (Bierbaum and Sahl, 1985; Zasloff, 2002).  
Due to their primary action on the membrane of target cells it has been found that 
the presence of cholesterol in the membrane reduces antimicrobial peptide activity 
due to the stabilising nature of cholesterol on the lipid bilayer (Zasloff, 2002). 
Furthermore, increasing the ionic strength of the environment decreases the activity 
of antimicrobial peptides by reducing the electrostatic interactions on which they rely 
for binding. 
Interestingly, many antimicrobial peptides link the innate and the adaptive immune 
defence systems. A large group of antimicrobial peptides referred to as defensins 
are able to recruit peripheral CD4+ T-cells as well as attract immature dendritic cells 
to the site of infection via chemotaxis, both of which can help fight the impending 
infection (Zasloff, 2002). 
For these reasons antimicrobial peptides are being increasingly evaluated for 
potential therapeutic and diagnostic purposes. 
 
1.4.1.3 Therapeutic and diagnostic value 
Several advantages are associated with the use of antimicrobial peptides as 
targeting agents. They are small and thus they are able to penetrate the extra 
vascular tissue and thereby be transported to the site of infection. They also show 
rapid clearance from circulation and fast excretion (Blok et al., 1999; Lupetti et al., 




2002). Their ability to better bind to pathogens over host cells (Figure 7B), leukocytes 
and other cells may be the reason for their excellence in distinguishing between 
infection and sterile inflammation. Additionally, they distribute more uniformly than 
monoclonal antibodies (Blok et al, 1999; Welling et al., 2002).  
As the antimicrobial peptides were among the first lines of defence before the 
development of the adapted immune responses, this indicates that the structure and 
function of the antimicrobial peptides are excellent candidates for utilization in 
imaging as well as therapy (Brouwer et al., 2008). That they have existed for so long 
and still function efficiently, indicates difficulty in developing resistance for 
microorganisms, which is an important property of new antibiotics as well as imaging 
agents (Zasloff, 2002; Lupetti et al., 2003; Walker et al., 2007). Finally, they can be 
produced in vitro relatively easy and at low cost as opposed to larger proteins (Blok 
et al., 1999). 
A disadvantage may be the very low plasma half-life of the peptides due to 
proteolytic cleavage. This can, however, be circumvented by substituting L-amino 
acids, with their D equivalent (Maloy, 1995; Blok et al., 1999; Zasloff, 2002). 
Many antimicrobial peptides have been evaluated for the targeting abilities and as 
new potential carriers of therapeutic or imaging components to sites of infection. One 
of the most successful and analysed to date is the ubiquicidine peptide fragment 29-
41. 
 





Ubiquicidine (UBI) is a 6.6kDa, 59 residue, human antimicrobial peptide found in low 
concentration inside and primarily synthesised by activated macrophages and 
human airway epithelial cells. It is also found in the human colon mucosa (Brouwer 
et al., 2006). It is, opposed to the majority of antimicrobial peptides, primarily found 
intracellularly and only released into the extracellular space upon damage due to 
acute infection (Brouwer et al., 2006). 
The structural motifs of ubiquicidine has been analysed multiple times and the main 
observations of its secondary structure indicate the existence of multiple -helices 
and a single -sheet. Analysis showed that fragments encompassing segments of 
an α-helical domain displayed much greater antibacterial activity than fragments 
comprising -sheet (Brouwer et al., 2006).  
The structure appears to be primarily lipophilic with a single lipophobic domain 
(Browuer et al., 2006). Interestingly, it was found that where the number of lipophilic 
and cationic amino acids had no observed effect, the order of residues was very 
important (Welling, 2002; Brouwer et al., 2006). 
The mode of function is primarily through electrostatic interactions with negatively 
charged groups on the surface of bacterial cell wall and for this reason UBI has been 
shown to have a broad targeting potential across many microorganisms (Walker et 
al., 2007). 
It is the most utilised peptide in radiopharmaceuticals for treating infectious agents, 
however, it is primarily fragments of the peptide rather than the native full length 
peptide that are used (Lupetti et al., 2003; Walker et al., 2007; Brouwer et al., 2008). 




A very commonly used derivative of the ubiquicidine peptide is the fragment UBI 29-
41, however other variants such as UBI 18-35 and UBI 31-38 also exist (Welling et 
al., 2001; Welling et al., 2002; Brouwer et al., 2006; Walker et al., 2007). The motive 
for the success of UBI 29-41 is attributed to that over the other peptides generated 
from ubiquicidine, UBI 29-41 had a high Target-to-Non Target (T/NT) ratio, which in 
targeting is pivotal (Welling et al., 2000). 
The half-life in circulation has been estimated to be approximately 16 minutes and it 
is excreted from the system primarily through renal clearance with little accumulation 
in liver, spleen and other tissues (Welling et al., 2002). No accumulation was 
observed in thyroid glands or stomach which have previously been showed to be 
accumulation sites for free 99mTc, indicating a stable conjugate, which is of utmost 
importance (Welling et al., 2002; Meléndez-Alafort, 2004). Finally, it is not believed 
to be immunogenic in humans, which has been validated in several studies, and 
more importantly it has been shown to localise to sites of infection (Akhtar et al., 
2005; Melendez-Alafort et al., 2005; Brouwer et al., 2006; Brouwer et al., 2008).  
Apart from the above mentioned advantages of using ubiquicidine as a targeting 
agent it has one further benefit that made it particularly suited for this project; it 
contains a single tyrosine residue allowing the peptide to be single-site labelled with 
125I and will therefore ease the monitoring of the labelling process. 
 
1.4.2 Iodine radio nuclides 
125I was the radionuclide chosen as Auger emitting radionuclide, despite the low 
energy, for several reasons.  




Initially it was chosen not only due to it being an Auger emitter, which was the type 
of radiation that was the focus of the radiation study, but it also has a long half-life 
(60 days) which is well suited for the optimisation of the experimental setup.  It would 
also allow careful optimisation of the labelling process without compromising the 
potency of the nuclide significantly.  
Furthermore, 125I is very well characterised as a radionuclide and has previously 
shown to induce a greater decrease in survivability in a rodent cell line even 
compared to two β-emitting isotopes. This shows that despite its low energy 
compared to for example 123I, it is still capable of inducing toxic effects in the target 
cells (Bradley et al., 1975; Narra et al., 1992; Adelstein et al., 2003). However, toxic 
effects of extracellular 125I on a mammalian system appeared to be very low, even 
when the nuclide was internalised into the cytoplasm but not incorporated into the 
genome (Bradley et al., 1975, Adelstein et al., 2003). It was interesting to investigate 
whether the reduced size of microorganisms compared to mammalian cells would 
overcome this. 
Finally, the labelling chemistry of 125I allows easy replacement with an isotope such 
as 123I, which emits Auger electrons of higher eV, thereby having a longer range, for 
therapeutic purposes or 131I for imaging purposes (Adelstein et al., 2003). The 
labelling method chosen for conjugation was the Iodogen labelling method. 
 




1.4.2.1 Radio labelling 
Iodination using the Iodogen labelling method uses the chemical 1,3,4,6-tetrachloro-
3α, 6α- diphenylglycouril to iodinate the ortho positions of tyrosine residues (Figure 
8). This is considered a less invasive iodination process compared to the previously 
utilised method of 
chloramines-T (N-chloro-4-
methylbenzenesulfonamide) 
as well as more efficient 
(Fraker and Speck, 1978). 
Being solid-phase shows 
indications of being less 
invasive on the structural integrity, and thus the functionality as well as the binding 
affinity, of the labelled proteins (Fraker and Speck, 1978). 
The Iodogen labelling is interesting in that it creates positively charged free iodine 
by oxidisation of the negatively charged iodine. This allows the free iodine to undergo 
an electrophilic attack on the ortho position(s) on the tyrosine residues in a neutral 
pH range. Evidence has shown that at more alkaline levels (pH>9), the imidazole 
ring of histidine residues has shown to be labelled as well (Pierce® Pre-Coated 
Iodination Tubes protocol).  
The mildness of the Iodogen labelling method compared to the previously utilised 
chloramine-T even allows labelling of live cells and the survivability of the cells 
labelled with Iodogen was only very slightly affected (Fraker and Speck, 1978). 
A            B 
 
Figure 8 A) Structure of 1,3,4,6-tetrachloro-3α, 6α- 
diphenylgly-couril (web 3), B) Structure of tyrosine. 
 




The Iodogen labelling methods was particularly useful with UBI 29-41 due to the 
existence of a single tyrosine residue.  
One disadvantage of using antimicrobial peptides and UBI 29-41for targeting is the 
very unspecific nature of the binding. If more specificity is required one of the most 
analysed and versatile targeting agents are antibodies.  
 
1.4.3 Antibodies 
1.4.3.1 Structure and function 
In monomeric form antibodies are large proteins composed of two heavy chains and 
two light-chains (Janeway et al., 2005). 
There are 5 isotypes of antibodies in vertebrates designated IgA, IgD, IgE, IgG and 
IgM. The size of the immunoglobulin varies between the subtypes with IgG being the 
smallest of approximately 150 kDa and the largest being IgM which forms both penta 
and hexamers of 950 kDa and 1150 kDa in total, respectively (Weisser and Hall, 
2009).The size of the antibodies is closely related to the primary function of each 
subtype. IgGs are by far the most common antibody comprising approximately 85% 
of antibodies in the blood and are the primary antibody generated when fighting 
infections (Weisser and Hall, 2009). IgGs can further be divided into 4 distinct 
isotypes: IgG1, IgG2, IgG3 and IgG4, where IgG1 and IgG3 has the most profound 
effector functions with IgG1 being the most efficient (Janeway et al., 2005; Weisser 
and Hall, 2009). IgMs, which are the largest are primarily involved in complement 
system activation. They are the first antibodies to be secreted during an infection 
and have, compared to the other subtypes, a relatively low affinity but compensates 




by forming pentamers (Janeway et al., 2005). IgE is slightly larger than IgG at 190 
kDa and is primarily involved in mast cell activation and release of histamine making 
this the primary effector against parasitic infection (Janeway et al., 2005). Finally, 
IgA is primarily secreted to epithelial surfaces and are for that reason primarily 
involved in antigen neutralisation as neither complement system or phagocytic cells 
are present in this environment (Janeway et al., 2005). The function of IgD, the final 
isotype of antibodies, is largely unknown. IgGs are however by far the most utilised 
antibody for therapeutic purposes as they are the primary antibody able to diffuse 
into the extravascular spaces and are potent in not only the neutralisation and 
opsonisation of antigens but also in sensitising the target for NK (Natural Killer cell) 
killing and complement system activation (Janeway et al., 2005).  
The antibody structure can be divided into two sub-domains: the Fc and the Fab 
domain (Figure 9). The Fab domain is important in antigen recognition and binding 
while the Fc region is important in transmitting the antigen binding to other cells in 
the immune system e.g. via binding to Fc receptors present on the surface of 
phagocytic cells (Janeway et al., 2005; Weisser and Hall, 2009). 





The antigen recognition site is created by a combination of the heavy- and light chain 
variable regions. The variable region in the heavy chain is composed by a 
recombination of variable (V), diversity (D) and junctional (J) gene segments. The 
light chain variable region is created by recombination of V and J gene segments 
(Janeway et al., 2005; Weisser and Hall, 2009). These variable domains come 
together to form a unique 3-dimensional pattern that is complementary to the antigen 
they recognise. For this reason the hyper variable regions are also referred to as the 
complementary determining region (CDR) of the antibody.  
 
 
Figure 9 Structural overview of antibody structure and components 
(A) Ribbon diagram of an IgG antibody solved by x-ray crystallography. (B) Shows a schematic 
representation of the ribbon diagram in (A) displaying the various immunoglobular regions of the 
antibody as well as the positioning of carbohydrates in the IgG molecule, the position of hinge 
region as well as the disulphide bridges. (C) Shows a stylized overview of the antibody and the 
positioning of the variable antigen binding region (red) and the conserved region (blue). (D)Depicts 
the positioning of the light chain (yellow) and heavy chain (green). (E)Shows a schematic 
representation of a single cleavage of the antibody by the protease papain (red arrow), which 
releases the fragments Fab and Fc. All images modified from Janeway et al., 2005. 
 
 




The general mode of antigen recognition is based on the complementarity in 
structure found on the surface of antigens. The binding itself is based on non-
covalent interactions such as electrostatic interactions, hydrogen bonds, Van der 
Waals forces and hydrophobic forces. So although these interactions are rather 
weak on their own, the better the complementary structure found on the antibody 
and the better the fit, the more interactions take place thereby increasing the overall 
binding affinity. 
Although the variable domains of 
heavy and light chains are the most 
versatile parts of an antibody, the 
diversity varies greatly as can be seen 
in Figure 10.  
The hyper variable domains are 
primarily responsible for the antigen 
recognition whereas the more 
conserved regions, referred to as 
framework regions (FR), are important 
in the stabilisation and correct folding 
of the antigen-recognising region of 
the antibody. This allows the hyper 
variable domains to be exposed on 
the surface of the protein for easier interaction with the antigen. For this reason the 
binding affinity of antibodies is often affected when scFvs are created.  
 
Figure 10 Schematic representation of the 
CDR- and FR regions 
 The CDR regions of the variable domains are 
interspersed in between the framework regions. 
The framework regions ensure correct folding, 
enabling and ensuring the assembly of the CDR 
regions into an antigen recognising region 
(Janeway et al., 2005) 
 
 




Of the three hyper variable domains, CDR3 (Complementary Determining Region 3) 
is the most variable and of the heavy and light chain domains it is only in CDR3 of 
the heavy chain in which hyper mutations take place. 
There are 3 CDRs per variable domain giving a total of 6 CDRs. Interestingly each 
CDR contribute differently to the overall antigen specificity accordingly: CDR3H 
(29%) > CDR2H (23%) > CDR3L (21%) > CDR1H (10%) > CDR1L (9%) > CDR2L 
(4%). Finally, the framework contributes approximately 4% to the binding affinity 
(Wilson and Stanfield, 1994; Weisser and Hall, 2009).  
Although there are a limited number of gene segments of each type, the 
recombination in itself also introduces variability. In addition, the antibodies undergo 
somatic hyper mutation, which introduces point-mutations, thus increasing the 
variability. This consequently results in virtually unlimited possibilities with regard to 
antibody design (Janeway et al., 2005).  
So due to the amazing versatility of the antibodies and the ease with they can be 
manipulated and designed to be targeted to virtually any target makes them very 
useful in both therapeutic and diagnostic settings. 
 
1.4.3.2 Therapeutic and diagnostic value 
Although monoclonal antibodies appear to be the ideal targeting agents there are 
several factors that may pose problems for the generation of new pharmaceuticals. 
These factors include immunogenicity, cross-reactivity with non-target-associated 
antigens, loss of antigen-binding following conjugation and limited ability of the 
antibody to access the inflamed area (Blok et al., 1999). Finally, they have a slow 




blood clearance rate (Goldsmith and Vallabhajosula, 2009). All these factors are 
especially important with regard to radio imaging and radio therapy. The long 
retention time reduces the imaging contrast and with regards to therapy, they have 
a tendency to have a non-uniform bio distribution and more importantly the long 
retention time could cause unwanted side-effects by extending non-target tissue 
exposure (Weisser and Hall, 2009). However, further engineering upon antibodies 
has generated new antigen recognition moieties, which have shown potential for 
both imaging and therapeutic application. 
 
1.4.3.3 Single chain variable fragments (scFv) 
Due to the large retention time of conventional antibodies, much research has been 
put into the separation of the antigen recognising part of the antibody to free the 
antibody of the Fc region.  
Many recombinant antibody fragments (rAb) have been generated including scFvs, 
dia-, tria- and tetrabodies, minibodies and bi- and multispecific scFvs (Weisser and 
Hall, 2009). ScFvs are however, the most researched and evaluated antibody 
fragment and is one the most advancing classes of therapeutic molecules (Weisser 
and Hall, 2009). 
ScFvs are antibody fragments composed of the VH and VL chains connected by a 
hydrophilic flexible linker consisting of 10-25 residues. Most commonly they have a 
high content of glycine, which due its flexibility allows the proper folding of the scFv 
and therefore is less likely to impact the binding affinity, which is often is seen 
(Desplancq et al., 1994; Weisser and Hall, 2009). However, the fragments can also 




be connected non-covalently (Fv), by a disulphide bond (dsFv) or both disulphide 
bond and linker (sc-dsFv), however when neither linker or disulphide bond are 
present the scFv shows very low stability and has a large tendency to dissociate at 
low concentrations (Glockshuber et al., 1990; Wörn and Plückthun, 2001; Weisser 
and Hall, 2009). 
The length of the linker has an impact on the aggregation of the molecules, whereas 
shorter linkers of 0-12 aa have a greater tendency to form dimers and trimers 
(Todorovska et al., 2001; Weisser and Hall, 2009). Linkers of these lengths prevent 
the scFv from folding properly, which promotes association with a second scFv to 
form dimers and even smaller linkers force the formation of trimers or even tetramers 
(Holliger et al., 1993; Illiades et al., 1997; Dolezal et al., 2003; Weisser and Hall, 
2009). This and other examples of recombinant antibodies can be seen in Figure 11. 
 
 
Figure 11 Examples of recombinant antibodies (rAb). 
(A) Conventional antibody. White arrow depicts antigen recognition site. Designations and colour-
codes are the same through the various representations (B) scFv-Fc, (C) conventional antibody 
with deleted CH2-domain (D) Minibody, scFv-CH3 (E) small immunoprotein (SIP). (F) ScFv (VH-
linker-VL), linker behind (G) diabody (H) streptavidin-based tetrameric molecule, scFv linked to 








.A big problem when designing scFvs from existing hybridoma fusion cell lines, 
expressing antibodies towards a desirable target, is the existence of aberrant kappa 
light chains that may be transcribed (Carroll et al., 1988). Aberrant kappa light chains 
are thought to be a remnant from the parental MOPC-21 tumour which is used for 
all standard fusion hybridoma cell lines (Carroll et al., 1998). The transcript does not 
result in a functional light chain for which reason it is vital to sequence and analyse 
the purified mRNA for transcriptional products that fulfil the structural motifs required 
that will result in functional light chains. The aberrant light chains can be particularly 
problematic by interfering with sequencing; however cloning into separate vectors 
will enable them to be distinguishable. Only one product from each hybridoma will 
result in a functional light chain (Carroll et al., 1988). 
When designing scFvs two conformations exist: VH-linker-VL and VL-linker-VH, with 
the former being more common. Expression efficiency, stability and antigen 
recognition all vary between the two constructs with the latter having greater binding 
activity (Desplancq et al., 1994; Weisser and Hall, 2009). 
The most common template for scFv is the isotype IgG1 due to it being the antibody 
with greatest effector functions. Furthermore, it has shown great reliability and has 
desirable physical properties for further engineering (Desjarlais, 2007; Weisser and 
Hall, 2009).  
As scFvs are much smaller than the conventional antibodies, they have a shorter 
half-life as they are below the 65 kDa cut-off size for filtration in the kidneys (Weisser 
and Hall, 2009). The average circulation half-life is therefore around 3.6 hours 
compared to 18-36 hours for a full size antibody (Khazaeli et al., 1991; Powers et 




al., 2001; Weisser and Hall, 2009). As they furthermore do not comprise the Fc 
region, Fc mediated recycling is not possible (Weisser and Hall, 2009). Thus, scFvs 
have a much shorter plasma half-life than the original antibody, which increases their 
applicability, especially with regard to imaging (Milenic et al., 2004). However, a short 
circulation half-life is not always beneficial as for example in many therapeutic 
settings. If a prolonged circulation half-life is required, the scFvs could be modified 
by either PEGylation, by including heavy-chain Fc fragments, by associating the Ab 
fragments with long-circulating serum proteins such as albumin or by including the 
Fc region both with and without the CH2 domain, that is primarily involved in the Fc 
receptor binding (Milenic et al., 2004; Weisser and Hall, 2009). Incorporation of 
cysteines has been shown to improve stability (Desplancq et al., 1994). 
As scFvs on their own have little therapeutic value they are often evaluated for 
conjugation purposes for either imaging or therapeutic settings. 
 
1.4.3.3.1 ScFv conjugates 
Due to their much higher clearance rate and great adaptability, much research has 
been put into the development of scFvs conjugated with either radioactive isotopes 
or toxins for targeted delivery of imaging or therapeutic agents to the sites of infection 
or tumours.  ScFvs have particularly garnered considerable attention in the 
development of anti-tumour drugs as they not only have a greater tissue penetration 
rate than traditional antibodies and therefore distribute more uniformly in tumours, 
but due to the targeting they are also more capable of binding to metastatic tumour 
sites. This also means both visualisation of the extent of the disease and monitoring 




of the progress of the therapy can be performed but also it more fundamentally aids 
in the eradication of the problematic metastases. 
ScFvs are particularly useful in combating infectious diseases. Whereas tumours 
express antigens that are often indistinguishable from non-tumour cells, infectious 
agents are antigenically very different from mammalian cells easing the design of 
novel targeting agents. Furthermore, scFvs can be modified to include segments of 
the Fc region, which has shown to re-introduce some of the immunogenic properties 
of the native antibody, such as promotion of opsonisation and complement system 
activation, further aiding in the eradication of the infectious agent alongside the 
effects of the conjugated toxic agent (Weisser and Hall, 2009). 
However, one issue when utilising recombinant antibodies for therapeutic or imaging 
purposes is immunogenicity. Most scFvs are expressed in non-mammalian 
expression systems and this can have an effect on the antigenicity profile of the 
recombinant targeting agent (Weisser and Hall, 2009). For this reason it is of vital 
importance to carefully choose the correct expression system as this can affect the 












1.5 Protein expression systems 
Once the targeting agent has been chosen and engineered it is often of vital 
importance to express the protein in the right expression system.  
There are several factors that are important to consider when choosing expression 
systems: 
1. Expression rate 
2. Expression stability 
3. Protein yield 
4. Post-translational modifications 
5. Toxicity of the product to the factory cells 
6. Ease of system 
7. Cost of large-scale manufacturing 
All of these factors need to also be included in the design of the vector containing 
the product, as different expression systems potentially require, for example, 
optimisations of promoter regions or codon optimisation (Casali, 2003). 
There are essentially 4 types of expression systems: bacterial, yeast, mammalian 
and plant expression systems, which will all be evaluated briefly below (Table 5). 
 
1.5.1 Bacterial expression systems 
Bacterial expression systems has many advantages including fast expression rate, 
high yields and has non-complex promoter regions associated with protein 
expression (Weisser and Hall, 2009). For this reason it is also one of the most 
commonly used methods for scFv production (Casali, 2003; Leong and Chen, 2008). 















Bacterial Up to g/L No Easy Low 





Mammalian mg/L Yes Complex Expensive 
Plant >1% of total 
soluble 
protein 
Yes Easy Expensive set-up- 
then low cost 
Table 5 Overview of various recombinant protein expression systems. 
 
There are, however, also many disadvantages depending on the protein that needs 
to be expressed. One of the biggest problems with bacterial expression systems is 
the lack of post-translational modifications. These are particularly important when 
expressing antibodies and some antibody derivatives such as glycosylations and 
proper folding are of vital importance for not only the function of the molecule but 
also for the immunogenicity of the product (Jefferis, 2005).  This may affect the use 
of the product in vivo, which is the eventual end-product. Most glycosylations are 
found in the Fc region of antibodies, however, 15-20% of antibodies have been found 
to have N-linked glycosylations in the Fab region (Youings et al., 1996; Jefferis, 




2005).  Therefore, a glycosylation profile has to be established prior to expression in 
order to evaluate the potential consequences of choosing a bacterial expression 
system. 
Expression of recombinant proteins in bacterial expression systems can happen via 
three routes that can all have effects on the structural integrity of the manufactured 
protein.  
 
The three routes are:  
1. Cytoplasmic secretion 
2. Periplasmic secretion 
3. Inclusion body formation in the cytoplasm 
 
The big problem with cytoplasmic expression of proteins is the very reducing 
environment often causing misfolding or the generation of insoluble inclusion bodies 
(Leong and Chen, 2008). However, it has been shown that by slight manipulation of 
the amino acid sequence, correct folding can be induced and even result in very high 
yields with as much as 3.1 g/L having been monitored (Martineau et al., 1998; Leong 
and Chen, 2008). Generally, secretion into the periplasmic space allows for better 
probability of correct protein folding and disulphide bond formation due to the more 
oxidising environment compared to the cytoplasm (Kipriyanov et al., 1997; Chen et 
al., 2004; Leong and Chen, 2008). Although inclusion bodies seem to be an 
undesirable result, it can be beneficial for the protein production if the generated 
engineered proteins are either toxic to the bacterial cells or proteolytically unstable 




(Leong and Chen, 2008). However, the inclusion bodies would require further in vitro 
refolding in order to result in functional products (Tai et al., 1990; Cao, et al., 2005; 
Leong and Chen, 2008). As a consequence the ability of the protein to be in vitro 
refolded has a direct impact on the final yield and for this reason the refolding step 
has to be carefully optimised for each product (Leong and Chen, 2008). 
One of the most common bacterial expression systems is E. coli, which has the 
advantage that it is very easy to manipulate and generally has potential to generate 
high yields, up to as much as several grams per litre culture (Martineau et al., 1998; 
Chen et al., 2004; Weisser and Hall, 2009). Furthermore, as it one of the most 
characterised microorganisms with a well-established knowledge of basic cellular 
processes; this allows easy genetic manipulation to attempt improvement of quality 
and yield of the engineered protein (Casali, 2003; Leong and Chen, 2008). 
Furthermore, bacterial expression systems due to their simple culturing processes 
and inexpensive fermentation costs are able to generate abundant and cheap 
products (Leong and Chen, 2008). They are however, not capable of post-
translational modifications, so if the desired product has a complex glycosylation 
profile or structure requiring disulphide bridges, eukaryote systems are required. 
 
1.5.2 Mammalian expression systems 
Mammalian expression systems have one advantage over bacterial expression 
systems, which is the ability to implement the correct post-translational 
modifications. This makes the end product more employable in vivo. 




However, one of the major drawbacks of mammalian systems is the complexity of 
use and the lower yields compared to bacterial systems. Nonetheless,   
concentrations comparable to yields attained in the yeast system P. pastoris have 
been achieved, between 1 and 10 mg/L (Braren et al., 2007; Leong and Chen, 2008). 
Mammalian system do however have more disadvantages compared to yeast 
systems including high large-scale running cost and complexity of the system, both 
of which increase the end price of the product, which can easily be avoided using 
other systems (Streatfield, 2007; Leong and Chen, 2008). 
A further disadvantage of mammalian systems over for example bacterial expression 
systems is the complexity of the cellular pathways. Where bacteria are fairly easy to 
manipulate to increase yields, mammalian cells are inherently more complex (Leong 
and Chen, 2008). 
Mammalian expression systems are generally considered more appropriate when 
dealing with complex proteins as they normally require a more complex folding and 
post-translational modifications as glycosylations, however as scFvs rarely contain 
glycosylations and are fairly non-complex proteins with regards to folding. Hence, 
mammalian systems are rarely considered a viable expression system over bacterial 
or yeast systems (Leong and Chen, 2008). 
However, if a complex eukaryotic system is required for protein expression, using 
the relatively new plant expression system can to some extent, circumvent the cost. 
 




1.5.3 Plant cell expression systems 
Plants as expression systems are relatively undeveloped; however, there are 
implications for future replacement of mammalian expression systems for large-
scale protein production.  
As plant cells are eukaryotic cells, they are, as mammalian cells, capable of complex 
post-translational protein modifications and are capable of complex protein folding. 
There have already been reports of successful scFv production in plants (Streatfield, 
2007; Leong and Chen, 2008). However, the yields are still considered sub-optimal 
for large-scale productions with only as little as 1% of the total soluble protein 
extracted. 
With regards to running costs, plant systems are only considered expensive in the 
start-up period. As it takes a while for the plants to grow and attain maturity, for the 
initial period the protein production is very low, however when the plant has fully 
grown, it is the very easy maintenance, which is a feature inherent to plants systems. 
Furthermore, one of the advantages is that all the harvesting techniques are already 
well researched. So when established, plant recombinant protein expression running 
costs are very low making this one of the primary advantages. 
Furthermore, protein pharmaceuticals expressed in plant systems are considered 
much safer than using native or recombinant animal cell lines (Streatfield, 2007). 
Plants are particularly considered interesting for the development of edible vaccines, 
particularly because protein purification is not required, further reducing the costs 
(Streatfield and Howard, 2003; Streatfield, 2007). 




However, there are still many hurdles such as batch-to-batch variability and 
unoptimised product extraction that needs to be overcome before plant systems can 
be considered a real competitor to mammalian systems (Streatfield, 2007; Leong 
and Chen, 2008). For this reason plant systems are for now not viable for large-scale 
production, but have great implications for the future in replacing mammalian 
systems for complex protein expression. For now the most utilised eukaryotic system 
is yeast. 
 
1.5.4 Yeast expression systems 
Yeast expression systems can to some extent be considered halfway between 
mammalian and bacterial expression systems. They are able to perform most post-
translational modifications as a lower eukaryote but are still able to give fairly high 
yields (approximately 5 times higher) when compared to  mammalian expression 
systems, and are reasonably low cost in large-scale manufacturing when compared 
to mammalian cells (Gasser and Mattanovich, 2007; Leong and Chen, 2008). 
As mentioned, the advantages of using a yeast strain over a bacterial strain are 
important when considering molecules that are dependent on post-translational 
modifications. As yeast are  eukaryotic they have  a higher degree of similarity to 
mammalian cells than bacteria and are able to perform post-translational 
modifications, as for example glycosylations, disulphide bond formation and 
proteolytic processing, which are executed by mammalian cell lines (Cereghino et 
al., 2002). However, although yeast is capable of glycosylation, they are not always 
capable of replicating the glycosylation profile generated by mammalian cells. S. 




cerevisiae for example has a higher glycosylation rate than P. pastoris, sometimes 
resulting in hyperglycosylation, which may render the product useless due to 
generated antigenicity (Cereghino et al., 2002; Porro and Mattanovich, 2004; Braren 
et al., 2007; Streatfield, 2007; Leong and Chen, 2008). 
Yeast expression systems are easily adaptable on a genetic level, and are capable 
of high levels of expression of proteins both intracellularly as well as extracellularly 
(Cereghino et al., 2002). 
Additionally, the purity of yeast product appears to be greater than that of both 
bacterial and mammalian systems, where toxic pyrogens can be found in E. coli 
product and potential oncogenic and viral nucleic acids from mammalian products 
(Cregg et al., 1993; Porro and Mattanovich, 2004; Leong and Chen, 2008). 
One of the problems with yeast expression systems is the great variance in product 
yields, however more research is needed to understand the intracellular processes 
that inhibit expression or secretion that may be present, which eventually can affect 
protein production (Huang and Shusta, 2005; Leong and Chen, 2008).  
The most common yeast expression systems for scFv production are 
Saccharomyces cerevisiae and Pichia pastoris, the latter of which is the expression 
system utilised in this project. 
 
1.5.4.1 Pichia expression system 
Pichia pastoris is a methylotrophic yeast, capable of metabolising methanol in small 
doses, surviving on methanol as the carbon source (Bora, 2012). 




Foreign gene expression is driven by the alcohol oxidase I gene (AOX1) promoter, 
which is considered one of the strongest promoters in the yeast species (Cereghino 
et al., 2002; Porro and Mattanovich, 2004; Bora, 2012). Technically there exist two 
genes encoding alcohol oxidase, AOX1 and AOX2, however AOX1 is vastly 
overrepresented and can be expressed to levels of more than 30% of total soluble 
protein in methanol fed cultures (Higgins and Cregg, 1998).  
When only glucose is present as carbon source, the promoter is repressed and there 
is hardly any gene expression, however, when the glucose is replaced by methanol, 
promoter activity is increased 1000 fold, thereby initiating foreign gene expression 
(Higgins and Cregg, 1998; Cereghino et al., 2002). For this reason it is important to 
rid the cells of any traces of glycerol when starting protein expression, otherwise the 
glycerol will greatly inhibit the expression rate. However, in some cases a gradual 
methanol feeding may be implemented if cell viability is vital, as methanol 
introduction greatly decreases the growth rate of the organism and concentrations 
that exceed 5g/L are generally considered toxic (Cereghino et al., 2002; Bora, 2012). 
The initial step of methanol oxidation by alcohol oxidase (AOX) results in the 
formation of formaldehyde and hydrogen peroxide. Due to the toxicity of hydrogen 
peroxide, the initial step in methanol metabolism is performed in the so-called 
peroxisome where the hydrogen peroxide is kept away from the rest of the cell 
(Higgins and Cregg, 1998). 
It is possible to get a secreted production of protein in P. pastoris. This is done by 
including the α-mating factor (MF-α) prepro signal immediately prior to the gene of 
interest (GOI) in the plasmid (Higgins and Cregg, 1998). This allows the protein to 




be transported out of the cells following post-translational modifications. The MF-α 
is translated as a N-terminal extension which acts as a secretion signal peptide 
allowing the peptide to be introduced to the secretory pathway and which, following 
signal sequence removal, cleaved by Kex2 proteinase as well as 2 Glu-Ala 
dipeptides by the Ste13 dipeptidase in the Golgi-apparatus from the final secreted 
protein (Higgins and Cregg, 1998; Cereghino et al., 2002, Porro and Mattanovich, 
2004). The dipeptidase does not appear to be entirely restricted to that sequence, 
however, which has previously resulted in a non-homogenous protein mixture, which 
could have implication for downstream pharmaceutical applications (Porro and 
Mattanovich, 2004).  
Although the signal sequence is inserted immediately prior to the GOI the efficiency 
of export of the final protein varies greatly (Cereghino et al., 2002). It has been found 
that the exchange of the signal sequence from other yeast strains has proven to be 
better suited for some proteins. The reason for this is mostly unclear; however there 
are indications that cis-acting elements in the signal sequence and the GOI might 
play a role as well as the structural nature of the protein. However, being that the 
exact reason for this difference in secretion efficiency is unknown it is mostly down 
to trial and error to find the right signal sequence. The S. cerevisiae α-mating factor 
prepro signal sequence, however, remains to be the most widely used sequence 
and is the one utilised in the plasmid that is used for the expression of the generated 
anti-LAM scFv (Porro and Mattanovich, 2004). 
Expression levels of P. pastoris has several times shown to be able to compete with 
bacterial systems in protein yields with up to as much as 12 g/L produced and 




routinely gives protein yields of between 5-40% of total protein in the cells (Bora, 
2012). 
Furthermore, P. pastoris is a fairly tolerant species that can grow under very variable 
conditions as pH range of 3-7, temperature range of 15-32ºC and Dissolved Oxygen 
(DO) level range of 5-40%, which allows much room for optimisation of growth 
conditions (Bora, 2012).  
The fact that P. pastoris preferably grows under respiratory conditions makes it more 
useful for large-scale manufacturing compared to organisms that preferably grow 
under fermenting conditions, as higher cell densities can be achieved and hence 
higher protein concentrations (Higgins and Cregg, 1998). In fact, oxygen is an 
important factor in methanol metabolism and oxygen is for this reason a rate-limiting 
step for recombinant protein expression. For this reason, growing P. pastoris 
cultures in a fermenter generally generates higher protein concentrations, as it is 
much easier to observe and manipulate the oxygen levels to the optimal levels 
(Higgins and Cregg, 1998). 
Furthermore, as P. pastoris preferably grows under respiratory conditions rather than 
fermenting conditions, there are fewer problems with the accumulation of toxic end 
products as ethanol and acetic acid with high cell density, as seen in organisms that 
preferably grow and express foreign proteins under fermenting conditions 
(Cereghino et al., 2002).  
Although P. pastoris is capable of glycosylations, this does not mean that it is 
completely identical to the mammalian product. There are two types of 
glycosylations, O- and N- linked. Although P. pastoris is capable of both it differs 




from the mammalian counterpart. In mammalian systems O-linked glycosylations 
comprise a variety of carbohydrates, including N-acetylgalactosamine, galactose 
and sialic acid. O-linked glycosylations in yeast is composed solely of mannose 
residues. Furthermore, it has been found that although the human counterpart of the 
human IGF-1 protein there existed no O-linked glycosylations, approximately 15% 
was found glycosylated when expressed in P. pastoris (Higgins and Cregg, 1998). 
Furthermore, the N-linked glycosylations differ as well. The oligosaccharide unit in 
mammalian cells is trimmed to a length of 5-6 mannose components whereas lower 
eukaryotes generally have longer chains containing 8-11 mannose sugars (Higgins 
and Cregg, 1998). The length is hypothesised to not only increase antigenicity of the 
end-product but also potentially interfere with the proper folding and/or function of 
the protein (Higgins and Cregg, 1998). This clearly demonstrates that although P. 
pastoris is capable of the same post-translational modifications as mammalian cells, 
it does not mean that the end-product necessarily is identical to the original protein. 
Another substantial problem with P. pastoris expression is the proteolytic 
degradation, especially by vacuolar proteases, due to stress responses, irregular 
growth rates, imbalances in the media and insufficient feeding (Zhang et al., 2007; 
Bora, 2012). Several modifications can be made in an attempt to reduce proteolytic 
degradation. By supplementing the media with amino-acid rich supplements such as 
peptone or casamino acid it is to some extent possible to reduce degradation, as the 
supplements act as decoys for the proteases allowing less proteases to degrade the 
expressed product. Furthermore, by changing the pH it is possible to reduce the 
proteolytic activity of the enzymes without affecting the growth of the organism. 




Finally, strains with protease mutations have been developed, in an attempt to 
increase protein yields and enhance stability of the product (Gleeson et al., 1998; 
Higgins and Cregg, 1998). This includes Pichia pink (P. pink), which is the organism 
utilised for scFv expression in this project. 
 
1.5.4.1.1 Pichia pink 
P. pink differs from the original P. pastoris cell line in several ways. First and 
foremost, several mutations have been introduced to the P. pink strain compared to 
the P. pastoris.  The first mutation is the knock-out mutation of the ade2 gene, which 
encodes phosphoribosylaminoimidazolecarboxylase, which is involved in the 6th 
step of purine biosynthesis. This gene is included in the pPinkα-HC vector utilised 
as the expression vector of the anti-LAM scFv. This allows the use of adenine-free 
media as the base for selection. 
The lack of ade2 is also the reason for the pink colour of the colonies of P. pink. This 
is caused by the accumulation of purine precursors. This is also why a colour shift 
from pink to white is seen in transformed P. pink, white being transformed, thus not 
accumulating the purine precursor. There are furthermore 4 subtypes of P. pink as 









































Table 6 Overview of knock-outs mutant variants of Pichia pink strains.  
 
As protease activity on the protein of interest can have a major impact on the 
expression levels, 4 variants of protease knock outs are available. Prb1 encodes the 
vacuolar proteinase B and pep4 encodes the proteinase A, an aspartyl protease, 
which among other things is involved in the activation of other vacuolar proteases 
such as proteinase B and carboxypeptidase Y (Gleeson et al., 1998). 
One of the side-effects of the protease knock out is the growth rate of the organism. 
The more knock out mutations the slower the growth rate. Furthermore, the knock-
out-mutants are generally weaker than the wt (wildtype) strain and require extra care 
in both storage and growth (Gleeson et al., 1998).  For this reason the knock out 








1.6 Rationale for this thesis 
In the light of the increasing emergence of microbial strains resistant to both first line 
and second line antibiotics it is becoming increasingly important to find new ways of 
sterilising these agents. Radioactive isotopes labelled to antimicrobial peptides have 
already been evaluated for their imaging potential and Auger electrons have been 
tested for their ability to destroy cancerous cell lines with limited success. It was 
interesting to combine these methods by conjugating Auger electrons to 
antimicrobial peptides to evaluate if this might be more advantageous compared to 
cancerous cell lines due to the reduced size of microorganisms. The use of 
antimicrobial peptides would enable the analysis to be executed on a range of model 
organisms due to the relatively non-specific binding. 
To alter the strategy a new specific targeting agent was designed. As a target M. 
tuberculosis was chosen which, being an intracellular bacterium is not only 
complicated to treat but also to diagnose. Therefore, there is a great need for new 
diagnostic tools and/or therapeutic agents. As scFvs are the isolated variable 
domains of monoclonal antibodies they are a good candidate as novel targeting 
agent. Due to the expressed nature and being abundant in M. tuberculosis cell wall, 
LAM seemed a good candidate as antigen to the scFv. 
Since therapeutic use would require large concentrations, P. pink was deemed a 
good choice for expression system as this would also allow any potential post-
translational modifications mimicking mammalian expression. 
 




1.6.1 Specific Aims 
Given the above, this thesis has the following specific aims: 
 
Chapter 3 - To optimise labelling of an anti-microbial peptide with radioactive iodine  
Chapter 4 - To evaluate the toxic effects of this radio labelled antimicrobial peptide 
on a range of model organisms 
Chapter 5 - To design in silico a targeted construct – i.e. an scFv – against LAM  











2 Materials and methods 
2.1 Materials 
Unless otherwise stated, all bulk chemicals were analytical grade and purchased 
from Fischer Scientific Ltd, Loughborough, Leicestershire, UK and all fine chemicals 
were purchased from Sigma-Aldrich, Poole, Dorset, UK 
Ubiquicidine 29-41 stock 
Material Provider/recipe 
Ubiquicidine 29-41 Alta Bioscience, Birmingham, UK 




5 mCi Na125I in 10-5 M NaOH 
pH 8-11 
Perkin Elmer, Waltham, MA, USA 
Tris Iodination Buffer pH 7.5 25 mM Tris HCl. 0.4 M NaCl 
Pierce Pre-Coated Iodination 
Tubes 
Thermo Fisher Scientific Inc., Waltham, MA, USA 
 
Instant Thin Layer Chromatography (ITLC) analysis 
Material Recipe 
ITLC Running Buffer 85 % Methanol, trace of Coomassie stain solution 








S. aureus NCIMB 8625  
C. albicans sc5314  
S. cerevisiae BY4741  
 




Bacterial and yeast maintenance 
Material Supplier 
BactoTM Peptone BD Biosciences, Cowley, Oxfordshire, UK 
DifcoTM Yeast Nitrogen Base 
w/o Amino Acids 
BD Biosciences, Cowley, Oxfordshire, UK 
Yeast extract Oxoid, Basingstoke, Hampshire, UK 
 
Media Concentration 
Lysogeny Broth  1% Bacto Peptone 
0.5% Yeast Extract 
1% NaCl 
YPD 2% Bacto Peptone  
1% Yeast extract 
2% Glucose 




Hybridoma CS-35 Maintenance 
Material Concentration 
Foetal Calf Serum media 10% Foetal Calf Serum 
DMEM 
CS-35 anti-LAM IgG3 
hybridoma cell line 
BEI resources, Manassas, VA, USA 
 
Antibody expression analysis 
SDS-PAGE 
Material Recipe/supplier 
NuPAGE LDS 4x sample buffer Invitrogen, Paisley, Scotland, UK 
Kaleidoscope pre-stained 
molecular weight standards 
Bio-Rad Laboratories, Hercules, CA, USA 
20x MES SDS Running Buffer 
pH 7.7 
50 mM MES, 50 mM Tris Base. 0.1 % SDS, 1 mM 
EDTA 
Rabbit anti-Mouse IgG 
Secondary Antibody, HRP 
conjugate 
Thermo Fisher Scientific Inc., Waltham, MA, USA 





Material  Concentration 
Bjerrum and Schafer-Nielsen 48 mM Tris Base, 39 mM Glycine, 20 % 
Methanol, 3.75x10-4% SDS 
Bio-Rad trans-blot transfer 
medium, 0.45 μm 
Bio-Rad Laboratories, Hercules, CA, USA 
Blocking Buffer 1x PBS 
5% Marvel Original Dried Skimmed Milk 
6x His MAb/HRP conjugate TAKARA BIO/Clontech, St. Germaine-en-Laye, 
France 
Washing buffer 1xPBS 
0.2% Tween 
Super Signal West Pico 
Chemiluminescent Substrate 
Thermo Fisher Scientific Inc., Waltham, MA, 
USA 
Amersham Hyperfilm ECL  GE Healthcare, Buckinghamshire, UK 
 
Gel Staining and drying 
Material  Recipe 
Coomassie Blue Staining 
solution 
0.25% Coomassie Brilliant Blue R250, 50 % 
Methanol, 10 % Acetic acid 
Destain solution 7.5 % Acetic acid, 5 % Methanol 
SilverXpress Silver Staining Kit Invitrogen, Paisley, Scotland, UK 
Gel Drying solution 40 % Methanol, 7.5 % Acetic Acid, 10 % Glycerol 
Gel Drying Film Promega, Madison, WI, USA 
 
VH and VL segment isolation 
Materials Provider 
Straight A's mRNA Isolation 
System 
Novagen, Darmstadt, Germany 
First Strand cDNA Synthesis Novagen, Darmstadt, Germany 
Ig Primer Set kit Novagen, Darmstadt, Germany 









Transformation of pPinkα-HC anti-LAM into XL-1 Blue Competent cells  
Material Recipe/provider 
XL1-Blue Competent Cells Agilent Technologies Inc., Santa Clara, CA, USA 
SOB 2 % tryptone, 0.5 % Yeast extract, 0.05 % NaCl, 
1% 1M MgCl2(filter sterilised and added after 
autoclaving) 
SOC 1 % filter sterilised 2 M glucose 
SOB medium 
LB-Ampicillin Agar LB-Agar 
1 % 10 mg/mL Ampicillin stock added where 
required 
 
Miniprep and Maxiprep of anti-LAM scFv pPinkα-HC vector 
Material Provider 
QIAprep Spin Miniprep Kit QIAGEN Ltd, Manchester, UK 
QIAGEN Plasmid Plus Maxi Kit QIAGEN Ltd, Manchester, UK 
 
Linearisation of anti-LAM scFv pPinkα-HC  
Material Provider 
EcoNI New England Biolabs, Ipswich, MA, USA 
NEBuffer4 New England Biolabs, Ipswich, MA, USA 
 
Pichia pink transformation 
Media Components 
PAD Agar 1.34% Yeast Nitrogen Base with Ammonium 
Sulfate without Amino Acids (YNB-aa) 










Protein expression induction 
All media and components were either filter sterilised or autoclaved prior to use. 
Media  Recipe/provider 
PPB (Potassium Phosphate 
Buffer) 
132 mL 1M K2HPO4 (dibasic) 
868 mL 1M KH2PO4 (monobasic) 
BMGY (Buffered Glycerol 
Medium) 
1% Yeast extract 
2% Bacto peptone 
100 mM Potassium phosphate buffer (PPB) pH 6 
1.34% Yeast Nitrogen Base with Ammonium 
Sulfate without Amino Acids (YNB-aa) 
4x10-5% Biotin 
1% Glycerol 
BMMY (Buffered Methanol 
Medium) 
Same as BMGY but with 1% Glycerol replaced 
with 0.5% Methanol 
1M SPB (Sodium Phosphate 
Buffer) pH 6 
1 M NaH2PO4 
YNBM 2.68% YNB, 0.5% methanol, 4x10-5 % biotin, 100 
mM SPB 
Casein 20% Casein stock 
cOmplete, EDTA-Free 
Protease Inhibitor Cocktail 
tablets (EASYpack) 
Roche Diagnostics Ltd, Burgess Hill, UK  
 
Protein purification using HisTrap 
All recipes for HisTrap column use were made with MilliQ water. 
Solution Recipe 
Sodium phosphate buffer 
(SPB) pH 7.4 
20 mM NaH2PO4, 500 mM NaCl 
HisTrap column imidazole 
wash buffer/equilibration buffer 
25 mM imidazole in SPB 
HisTrap column imidazole 
wash/equilibration buffer 
100 mM imidazole in SPB 
HisTrap column imidazole 
elution buffer 
100-500 mM imidazole in SPB 
HisTrap column cleaning 
solution 
20% EtOH 
HisTrap column "stripping" 
buffer 
2 M imidazole in SPB 
HisTrap column recharging 
solution 
0.1M NiSO4 





2.2.1 Ubiquicidine 29-41 (UBI 29-41) stock 
UBI 29-41 was chosen as the antimicrobial candidate as it has a wide host range 
and has already been evaluated by other groups (Welling et al., 2002; Brouwer et 
al., 2006; Walker et al., 2007). The UBI 29-41 peptide (AltaBioscience) was 
resuspended in 0.01 M Acetic acid pH 4 to a stock concentration of 0.5 mM and 
stored at -80°C as per (Welling et al., 2002). 
 
2.2.2 Labelling of UBI 29-41 with NaI 
Pierce Iodination Tubes were utilised for the activation of the iodine. The labelling 
process followed the first 6 steps of the manufacturers’ protocol. 
A Pierce Pre-coated Iodination Tube was wetted with 1 mL Tris Iodination Buffer and 
the buffer was hereafter discarded. 100 μL of Tris Iodination Buffer was then added 
to the tube at the bottom. 10 μL NaI (5 mM) was added to the buffer and mixed. The 
mixture was incubated at RT for 6 mins to allow the iodine to be activated. The tube 
was flicked every 30 secs to ensure homogenous activation. The activated iodine 
mix was added to 1 nmol of protein and incubated for 9 mins again with flicking of 
the tube every 30 secs to ensure even labelling.  
Several concentrations of "cold" NaI, the initial source of Iodine, were tested- 1 mM, 
2 mM, 3 mM, 4 mM and 5 mM. 
 




2.2.3 Analysis of labelling using HPLC-MS 
100 μL of labelled and unlabelled UBI 29-41 was analysed using HPLC-MS for 
labelling optimisation. This was done by Kevin Howland at the Department of 
Biosciences, University of Kent. 
Electrospray mass spectra were recorded on a Bruker micrOTOF-Q II 
mass spectrometer. Samples were separated on-line by reverse-phase HPLC on 
a Restek Viva Column (C18, 3 µm, 300Ǻ, 2.1 mm x 150 mm) running on an Agilent 
1100 HPLC system at a flow rate of 0.2 ml/min using a water, acetonitrile, 0.05% 
trifluoroacetic acid gradient. The eluant was monitored at 214 nm and then directed 
into the electrospray source, operating in positive ion mode and mass spectra 
recorded from 50-3000 m/z. Data was analysed with Bruker’s Compass Data 
Analysis software. 
 
2.2.4 Labelling of UBI 29-41 with 125I 
Labelling of UBI 29-41 with 125I was conducted identically to non-radioactive iodine 
labelling (section 2.2.2); however, this was conducted in a flow chamber behind lead 
fortified glass shield for protection. 1.0 mCi (37 MBq) Na125I was furthermore added 
instead of 5 mM NaI. 
 
2.2.5 Labelling analysis by Instant Thin Layer Chromatography (ITLC) 
ITLC was performed on 10x1 cm strips of ITLC paper (Pall Life Sciences, 
Portsmouth, UK). 2 μL radio conjugated UBI 29-41 or activated Na125I was loaded at 
the centre of the paper 2 cm from the bottom and allowed to dry for 1 hour. The 




bottom of the strip was placed in 85% methanol containing a trace of Coomassie 
staining solution for visualisation of the soaking process. This was done until the 
solvent reached the top of the paper and the strip was removed and allowed to air 
dry from 1 hour. The paper was then analysed using Bioscan Miniscan radio TLC 
strip scanner (Bioscan Europe, Ltd., Paris, France) at 0.5 mm/sec and ITLC LAURA 
imaging software (LabLogic Systems Limited, Sheffield, UK) for analysis. 
 
2.2.6 HPLC analysis of 125I labelled UBI 29-41 
The HPLC analysing the hot labelled UBI 29-41 was conducted at the Rayne 
Institute, St. Thomas Hospital, London. It was performed on an Agilent HPLC using 
an Ascentis Express C18 reverse phase column (10 cm x 4.6 mm, 2.7 μm)  using 
an Acetonitrile (ACN) + 0.05% Trifluoroacetic acid (TFA) gradient for elution of the 
labelled product. The gradient was as follows: 
0-10 mins = 5% ACN + 0.05% TFA 
10-15 mins = 20% ACN + 0.05% TFA 
15-18 mins  = 80% ACN + 0.05% TFA 
18-21 mins  = 5% ACN + 0.05% TFA 
The flow rate was set at 2 mL/min and the eluate was collected in fractions of 1 min 
for the first 9 minutes, 30 seconds from 9-14 minutes and 1 minute fractions from 
14-21 minutes. The fractions were then analysed on a Wallack LKB 1282 Gamma 
Counter Compugamma. 
 




2.2.7 Strain growth and model organism maintenance 
2.2.7.1 Organisms 
Four organisms were included in the toxicology experiments: the Saccharomyces 
cerevisiae strain BY4741, the Candida albicans strain sc5314, the Escherichia coli 
strain K-12 and the Staphylococcus aureus strain NCIMB 8625 (. It was decided to 
include a wide variety of organisms as representatives of various microbial strains. 
The S. cerevisiae strains were chosen to represent non-pathogenic yeast strains, 
where C. albicans represented the pathogenic strains. E. coli represented gram 
negative bacterial strains and S. aureus the gram positive bacterium.  
 
Table 7 Overview of model organisms utilised 
Strain Genotype References 
S. cerevisiae  
BY4741 
MATα his3Δ1 leu2Δ0 
met15Δ0 ura3Δ0  
Cohen and Engelberg, 
2007 
C. albicans  
sc5314 
Wt Diez-Orejas et al., 1997 
S. aureus  
NCIMB 8625 (FDA 209-P) 
Wt Cowan and Shaw, 1954;  
Trakulsomboon et al., 
2001 
E. coli  
K-12 MG1655 
Wt Jensen, 1993 
McVicker et al., 2011 
 
 




2.2.7.2 Growth curves 
All yeast strains were grown in YPD medium consisting of 2% Glucose, 1% Yeast 
extract and 2% Bacto Peptone. C. albicans was grown at 37°C and the S. cerevisiae 
strains were grown at 30°C. All bacterial strains were grown on LB medium made up 
of 1% NaCl, 0.5% Yeast extract and 1% Bacto peptone and grown at 37°C. 
To establish growth curves, 5 mL media was inoculated with one strain and 
incubated for 1 hr prior to distribution into 24 well plates and loading into the plate 
reader (SpectroMax multimode plate reader; Molecular Devices, Sunnyvale, CA, 
USA). The reader was set to grow the organisms at the appropriate temperature and 
shaking speed, and make measurements of the cultures every 30 min for 24 h for 
the bacterial strains and 48 h for the yeast strains. 
OD600 comparisons were made by making several dilutions of the finished cultures 
and measured on an Eppendorf BioPhotometer Plus spectro-photometer (Eppendorf 
AG, Hamburg, Germany) as the data from the two machines was incomparable 
otherwise. 
 
2.2.7.3 OD600 versus cell number  
10 mL appropriate media was inoculated with overnight culture to an OD600 of 0.1 
and OD600 measurements were made each hour, as well as dilutions were made and 
the cell numbers were counted using a standard haemocytometer. The linearity 
between the two data sets was compared allowing conversion of OD600 to cell 
concentration. 




2.2.8 Hydrogen peroxide toxicity assay 
Overnight cultures of the model organisms were diluted 1:1000 and grown at the 
optimal growth temperature until they reached the beginning of the log phase, 
established by OD600 readings. They were hereafter diluted appropriately to cell 
number which would ultimately result in approximately 100 colonies per petri-dish. 
Diluted cell cultures were added hydrogen peroxide for a variety of final 
concentrations (0.5 mM to 70 mM) and media was added to a final volume of 100 
μL. 
The cultures were incubated at room temperature for 1 hour and hereafter spread 
onto plates. Yeast strains were grown in 5cm petri dishes; bacterial strains were 
grown in large 9cm petri dishes for improved spreading and reproducibility of results. 
Following incubation 50 μL was diluted in 450 μL media. For the yeast strains 20 μL 
was spread to the small petridishes in triplicates and grown at the optimal 
temperature for 1 day (C. albicans) and 2 days (S. cerevisiae BY4741). For the 
bacterial strains 100 μL was spread to the large petri dishes in triplicates and grown 
at 37°C for 1 day. 
 
2.2.9 UBI 29-41 toxicity assays 
Model organisms were diluted from overnight cultures and grown to the beginning of 
the log phases. The cells were added to Eppendorf tubes with media and UBI 29-41 
to a concentration of 0 μM, 50 μM and 100 μM and a final volume of 100 μL. The 
procedure was otherwise conducted as in section 2.2.8. 




2.2.10 Cold iodine toxicity experiments 
The cold iodine toxicity experiments were conducted as elaborated in section 2.2.8. 
The cells were subjected to two levels of iodine: 0.5 mM and 1 mM. A control group 
not subjected to iodine was included. All plates were done in triplicate. 
 
2.2.11 Toxicity analysis of 125I-UBI 29-41 
The experiment was conducted as per the protocol for innate toxicity assays (section 
2.2.9). The dose added to the cells was based on the theoretical MBq values. Two 
doses were tested: 1 MBq and 5 MBq. The actual values following addition to the 
cells was measured using a dose calibrator set on 125I setting (Dose Calibrator Model 
VDC-404, Veenstra Instruments, Joure, Holland). Following incubation, the cells 
were washed with their respective medium to minimise the amount of free iodine 
transferred to the plates. This was done by spinning at 13,000 rpm in a Eppendorf 
table-top centrifuge, removal of the media with care not to remove the pellet and 
resuspending pellet in the appropriate media for the organism,. This was done 3 
times to remove any excess 125I, whether labelled or not. The cells were hereafter 
plates and incubated as previously elaborated (section 2.2.8). All experimental 
procedure was performed in flow chamber behind lead glass shielding. 
 
2.2.12 Binding experiments 
The experiment was conducted as elaborated in section 2.2.11. Radioactivity 
associated with S. cerevisiae and E. coli was measured using dose calibrator before 




and after washing as explained above. This was done for the doses of 1 MBq and 5 
MBq and the actual doses were established using a dose calibrator.  
 
2.2.13 Hybridoma cell line maintenance 
For the purification of mRNA of the anti-LAM monoclonal antibody the murine cell 
line CS-35 was utilised. This was obtained from BEI resources (Bei Resources, 
Manassas, VA, USA). The cells were revived by gently thawing the cells and adding 
the cells to their appropriate media in a T25 flask. The cells were the day after spun 
down and transferred to fresh media. 
Cells were grown on RPMI media containing 10% Foetal Calf Serum at 37°C, 5% 
CO2.  
2.2.14 SDS-PAGE analysis 
Precast NuPAGE Novex 4-12% Bis-Tris Gel, 1.0 mm, 10 well were loaded onto an 
Xcell SureLock gel running tank. 500 mL 1x MES running buffer was added to the 
tank. The samples to be analysed were added to 5 μL NU-PAGE LDS sample buffer 
(4x) (Invitrogen, Paisley, Scotland, UK) and heated to 70°C where after they were 
carefully loaded to the gel alongside 6 μL Kaleidoscope pre-stained molecular weight 
marker (Bio-Rad Laboratories, Hercules, CA, USA) The gels were run at 200 V for 
35 mins. 
 
2.2.15 Transfer of proteins to nitrocellulose membrane 
NuPAGE gels were soaked in Bjerrum and Schafer-Nielsen buffer at room 
temperature for 30 mins at room temperature. Nitrocellulose membrane (Transblot 




transfer medium 0.45 μm; Bio-Rad Laboratories, Hercules, CA, USA) and 4x extra-
think blotting paper (Bio-Rad) were soaked in Bjerrum and Schafer-Nielsen buffer 
for 10 mins. Both blotting paper and Nitrocellulose membrane was cut to the size of 
the gel.  
The papers were assembled accordingly (from top to bottom): 2x buffer soaked 
blotting paper, SDS-PAGE gel, nitrocellulose membrane, 2x blotting paper. 
The sandwich was loaded to a Trans-blot semi-dry electrophoretic transfer cell (Bio-
Rad Laboratories, Hercules, CA, USA) and 10V was passed through the gels for 30 
mins. 
 
2.2.16 Western blot analysis of anti-LAM IgG3 expression 
30 mL blocking buffer (1x PBS, 5% Marvel, 0.2% Tween) was added to the 
nitrocellulose membrane with transferred protein and was shaken at room 
temperature for 1 hour. The blocking buffer was hereafter discarded and replaced 
by 1:1000 rabbit anti-mouse polyclonal IgG HRP conjugate (Catalogue#: PA1-
28761; Thermo Fisher Scientific Inc., Waltham, MA, USA) in blocking buffer at room 
temperature for 1 hour with shaking.  The nitrocellulose membrane then underwent 
three 10 mins washes in 2% Tween in PBS with shaking. The nitrocellulose 
membrane was then exposed to Super Signal West Pico Chemiluminescent 
Substrate (Thermo Fisher Scientific Inc., Waltham, MA, USA) for 5 mins according 
to manufacturer’s protocol. The membrane was hereafter transferred to a film 
cassette and exposed to Amersham Hyperfilm ECL (GE Healthcare, 




Buckinghamshire, UK) in a darkroom. The film was developed using a Compact X4 
developer (Xograph Healthcare Ltd., Gloucestershire, UK) 
 
2.2.17  mRNA purification and agarose gel analysis 
For mRNA purification the Straight A’sTM mRNA Isolation System (Novagen, 
Darmstadt, Germany) was used.  2x107 cells were harvested for the purification of 
mRNA. Cells were counted using a haemocytometer. 
Cells were washed with PBS and quickly after transferred to an RNase free 
Eppendorf tube where after 5 mL lysis buffer was added. Immediately 50 μL DTT 
was added to a final concentration of 10 mM. The cells were homogenised for 1-2 
minutes by pipetting up and down until the mixture appeared homogenous in colour 
and texture, then centrifuged for 15 min at 9000xg at RT to remove insoluble 
material. 
 
2.2.17.1 Preparation of magnetic beads 
Magnetic beads were prepared in the meantime: 400 μL (4 mg) magnetic bead 
solution was transferred to an RNase free 1.5 mL Eppendorf tube and put onto a 
magnetic column. The beads were captured and the storage solution decanted. The 
beads were washed with 400 μL wash buffer and vortexed gently until beads were 
resuspended. The beads were again captured on the magnetic column and the 
supernatant decanted. 400 μL wash buffer was added again and the magnetic beads 
once again resuspended and ready for use. 
 




2.2.17.2 mRNA purification 
Following centrifugation, the supernatant was gently added to a clean RNase free 
15 mL falcon tube. The washed beads (from section 2.2.17.1) were hereafter added 
and the cell mixture was allowed to incubate at room temperature (RT) for 5 mins.  
The particles were hereafter captured on the magnetic column as described 
previously and supernatant was decanted. 6x400 μL (2.4 mL) wash buffer was 
added, the solution mixed, beads captured and supernatant decanted. This was 
repeated with the only alteration that the tube was removed slowly to ensure all 
beads were at the bottom of the tube. Following the decanting of the supernatant 
400 μL wash buffer was added, the solution mixed and the beads were transferred 
to an RNase free 1.5 mL Eppendorf tube. The beads were once again captured and 
as much supernatant as possible was removed. 0.5 mL nuclease free water was 
added and mixed briefly where after the mixture was incubated at 60°C for 10 mins 
to elute mRNA. 
The beads were again captured, but the supernatant was now added to a new 
RNase free 1.5 mL Eppendorf tube and 2 μL 10 mg/mL glycogen and 50 μL 3M 
Sodium acetate was added. Hereafter 331 μL (0.6 volumes) isopropanol was added 
to precipitate the mRNA and the mixture was mixed by vortexing followed by 
centrifugation at 14.000xg for 10 mins. 
The supernatant was removed with care not to touch the pellet. The pellet was 
washed with 0.5 mL 70% EtOH made with RNase free water and spun at 14.000xg 
for 5 mins. The supernatant was again removed, as much as possible, with care not 




to touch the pellet. The pellet was resuspended in 25-50 μL RNase free water and 
the absorbance at 260 nm was measured. 
The product was analysed on a 1 % agarose gel visualised by incubating in EtBr. 
 
2.2.18  cDNA construction 
The purified mRNA was immediately converted to cDNA using the First Strand cDNA 
Synthesis Kit (Novagen, Darmstadt, Germany) using oligo(dT) primers. 1 μL mRNA 
mix was mixed with 0.5 μL oligo(dT) primers and 11 μL nuclease free water and 
heated at 70°C for 10 mins where after 4 μL First Strand buffer, 2 μL 100 mM DTT, 
1 μL dNTP mix and 0.5 μL MMLV reverse transcriptase was added and incubated 
at 37°C for 1 hour. The solution was stored at 4°C. 
 
2.2.19  PCR amplification and analysis of anti-LAM hybridoma VH and VL 
gene fragments and agarose gel analysis 
The light and heavy chain fragments were amplified using the Mouse Ig- primer set 
from Novagen (Novagen, Darmstadt, Germany), specific for the amplification of a 
variety of mouse heavy and light chain fragments. The cDNA previously generated 
was used as template and the primer combinations were assembled as directed by 









The following program was used for the amplifications: 
94°C for 1 min 
94°C for 1 min 
50°C for 1 min  30x cycles 
72°C for 2 mins 
72°C for 6 mins 
4°C hold 
The PCR products were analysed on a 1% agarose gel and visualised with ethidium 
bromide. Positive PCR products were gel purified according to manufacturers' 
protocol using the QIAquick Gel Extraction Kit (QIAGEN Ltd, Manchester, UK). 
 
2.2.20  Ligation of amplified gene segment into pGEM-T Easy vector and 
transformed into XL1-Blue competent cells 
Following the manufacturers' protocols, the positive gel purified PCR products were 
ligated into the pGEM-T Easy vector (Novagen, Darmstadt, Germany) using T4 
ligase as instructed in the manufacturers notes (Figure 12).  
 





Each ligation was analysed by digestion with BstZI for insert and the vectors 
containing insert were transformed into XL1-Blue competent cells (Stratagene) for 
amplification according to the manufacturers' instructions. Successful clones were 
analysed for vectors containing insert. DNA was extracted using a QIAprep Spin 
Miniprep Kit (QIAgen) and the purified products were digested with BstZI for insert 
verification by analysis on a 1 % agarose gel. Vectors with confirmed inserts were 
sent to Beckman Coulter Genomics (Beckman Coulter (UK) Ltd., High Wycombe, 
UK) for sequencing with M13 forward and reverse primers. 
 
 
Figure 12 Schematic representation of the pGEM-T Easy vector. 
The pGEM-T Easy vector has already been linearised prior to ligation and contain a single 3'-T 
overhang at the insertion site. This combined with the 5' overhangs generated by the Taq-
polymerase utilised for the amplification of the variable domains made ligation straightforward 
(From Novagen, Darmstadt, Germany). 
 




2.2.21  Sequencing analysis and editing 
All sequences were initially analysed using Chromas Lite for quality control. 
Questionable regions were deleted in BioEdit which was also used for annealing 
sequences and removal of vector sequence 
 
2.2.22  In silico assembly and optimisation of variable domains  
Using expasy.org the result from the removal of vector sequence allowed the 
translation of the inserts in all reading frames. This allowed the identification of the 
most promising inserts which were then compared to published variable domain 
sequences in "Sequences of proteins of immunological interest" (Kabat et al., 1991). 
 
2.2.23  Vector construction 
StuI was chosen as the 5’ restriction site and KpnI at the 3’ end for vector 
linearisation in order to ensure correct orientation of the insert. The insert was 
designed with a MlyI restriction site in the 5’ end and a KpnI restriction site in the 3’ 
end. The insert was furthermore modified with a His-tag in the 3' end and two stop 
codons were introduced as well to ensure termination of translation. The in silico 
designed insert was sent to GeneArt along with pPinkα-HC vector (Figure 13) for 
manufacture. 





2.2.24  Growth of P. pink 
5mL BMGY in a sterile falcon tube was inoculated with P. pink strain I and grown 
overnight at 30°C shaking at 180 rpm.   
 
2.2.25  Transformation of Pichia pink strains 1 with pPinkα-HC containing 
anti-LAM scFv 
Prior to transformation into Pichia pink, the vector containing the anti-LAM scFv was 
linearised using EcoNI (New England Biolabs, Ipswich, MA, USA). This was one of 
 
Figure 13 pPinkα-HC vector including important restriction sites. 
Schematic overview of the pPinkα-HC vector and the location of the two important features: the α 
mating factor signal sequence (αMF-SigSeq), which allows the secretion of the gene of interest 
(GOI), which is inserted immediately after this. Furthermore, the vector contains the ADE2 gene 
which allows only the transformed cells to grow on the nutrient selective adenine deficient PAD 
plates. Furthermore, the restriction sites recommended by Invitrogen are included to allow optimal 
insertion of GOI at the site of interest. In this project, KpnI was chosen as 3’ end restriction enzyme 
(RE 2). StuI and MlyI was kept as restriction enzymes for the 5’ end preparation (From Invitrogen, 
Paisley, Scotland, UK). 
 




the restriction enzymes recommended by Invitrogen as this enables cleavage at an 
inconsequential site. The gene of interest was analysed prior to purchase for the 
presence of EcoNI cleavage sites and found to contain no such sites. Further gel 
analysis confirmed a single cleavage site. The plasmid was digested using the 
recommended NEBuffer 4 at 37°C for 1 hour and de-activated at 65°C for 10 min. 
Following digest with EcoNI the plasmid DNA was purified using the QIAGEN 
QIAquick Gel Extraction Kit (Cat No. 28704). 
100 mL of YPD media was inoculated with Pichia pink and left to grow for 2 days. 35 
mL of the culture was hereafter harvested by centrifugation at 3000 rpm for 3 min at 
room temperature using Beckman Avanti J-25 JA rotor 25.50 (Beckman Coulter (UK) 
Ltd., High Wycombe, UK). The pellet was resuspended in 45 mL sterile distilled 
water and again spun at 3000 rpm for 3 min at room temperature using the Beckman 
Avanti J-25 JA rotor 25.50. 
The pellet was resuspended in 1 mL ice-cold sterile 1M sorbitol and transferred to a 
sterile Eppendorf tube. The pellet was washed 6 times by pulse centrifuging the 
Eppendorf tube at 10,000 rpm, removing the supernatant and resuspending the 
pellet in new 1 M ice-cold sterile sorbitol. Following the final wash, the pellet was 
resuspended in an equal volume of 1 M ice-cold sterile sorbitol. 80 μL of each culture 
was added to a new sterile Eppendorf tube and added 5 μL linearised plasmid. The 
tubes were incubated on ice for 30 min. Negative controls without plasmid DNA was 
prepared in parallel. The contents of the Eppendorf tubes were transferred to chilled 
2mmElectroporation cuvettes (Molecular Bio Products, cat# 5520), making sure the 
cells were at the bottom of the cuvette. The cuvettes were wiped completely dry prior 




to electroporation. The cells were electroporated at 2.0 kV, 200 Ω, 25 mF using the 
Bio-Rad Pulse Controller (Model#: 1652098; Bio-Rad Laboratories, Hercules, CA, 
USA) and the Bio-Rad Gene Pulser (Model#: 1652078; Bio-Rad Laboratories, 
Hercules, CA, USA). 1 mL YPD media containing 1/10 20% Dextrose was added to 
the cells immediately after electroporation and incubated at 30°C for 1 hour.  
100 μL of the cell mixture was plated onto 4 PAD plates containing 20% Dextrose 
and 1 plate YPD plate containing 20% Dextrose. Of the negative controls only 1 PAD 
and 1 YPD plate was prepared. The plates were incubated for 3-5days at 30°C in 
loosely tied bags until colonies appeared. 
 
2.2.26  Protein expression screening  
White colonies from the PAD plates from the transformed P. pink strains were 
isolated on new PAD plates as well as transferred to BMGY and grown for 48 hours.  
1 mL of the culture was taken out as T=-1 protein expression prior to the exchange 
of the BMGY media to freshly made BMMY media to induce protein expression. The 
exchange of the media was done by centrifuging the cells at 5000 rpm for 5 mins at 
room temperature using the Eppendorf 5810R Centrifuge (Eppendorf AG, Hamburg, 
Germany). The pellet was resuspended in 5 mL BMMY and another sample was 
taken as T=0 for later analysis. The cells were incubated at 30°C shaking at 200 rpm 
and 1 mL samples were taken every 24 hours. Methanol was added to each sample 
to a final concentration of 0.05%. The last sample was taken after 96 hours giving a 
total of 6 time points. 




The samples taken from the cell cultures were centrifuged in a table-top Eppendorf 
centrifuge at 13,000 rpm for 1 min and the supernatant was transferred to a new 
tube for further analysis and both supernatant and pellet was stored at -20°C. 
 
2.2.27  Dot blot analysis of anti-LAM scFv screening 
Nitrocellulose membrane (Transblot transfer medium 0.45 μm, Bio-Rad Laboratories, 
Hercules, CA, USA) was wet with 1xPBS prior to insertion into the dot-blot cassette 
(Bio-Rad Laboratories, Hercules, CA, USA). Once mounted, 200 μL of each time 
point sample was loaded as well as a positive control in the anti-CD33 (Emberson 
et al., 2002). Using a vacuum pump, the samples were loaded onto the membrane 
which hereafter briefly was air dried. The dots were hereafter visualised using 
immunoprobing techniques described in section 2.2.16.  
 
2.2.28  Large-scale production of anti-LAM scFv 
The anti-LAM scFv expressing Pichia pink was initially grown in BMGY media until 
it reached an OD600 of ~60. The culture was pelleted using Eppendorf 5810R 
Centrifuge (Eppendorf AG, Hamburg, Germany) and was then resuspended in 1/3 
the volume of BMMY media to reach an OD600 of ~160-180. The final volume for 
large-scale production was aimed at 100 mL BMMY. 
 
2.2.29  ScFv purification 
For purification of the His-tagged scFv a 1 mL HisTrapTM nickel affinity column (GE 
Healthcare, Buckinghamshire, UK) was used. 




Supernatant from transformed Pichia pink strains was collected 24 hours following 
exchange of BMGY media to BMMY and filter sterilised to remove any residual cell 
debris that might obstruct the HisTrapTM column. A sample was taken to illustrate 
protein concentration prior to purification. 
The tubing in the peristaltic pump was washed with 20% EtOH in MilliQ water for 2 
CV (Column Volumes) at a flow rate of 1 mL/min. The tubing was hereafter washed 
with MilliQ water for 2 CV. 
The HisTrapTM column was connected to the tubing taking care not to introduce 
bubbles that might block the flow in the column. The column was washed with 5 CVs 
of MilliQ water, and equilibrated with 5 CVs 25 mM imidazole in 1x Sodium 
Phosphate Buffer, pH 7.4. The supernatant was passed through the column and a 
sample was collected to later be able to ensure that the protein indeed had bound to 
the column. 
The column was then washed with 5 CVs of equilibration buffer and again a sample 
was taken to ensure that the protein was not eluted in the washing. 
The scFv was now eluted from the column using 100 mM imidazole and 500 mM 
imidazole, both in 1x Sodium Phosphate Buffer, pH 7.4. 10 samples of 1 mL each 
was taken for each elution buffer. 
The column was finally washed with 20% EtOH in MilliQ water and stored at 4°C. 
 
2.2.30  Optimisation of imidazole concentration 
The initial wash buffer has an imidazole concentration of 100 mM and elution buffers 
with imidazole concentrations of 150 mM, 200 mM, 250 mM, 300 mM and 500 mM 




were analysed. Due to premature elution the wash buffer imidazole concentration 
was lowered to 25 mM with 100 mM included as an elution buffer 
 
2.2.31  Recharging of HisTrapTM columns 
Prior to recharging the HisTrapTM column it was stripped using a “stripping buffer” 
consisting of 2M imidazole in Sodium Phosphate Buffer, pH 7.4. 5 CV of stripping 
buffer was passed through the column at a speed of 1 mL/min, which was 
unchanged for all procedures. Hereafter, the column was recharged with a reload 
buffer consisting of 0.1M NiSO4 in MilliQ water. 2 CV of reload buffer was passed 
through the column. Finally the column was washed using 20% EtOH in MilliQ water, 
disconnected from the peristaltic pump and stored at 4°C. 
 
2.2.32  Western blot analysis of scFv purification 
The western blot was performed as previously directed (section 2.2.16) with anti-His 
HRP conjugated antibody as visualising agent. The antibody was used at a 1:2000 
dilution in blocking buffer. 
 
2.2.33  Coomassie stain analysis of elutions for degradation analysis 
The gels, run as in section 2.2.14, were removed from the cassette and suspended 
in Coomassie staining solution (0.25 % Coomassie Brilliant Blue R250, 10 % acetic 
acid, 50% methanol) for 1 hour. The gels were hereafter destained using destaining 
solution (5% methanol, 7.5% acetic acid) for 1+ hours until bands were clear. 
 




2.2.34  Silver stain analysis of scFv purification 
Gels were run as in section 2.2.14 and silver staining was executed with the use of 
SilverXpress Silver Staining kit  (Invitrogen, Paisley, Scotland, UK) and was carried 
out according to manufacturer’s protocol. 
 
2.2.35  Gel drying 
Gels were dried using Gel Drying Film (Promega, Madison, WI, USA) according to 
manufacturer’s protocol. 
 
2.2.36  Minimal media vs. complex media with and without casein 
The cells were grown to and OD600 of 60 in regular BMGY media as described in 
section 2.2.28. The cells were hereafter divided into 2 flasks and added BMMY and 
YNBM to an OD600 of 160-180. Each flask was further divided into two separate 
flasks, ending up with 4 flasks in total. In one flask of BMGY and one in YNBM 1% 
casein was added. The cultures were hereafter grown and analysed as described 
previously. 
 
2.2.37  Temperature and protease inhibitor analysis 
Culture setup was performed as described (section 2.2.28). As the cultures had been 
transferred to BMMY to an OD600 of 160-180 the culture was divided into 4x50 mL 
aliquots and transferred to 4x 250 mL flasks.  Two flasks were hereafter added a 
protease inhibitor tablet (Roche Diagnostics Ltd, Burgess Hill, UK). One flask without 




protease inhibitor and another flask with was grown for 24 hrs at 20°C and the same 
at 25°C. The cultures were hereafter grown and analysed as previously directed. 
 
  




3 Labelling optimisation of UBI 29-41 
3.1 Introduction 
When designing an experimental strategy for the evaluation of the toxicity of a 
labelled compound, an important first step prior to performing toxicity studies was to 
optimise the labelling of the targeting agent. This not only eases later evaluation of 
the toxic effects by knowing the exact level of labelling, but would be beneficial if the 
amount of radioactive iodine used could be minimised to not only reduce solid waste 
accumulation but also make the stock last longer. 
 The targeting agent used in the toxicity studies was fragment 29-41 
(TGRAKRRMQYNRR) of the antimicrobial peptide Ubiquicidine (UBI 29-41). An 
antimicrobial peptide was chosen for the initial toxicity studies, based on the broad 
targeting range of the peptide due to it binding via electrostatic interactions (see 
section 1.4.1.2). This would allow the testing of the effects of Auger electrons on a 
range of model organisms, which will be evaluated later. 
125I had several advantages as the initial isotope for radiotoxic evaluation of Auger 
electrons. It has a long half-life (60 days), it has an uncomplicated labelling 
technique, the labelling chemistry for iodine would likely allow easy replacement with 
isotopes such as 123I emitting higher energy Auger electrons, which albeit having a 
lower LET has a longer range, and finally it may have uses as an imaging agent as 
it also emits γ-radiation. 
The use of UBI 29-41 had further advantages as the labelling method utilised was 
Iodogen labelling. As mentioned previously (section 1.4.2.1), this labels the ortho 
positions of the hydroxyl group on tyrosine, of which only one exist in UBI 29-41. 




In the initial optimisation steps of the labelling process, “cold” iodine was to be 
utilised as this would enable analysis of the labelled product using HPLC-MS, which 
would enable the analysis of the homogeneity and labelling efficiency of the Iodogen 
labelling method for this peptide. UBI 29-41 has a single tyrosine residue and thereby 
two labelling positions as iodine is conjugated in the orthopositions of the hydroxyl 
group of which there are two.  
Prior to labelling UBI 29-41 with “hot” iodine, the labelling process was investigated 
and before directly assessing the effect of the radiation on the model organisms.  
Since HPLC-MS equipment in the department is not suited for the handling of 
radioactive materials, the initial evaluations of the labelling was done using non-
radioactive iodine. It was furthermore of interest to study the stability of the labelling 
to not only evaluate the possibility of batch creation, but also for analysis of the 
stability of the conjugate during the experiments. 
 
3.1.1 Specific aims 
Given the above, this chapter had the following specific aims: 
1) To successfully label UBI-29-41 with 'cold' iodine using the Iodogen labelling 
techniques 
2) To analyse the labelled UBI29-41 by HPLC-MS, thereby confirming the success 
of the labelling protocol 
3) To adjust the labelling parameters based on (2) to optimise labelling reaction for 
uniformity of labelling and to minimise use of radioactive products 




4) To perform labelling with 'hot' iodine based on the optimised protocol established 
by the above 
5) To assess the stability of labelled UBI 29-41 and thereby suggest the maximum 
time labelled products should be stored before subsequent experiment. 
  




3.2 Optimisation of iodine concentrations for labelling using non-
radioactive iodine 
In order to be able to ensure reproducibility of experiments and correct interpretation 
of results the labelling process had to be carefully characterised and optimised. 
HPLC-MS at the University of Kent is not cleared for use with radioactive material 
and for this reason the molecular analysis of the labelling process had to be done 
using “cold” iodine instead of 125I.  
The first step was to test UBI 29-41 labelled with a range of “cold” iodine 
concentrations (see section 2.2.2). UBI 29-41 was labelled with concentrations of 
cold activated NaI ranging from 1 mM to 3 mM to 2 nmol of UBI 29-41 per labelling 
in 100 μL Tris iodination buffer. The labelled product was analysed using reverse 
phase HPLC using a C18 column at a flow rate of 0.2 ml/min using a water, 
acetonitrile, 0.05% trifluoroacetic acid gradient. The retention times were detected 
and are visualised in Figure 14. 
As can be seen in Figure 14, increasing the concentration of activated iodine to the 
UBI 29-41 solution changed the running time in the HPLC by changing the chemical 
composition of the peptide. The retention time on HPLC is affected by the polarity of 
the peptide. Increased polarity reduces retention time and the addition of two iodides 
would make the tyrosine less polar, thereby increasing running time in the HPLC. As 
can be seen three peaks are visible. As there are two ortho-positions to the hydroxyl 
group in tyrosine means that the tyrosine can be semi-saturated with only one of the 
ortho positions filled. The intermediate peak is consistent with this. The rightmost 
peak is consistent with both ortho groups being saturated. 






Figure 14 Overview of HPLC analysis of labelling optimisation of UBI 29-41. 
HPLC data of UBI 29-41 labelled with 3 concentrations of NaI. The top figure shows retention time 
in HPLC with 1 mM NaI, the middle figure 2 mM and the bottom figure at 3 mM. Retention time of 
UBI 29-41 increases as it becomes saturated. The two top figures show three peaks at varying 
intensity indicating non-saturated labelled UBI 29-41. As the concentration increases so does the 
proportion of the rightmost peak, representing the fully labelled UBI 29-41.  
 









As can be seen in Figure 15, there is a right-shifting when comparing the unlabelled 
UBI 29-41 (top) with fully labelled UBI 29-41 (bottom). The increase in mass 
corresponds to the addition of two iodine atoms as well as the addition of a single 
 
Figure 15 MS analysis of the un-labelled and the fully labelled UBI 29-41. 
This figure shows the MS analysis of the molecular weight of unlabelled (top) and labelled 
(bottom) UBI 29-41. Labelling was performed using a stable isotope of iodine to prevent 
radioactive contamination of the HPLC-MS equipment. The weight of the unlabelled UBI 29-41 is 
both consistent with literature (Akhtar et al., 2005) and also appears homogeneous. More 
importantly, the labelled UBI 29-41 population is also homogeneous. The increase in mass is 
equivalent to two iodides and a single oxygen due to oxidation of UBI 29-41 as a consequence 
of the labelling process as well as loss of two hydrogen atoms which were replaced by iodine. 
 




oxygen and loss of two hydrogen atoms. The calculations are summarised in Table 
8 and Table 9: 
 
Table 8 Overview of UBI 29-41 amino acid composition. Upon bond formation water is 
removed (depicted in red) 
Amino acid Number of amino 
acids in peptide 
Mass Combined mass 
Threonine (T) 1 119 Da 119 Da 
Glycine (G) 1 75 Da 75 Da 
Arginine (R) 5 174 Da 870 Da 
Alanine (A) 1 89 Da 89 Da 
Lysine (K) 1 146 Da 146 Da 
Methionine (M) 1 149 Da 149 Da 
Glutamine (Q) 1 146 Da 146 Da 
Tyrosine (Y) 1 181 Da 181 Da 
Asparagine (N) 1 132 Da 132 DA 
H2O 12 18 DA 216 Da 
Total mass   1691 Da 
 
This mass is identical to the mass of the unlabelled peptide found by MS and found 
in literature. During labelling it was expected that two hydrogen atoms were replaced 
with two iodides including the addition of an oxygen atom. This is summarised in 
Table 9. 
 




Table 9 Overview of the labelling of UBI 29-41 comprising the replacement of two hydrogen 
atoms (depicted in red) with iodide atoms. 
Component Number Mass Combined mass 
UBI 29-41 1 1691 Da 1691 Da 
Iodine 2 127 Da 254 Da 
Hydrogen 2 1 Da 2 Da 
Oxygen 1 16 Da 16 Da 
Total mass (fully labelled)   1959 Da 
 
This theoretical mass of the fully labelled peptide calculated is the exact molecular 
weight found by MS. 
The amount of peptide used was 2 nmol, whereas the amount of iodine included 
ranged from 1 × 10−7 𝑚𝑜𝑙 (1 mM in 100 μL Tris iodination buffer) to 5 × 10−7 𝑚𝑜𝑙 (5 
mM in 100 μL Tris iodination buffer), meaning the peptide to iodine ratio ranged 
between 1:50 and 1:250.These results verified the successful incorporation of iodine 
using the commercially-obtained Iodogen method, under the conditions described 
here. They are not, however, directly comparable to labelling with Na125I under the 
Iodogen tube manufacturers’ recommended conditions; these recommend the use 
of 1 mCi (37 MBq) Na125I. This represents a much lower molar concentration of 
sodium iodide than used in these “cold” experiments, although information obtained 
from the suppliers prior to the experiments had indicated that the molar concentration 
of the Na125I used was 5 mM. This means that, while the cold experiments provided 
useful detailed information about the labelling including MS data the stoichiometry 
of the Iodogen process would be different between the “hot” and “cold” experiments. 




Purification of the labelled peptide on a PD10 column was attempted, however, the 
cationic nature of the peptide and low concentration made it unfeasible. Anionic 
exchange column purification was attempted as well, however with the same result 
(data not shown). As free 125I was later included as an activity control it was decided 
that a surplus of free 125I would be acceptable 
Since HPLC-MS was not a feasible method for the routine analysis of “hot”-labelled 
peptide due to equipment restrictions in the department, a method was required for 
the evaluation of the labelling efficiency prior to experiments in order to ensure that 
UBI 29-41 had been successfully labelled and remained stable. For this ITLC was 
implemented and is described in section 3.3. 
 
3.3 Optimisation of iodine concentrations for labelling using 
Na125I 
Radio iodination was undertaken according to the protocol published by the 
manufacturers of the iodination tubes, using 2 nmol peptide and 1mCi (37 MBq) 
Na125I. In order to assess incorporation of radioiodine, instant thin layer 
chromatography (ITLC) was used. This was compared with ITLC analysis of 
activated Na125I; this allowed the determination of the extent of non-incorporation of 
radioiodine under different experimental conditions, and also to measure stability in 
later experiments. ITLC profiles are presented in Figure 16, which demonstrates a 
clear difference in profiles between the free iodine (left) and the labelled UBI 29-41 
(right). The free iodine had travelled furthest on the ITLC paper at around 80 mm, 
where the radio labelled UBI 29-41 was retained at the loading point. These profiles 




would later be used to rapidly analyse radio labelled product prior to experiments 
whether labelling had been successful, which proved a simple, but important tool in 
verifying radio labelling efficiency. Furthermore, as can be further seen in the radio 
labelled profile of UBI 29-41, there is a very small peak at the end of the ITLC paper 
(red circle in figure to the right), correlating with the free iodine peak and indicating 
that there is a small excess of iodine that has not been conjugated to UBI 29-41.  
 
Subsequent experiments investigated the impact of a reduction in the activity of 
Na125I used in the procedure. These experiments again showed a large peak at the 
origin, corresponding to the labelled peptide, and a small peak around 90 mm from 
the origin, corresponding to free iodine, under the conditions recommended by the 
manufacturers (Figure 17A). Reducing Na125I to half (Figure 17B) and one tenth 
(Figure 17C) of the recommended activity led to absence of the free radioiodine 
peak. This indicates that the activated 125I has been either labelled to UBI 29-41or 
bound to the tube in a fashion leaving no iodine free in solution.   
 
Figure 16 ITLC profiles of radio labelled UBI 29-41 and free iodine. 
The left figure shows the profile of free activated iodine. The right figure shows the profile of 
successfully labelled UBI 29-41 having very little free iodine (red circle). The labelled UBI 29-41 
prevented the migration when compared to the free iodine. ITLC analysis of the radio labelled 
UBI 29-41 was performed prior to all radio toxicity experiments in order to ensure distinction 
between free iodine and targeted iodine experiments. 
 
 






3.4 HPLC analysis of 125I labelled UBI 29-41 
Due to the significantly lower concentration of Na125I compared to NaI it was 
desirable to further analyse the nature of the labelling using hot iodine. Although this 
was undertaken at the Rayne Institute at St. Thomas Hospital, and therefore not 
feasible for routine analysis, it could potentially provide useful information about the 
radio labelling process that ITLC could not provide, such as number of 125I 
conjugated to UBI 29-41.  
 
Figure 17 ITLC analysis of radio labelling optimisation. 
 Using ITLC UBI 29-41 labelled with various concentrations of activated 125I was analysed and 
compared to establish the optimal labelling conditions for the later toxicity assays. (A) UBI 29-41 
labelled with the125I activity recommended by Pierce. (B) Is UBI 29-41 labelled with half the activity 
recommended and (C) is UBI 29-41 labelled with 1/10 the activity recommended. 
 




The analysis was undertaken using a C18 column on a reverse phase HPLC using 
an acetonitrile (ACN) + 0.05% trifluoroacetic acid (TFA) gradient for elution of the 
labelled product as well as any free iodine. 
Initially, the unlabelled peptide was tested to verify the gradient as well as notify at 
what point the unlabelled peptide elutes, to have a reference point for later 
radionuclide analysis. Furthermore, it was important to confirm the stability of the 
unlabelled peptide following its extended period of storage. 20 μL was injected and 
the eluate was analysed by standard UV chromatogram at a flow rate of 1 mL/min.  
As can be seen in Figure 18 there appears to be a large single peak around 9 
minutes. This gives confirmation that the peptide has not degraded and furthermore 
gives a frame of reference for radio labelling analysis. The reference point allowed 
the implementation of refined fraction collection around the expected elution time 
and thereby improved resolution. As there were potentially two peaks, one for single 
labelled and one for double labelled UBI 29-41, it was desirable to obtain a resolution 
that would allow the distinction to give an indication of the level of single and double 
labelled peptides at various Na125I concentrations. Initial experiments with radio-
HPLC were unsuccessful due to non-compatibility of the available Bioscan radio 
probe with 125I detection (data not shown), therefore the eluate from the HPLC was 
collected in 30 sec-1 min fractions and analysed using a gamma counter.  





Following the pre-analysis of the unlabelled peptide, the labelling process was 
performed as previously described (section 2.2.2). Two activities of Na125I were 
evaluated; the Pierce recommended activity (1 mCi) and 1/10 (0.1 mCi) the 
recommended activity, to mirror and verify the ITLC data previously collected.  
The radio labelled peptide was initially analysed on a regular UV chromatogram to 
verify the position of the peptide in relation to the results from the gamma counter. 
As can be seen in Figure 19, around 9 minutes there is no peak indicating that the 
peptide concentration was too low to be detectable by UV chromatogram. In order 
to prevent saturation the gamma counter later, 1 MBq (2.7 µL) of labelled peptide 
was diluted into 1 mL of water. This gave a peptide concentration of 54 nM, of which 
 
Figure 18 HPLC UV chromatogram of unlabelled UBI 29-41 
HPLC UV chromatogram of unlabelled UBI 29-41 to verify that the organic solvent gradient was 
suitable for peptide elution as well as do initial analysis of the integrity of the peptide. It furthermore 
provided a reference point for later radio labelled studies as the unlabelled peptide is not visible 
on the gamma counter. Finally, it gave information about the expected retention time of the radio 
labelled peptide allowing an increase in the resolution of the collected fractions by reducing the 
volume of the fractions around the expected elution time. 




20 µL was injected into the HPLC for analysis. This was sufficient to allow efficient 
gamma detection, despite not allowing detection of the product by UV. It did, 
however, prevent the estimation of unlabelled peptide in the batch as this would not 
show up in subsequent gamma detection analysis. 
 
 
The eluate from the HPLC was collected in fractions with increased resolution 
around the expected peptide elution. From 0 to 9 minutes 1 min fractions were 
collected, from 9 to 14 minutes 30 sec fractions were collected and the remaining 
eluate was collected at 1 min fractions. The fractions were hereafter analysed on a 
Wallack LKB 1282 Gamma Counter Compugamma.  
 
Figure 19 HPLC UV chromatogram of UBI 29-41 labelled with the recommended activity of 
Na125I 
HPLC UV chromatogram of the diluted radio labelled UBI 29-41. Due to the dilution no peak is 
visible around 9 minutes as was expected. The large peak at the beginning is the solvent front 
and is expected. The white areas is the baseline coloured white. 





As can be seen in Figure 20 there is a small peak in the first couple of fractions. This 
presumably represents free iodine in the sample or low level contaminants. The 
remaining activity elutes between minutes 9 and 17. The primary peak is found 
between 10 and 14 minutes, with the rest being eluted following increase in organic 
solvent concentration. There is a second peak around the 13:30 min fraction, 
however this was probably due to an over collection. In that tube compared to the 
previous fraction, at the point that fraction collection switched from 30 sec to 1 min 
in duration. 
The resolution provided by the fraction collection was significantly lower when 
compared to the HPLC of the cold labelled peptides (Figure 14). In order to allow 
 
Figure 20 HPLC analysis of UBI 29-41 labelled with the recommended activity of Na125I. 
This graph shows the fractional analysis of the activity eluted from the HPLC at various 
concentrations of organic solvent. The peak around 1-5 mins represents the free iodine in the 
sample whereas the peak beginning around 9 minutes ending at 17 minutes represents the 
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better separation of the peaks, a longer HPLC run with a more optimised organic 
solvent gradient would be required; in particular a more suitable radio probe would 
be required for greater resolution. 
Analysis of labelling was then conducted with 1/10 the recommended Na125I activity 
with fractions collected, as mentioned above, using the same organic solvent 
gradient. Between the two samples, the column was washed with a high organic 
solvent concentration to wash any residual 125I out of the system. The fractions 
collected were inserted into a diagram as above and the results are visualised in 
Figure 21. 
The results are very similar to those in Figure 20. The large peak at the beginning of 
the fractions is likely to be residual 125I from the previous experiments that had not 
been eluted in the wash and is not included in the calculations of the labelling yield. 
Radioiodine is known for its ability to adhere to solid matrices. Interestingly, on the 
major peak representing radio labelled UBI 29-41 there appears to be a shoulder to 
the left, which could be indicating a higher percentage single labelled peptide. It has 
to be taken into consideration that the counts obtained from the single- and double- 
labelled peptides are not 1:1, as the double-labelled peptide would containing double 
the number of 125I atoms. This would influence relative peak volume of an equal 
amount of single- and double-labelled peptides. While the resolution is not sufficient 
to confirm, the shoulder may correspond to a greater proportion of single-labelled 
species. If compared to the diagram showing UBI 29-41 labelled with the 
recommended activity there is less sign of a shoulder to the left of the peak, and if 




anything a slight shoulder to the right, possibly the result of a greater proportion of 
double-labelled species. 
 
When comparing the two peaks of presumably labelled UBI 29-41 from Figure 20 
and Figure 21, the level of 125I in the low activity evaluation is not 1/10 the level of 
the peptide labelled with the recommended activity as would be expected. When 
comparing the summarised peak counts of the major peak in Figure 20 
(recommended) of 1,855,040 CPM (minutes 9-17) and Figure 21 (1/10) of 1,051,809 
CPM (minutes 9-16) the 1/10 activity labelled population comprise 57% of the activity 
of the peptide labelled with the recommended activity. As the same amount of 
peptide is available, 2 nmol, it is likely that there is more free iodine in the reaction 
mixture labelled with the recommended activity than the peptide labelled with 1/10 
 
Figure 21 HPLC analysis of UBI 29-41 labelled with 1/10 the recommended activity of Na125I 
Overview of the fractional analysis of the eluate from HPLC of UBI 29-41 labelled with 1/10 the 
recommended activity of Na125I. The profile resembles that of Figure 20; however there is a slight 
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the activity. Although normally a labelling yield can be calculated, the adhesive 
nature of 125I complicates the correct estimation of free iodine.  
In summary, the analysis of labelled products by HPLC and associated fraction 
collection and gamma counting provided insight into the nature of the labelling which 
the ITLC could not provide, including a low resolution evaluation of the level of single- 
and double- labelled peptide in the samples to later be used for toxicity assays. 
Enhancing resolution using an appropriate radio probe would be a valuable 
extension to these studies and characterise the proportion of single- and double-
labelled peptide species. 
 
3.5 Stability analysis of 125I-labelled UBI 29-41 
During the labelling optimisation of UBI 29-41, indications started to occur that over 
time the labelling profile of UBI 29-41 slowly shifted from a labelled profile to a free 
iodine ITLC profile indicating issues with labelling stability when stored in Tris 
iodination buffer at 4°C. Then it became important to monitor stability of the 125I-
labelled UBI 29-41 and its implication for subsequent experiments. It was 
furthermore important to establish how fast this degradation occurred, in order to 
identify the time-frame in which they could be used in toxicity assays. 
A batch of labelled UBI 29-41 was analysed at a range of time points post-labelling 
using ITLC and compared to the free iodine ITLC profile in order to establish the 
degree of degradation over time. The peptide was labelled as previously described 
and, using ITLC, the labelling profile was established immediately after labelling and 
then after 6, 12, 24, 48, 72 and 144 hours. The labelled peptide was stored in Tris 




Iodination buffer at 4°C. As can be seen in Figure 22, the degradation over the 
course of 144 hours was substantial with loss of peak volume at the origin and 
increase of the peak at around 80 mm. At the end of the experiment the profile of 
the labelled UBI 29-41 was identical to the free iodine profile indicating complete 
degradation of the labelling, and the trend of dissociation over the time series was 
clear, within the accuracy permitted by ITLC. 
In order to analyse whether this could be due to the use of too high a concentration 
of 125I causing the labelling to destabilise, the experiment was repeated using 1/10 
the recommended Na125I (Figure 23). 
The profile for 1/10 Na125I was identical to the ITLC profiles from the stability of 
analysis using the recommended levels. This shows that the levels of radioactive 
iodine appeared to have no effect on the stability of the labelling within the frames of 
the experiment. It was not desirable to go lower in concentration as it was felt that 
this might have too much of an impact on any potential toxicity to be seen in later 
toxicity experiments. Consequently, it was decided to proceed with the toxicity 
experiments using the recommended levels of Na125I. However, due to the stability 
assays it was concluded that radio labelling had to be done immediately prior to the 
radio toxicity experiments in order to attempt minimising the effects of the 
dissociation of the iodine from UBI 29-41 despite the long half-life of 125I. 
Furthermore, prior to all experiments, ITLC analysis of the radio labelled UBI 29-41 
had to be performed to ensure that labelling had been successful. 






Figure 22 Time course stability analysis of radio labelled UBI 29-41 using recommended 
concentrations of Na125I. 
This figure shows an overview of the stability of the labelling of UBI 29-41 over the course of 6 days 
using the recommended amount of Na125I as recommended. (A) Free iodine profile (B) T=0 (C) T= 
6 hrs (D) T= 24 hrs (E) T= 48 hrs (F) T= 72 hrs (G) T= 144 hrs.  
 






Figure 23 Time course stability analysis of radio labelled UBI 29-41 using 1/10 of the 
recommended concentrations of Na125I. 
A complimentary experiments to the previous stabilisation experiment (Figure 18). 1/10 of the 
amount was used to test if the  observed deterioration of labelling  was due to the concentration of 
iodine.(A) Free iodine (B) T=0 (C) T= 6 hrs (D) T= 24 hrs (E) T= 48 hrs (F) T= 72 hrs (G) T= 144 
hrs. 
 





The aims of this chapter were to analyse the labelling efficiency and optimal labelling 
conditions of the antimicrobial peptide fragment UBI 29-41 with 125I. This was 
preliminary work for the later analysis of the radio toxicological effects of Auger 
electrons.  
Two strategies were taken to optimise and analyse radio labelling. Firstly, the 
Iodogen labelling procedure was assessed using non-radioactive sodium iodide as 
a replacement for Na125I. The “cold” version of the procedure allowed a refined and 
detailed characterisation of peptide iodination products using state-of-the-art LCMS 
technology. This was coupled with ITLC analysis of the standard “hot” procedure, 
carried out as per manufacturers’ instructions, to verify successful incorporation of 
radio iodide into UBI 29-41 and monitor stability of the radio peptide over time. While 
these different analyses were performed on products obtained using different 
chemical conditions, most notably the concentration of sodium iodide, they did 
provide insight into the radio labelling process and assisted in establishing the most 
appropriate chemical conditions. 
The cold labelled experiments were useful in analysing the labelling chemistry using 
the available HPLC-MS. This allowed the verification of the hypothesis that two 
iodine atoms were able to bind to the peptide. This is consistent with 3 levels of 
labelling of UBI 29-41 found (Figure 14). The first peak represents un-labelled UBI 
29-41, the second peak single labelled UBI 29-41 and the final peak is double 
labelled UBI 29-41. As the Iodogen labelling method labels the ortho positions of 
tyrosine residues, and there being two ortho positions on the single tyrosine present 




in UBI 29-41, the most likely interpretation of these results is that the first peak is the 
unlabelled UBI 29-41, the second single labelled and the final top is the double 
labelled peptide. Comparing the diagrams showing an increasing concentration of 
iodine further strengthens this argument. This shows that the right-most peak, 
representing the double labelled peptide increases as the other peaks decrease in 
size. Furthermore, as the final peak is analysed using MS it shows that the increase 
in size compared to the unlabelled peptide correlates with the substitution of two 
hydrogen atoms with two iodine and addition of oxygen by the mechanism 
elaborated in the introduction (Bennett et al., 2000). The MS analysis of the 
unlabelled UBI 29-41 added further information as it confirmed the size of the 
antimicrobial fragment and furthermore elucidated that the buffer in which it was kept 
prevented degradations as only one peak was present following storage for up to a 
year. MS analysis was performed several times to confirm the stability of UBI 29-41 
and no degradation was observed (data not shown). 
Unfortunately, due to the constraints of radioisotope-proof equipment the labelling 
analysis used for cold iodine labelled UBI 29-41 was not available for routine analysis 
when using 125I due to the long half-life, the volatile nature of 125I and that the HPLC-
MS equipment was not cleared for using radioactive isotopes. For this reason ITLC 
was implemented for rapid analysis of the radio iodinated product. This is commonly 
used in the analysis of radio labelled proteins (Pedraza-Lopéz et al., 2000; 
Chattopadhyay et al., 2010). 
A profile for free iodine and labelled UBI 29-41 was established, where after the 
amount of radioactive iodine added in the labelling process was manipulated to see 




if this had effect on the labelling. As anticipated, and in agreement with the HPLC 
labelling analysis, there indeed appeared to be unsaturated UBI 29-41 at lower 
concentrations of radioactive iodine, however it has to be appreciated that these 
concentrations were not comparable. This was visible by the disappearance of the 
peak at the furthest travelling distance, indicating the free iodine, as seen in the free 
iodine profile. As this peak completely vanished at half the activity and 1/10 the 
activity, there was no longer any certainty that all ortho positions of all tyrosine 
residues had been filled, indicating that at best a heterogeneous population of 
labelled UBI 29-41 was achieved. As a homogeneous population was desired it was 
decided that the original and Pierce recommended concentration of Na125Iwould be 
used. 
However the limitations of ITLC included the inability to evaluate the nature of 
labelling. As the concentration of Na125I was much lower than the concentrations of 
NaI analysed HPLC was implemented for a single analysis of the radio labelled 
product at the Rayne Institute, St. Thomas' Hospital. Although the resolution of the 
fragment collection did not allow for proper distinction of the single and double 
labelled peptide there were some indications, albeit at a low resolution, of a variance 
between peptide labelled with the recommended activity and peptide labelled with 
1/10 the amount of Na125I. The labelling profile of the radio labelled peptide was 
significantly different compared to the regular HPLC elution profile as radioactivity 
associated with the peptide was measured rather than concentration of the peptide. 
As UBI 29-41 contains two ortho positions of the tyrosine residue means that two 
radio nuclides would be associated with the fully labelled peptide and only a single 




125I associated with non-saturated UBI 29-41. Therefore, twice the number of UBI 
29-41 labelled with a single radionuclide is required to give the same signal as the 
fully labelled peptide. Finally, the non-labelled peptide would not be detected, 
reducing the maximum peak numbers from 3 to 2. When comparing this to the results 
obtained from the radio labelled HPLC fraction analysis, there is a small shift of a 
shoulder to the right in the analysis of UBI 29-41 labelled with the recommended 
activity  to a an elution profile with a shoulder slight to the left. This may represent a 
shift to singly-labelled peptide as Na125I was decreased. Collectively, the ITLC and 
HPLC data confirmed that to take full advantage of the targeting agent and maximise 
potential toxicity it appears that the optimal labelling is using the recommended 
levels of Na125I. 
The original intention was to produce batches of labelled UBI 29-41and remove 
samples as required for subsequent experiments, described in chapter 4.This was 
considered to be the technically optimal strategy for toxicity analysis to maximise 
batch for comparability. Furthermore, as the half-life of 125I is 60 days it was 
hypothesised that the variance in radiation would be minimal within the time frame 
in which it was intended to be used; this variance would be monitored at each toxicity 
assays by the establishment of the actual activity using a dose calibrator. However, 
as it was standard procedure to run an ITLC analysis of the labelled product prior to 
all experiments, it quickly became apparent that the stability of the labelled product 
was limited. For this reason it was decided to monitor a batch of labelled UBI 29-41 
over the course of several days. Over the course of the 144 hours in which the 
experiment was run a clear trend was visible. There seemed to be a clear 




destabilisation of the labelled product resulting in the profile to shift from a labelled 
one to one resembling the free iodine profile.  
This could be the result of the high energy of the labelled iodine destabilising the 
covalent bond causing radiolysis as found by Uenak and Uenak (1985). It was found 
that within a diameter of about 30 Å Auger electrons were radiolytically active, and 
outside this sphere the absorbed dose was not high enough to cause radiolysis in 
iodobenzene. This can be compared to the case of iodine labelled tyrosine, as 
tyrosine comprises a benzene ring to which the iodine is directly labelled. A similar 
result was found by Kauffman and Johnson that found that the 125I labelling of 
Staphylococcal enterotoxins at high specific activity lost association with the 
peptides over the period of 71 days (Kauffman and Johnson, 1975), although this is 
significantly longer than the 6 days reported here. It has to be noted that these 
peptides were labelled using chloramine-T and not Iodogen. In order to establish 
whether it potentially could be due to the high concentration of high energy 
radioactive isotopes, a 1/10 iodine concentration was analysed similarly to the first 
stability analysis experiment. Interestingly, this showed the same trend as the 
previous experiment. This indicates that the level of radiation has no effect on the 
stability of 125I conjugated UBI 29-41, at least at the levels analysed in these 
experiments. Previous experiments by Kauffman and Johnson showed that lowering 
the specific activity labelled to the staphylococcal enterotoxins analysed decreased 
the level of dissociation of the radionuclide (Kauffman and Johnson, 1975). Again, it 
has to be noted that the labelling process used was chloramine-T and not Iodogen. 
Furthermore, the levels of radioactivity analysed ranged from 1.4 MBq/μg protein to 




1.8 MBq/μg protein. In order to compare this data with the conditions investigated 
here an activity to peptide mass relation had to be established. The molecular weight 
of UBI 29-41 was found and confirmed by literature to be 1691 Da or g/mol. 2 nmol 
was utilised for the labelling which gives a total of 3.4 µg UBI 29-41 per labelling 
experiment. As an activity of 37 MBq was added to the labelling experiments this 
gives an activity of 10.9 MBq/µg UBI 29-41. Thus, taken into consideration, it seems 
reasonable to expect that the dissociation levels would increase even further when 
compared to the study by Kauffman and Johnson (1975). They saw a decrease in 
conjugation from 79% to 55% when they increased the activity from 1.4 MBq/μg to 
1.8 MBq/μg and stored at 1°C (Kauffman and Johnson, 1975). 
To further analyse whether the degradation was due to radiolysis it would be 
interesting to also analyse the stability of the labelled product using other radioactive 
iodine isotopes as 123I. This has a shorter half-life but has higher energy Auger 
electrons, however this would prevent stability analysis of the conjugation for the 
same time frame as 125I (144 hours.). If the destabilisation of the labelling was indeed 
due to radiolysis, by exchanging the isotope for one emitting higher energy Auger 
electrons, you would potentially see a faster destabilisation of the labelling.  
In order to establish whether the degradation of the radio labelled peptide was due 
to a chemical degradation of the labelling process, it would be informative to run the 
same experiments over the same time frame with non-radioactive iodine and analyse 
the stability of the product using HPLC-MS. If destabilisation is due to chemical 
degradation you would see the same trend as seen in the ITLC analysis of the radio 




labelled UBI 29-41 in the format of a reversion of Figure 14 from bottom to top. This, 
however, would have to be run on HPLC. 
In the original Pierce Iodogen labelling protocol, there are steps of purification, which 
are left out in these settings. Initially it was attempted to purify the labelled peptide 
using both standard PD10 columns as well as anionic exchange columns, however 
no peptide was recovered from either column. Furthermore, the purifications steps 
using columns would later cause additional issues with regards to the accumulation 
of solid waste of which the storage capacity in the department was limited, both with 
regards to dose and bulk. This resulted in the final steps of the protocol being cut 
out and the freshly labelled peptide would be considered ready for use. In the 
absence of HPLC-MS equipment in the department cleared for radioactive use, 
analysis of non-radioactive iodinated products was performed. Although not optimal, 
the cold labelling analysis did provide information about the labelling nature of UBI 
29-41 showing that two iodides could be added to each peptide. The ITLC also 
provided information directly comparable to the toxicity experiments as this showed 
not only that there appeared to be a successful labelling of the peptide but also 
provided information about the stability of the product.  
The importance of establishing the labelling stability is first and foremost significant 
to ensure correct analysis of the later radio toxicity experiments. As Auger electrons 
are very reliant on close proximity to the target DNA it is vital that the damaging 
agent is not dissociated from the targeting moiety. Furthermore, for more 
downstream applications, in therapeutic and diagnostic settings it is vital that the 
radioactive isotope is not dissociated from the targeting agent. This would lead to 




increased accumulation in non-target tissues and in diagnostic settings it could lead 
to misinformation of the disease in question. In a therapeutic setting it would be 
detrimental in other ways, as there would be no control over the radioactive isotope 
and damage to non-target tissues, in the case of iodine a common organ is the 
thyroid gland, would be very likely. As Auger electrons are DNA damaging agents, 
this could lead to, for example, an increased risk of cancers and therefore further 
complicate treatment.  
Following this series of optimisations of labelling of the initial targeting agent, UBI 
29-41, the next step was to analyse the effects of the Auger electrons emitted from 
the targeted iodine. 
  




4 Analysis of radio-toxicological effects of Auger 
electrons 
4.1 Introduction 
The aims of this chapter was to study the effects of the 125I radio labelled UBI 29-41 
from chapter 3 and the effects of Auger electrons on the survival rate of a range of 
model microorganisms. Auger electrons have previously been evaluated for the 
potential toxic effects on cancerous cell lines (Xu et al., 2002; Bodei et al., 2003; 
Kassis, 2003; Brady et al., 2013; Paillas et al., 2013) and we wanted to evaluate if 
this effect could be successfully transferred to microorganisms as a new approach 
to fight complicated and/or resistant strains. The primary mechanism of Auger 
electron toxicity is via the generation of double strand breaks (DSBs) in the cell DNA 
(Sharkey and Goldenberg, 2011; Balagurumoorthy et al., 2012). 
To take variance in size and potential difference in susceptibility into consideration it 
was decided to include a broad range of organisms. Four model organisms were 
chosen for the toxicity assays to obtain a broad characterisation of the toxicity of the 
Auger emitting isotope 125I. E. coli was used to represent gram negative bacteria, S. 
aureus to represent gram positive bacteria and C. albicans to represent pathogenic 
yeast. Finally, S. cerevisiae BY471 was included as this is a very well established 
as model organisms in biomedical settings (Cohen and Engelberg, 2007). 
In order to characterise the effects of toxic agents on the organisms, growth 
characteristics were initially established alongside cell number/absorbance density 
correlation to ease the analysis of the effects of radiation per cell. 




As UBI 29-41 is a known antimicrobial peptide, it is toxic to microorganisms in itself. 
Therefore, the innate toxicity of the initial targeting agent as well as the labelling 
buffer and iodine alone had to be established in order to rule out effects of the 
targeting agent on the survival rate of the model organisms. 
Finally, non-targeted 125I had to be included as a negative control to evaluate if the 
targeting had any effect. 
 
4.1.1 Specific aims: 
 To evaluate the growth characteristics of the five model organisms 
 To analyse the innate toxicity of non-labelled UBI 29-41 in each of the species 
 To evaluate the toxic effects of 125I- labelled UBI 29-41 compared to non-
targeted 125I 
 To assess the usefulness of radio labelled UBI 29-41 as an antimicrobial 












4.2 Characterisation of model organisms 
Prior to toxicity assays the growth curves of the model organisms had to be 
characterised. The model organisms included in this project were: Escherichia coli 
K-12, Staphylococcus aureus NCIMB 8625, Candida albicans sc5314 and 
Saccharomyces cerevisiae BY4741. This was required to ensure that the toxicology 
experiments are conducted in a way in which the fitness of the cells is as comparable 
as possible. Furthermore, it was desirable to keep the number of cells for the 
experiments constant in order to better compare the effects of the doses the 
organisms were subjected to. 
The four organisms were grown as described in section 2.2.6.1. Bacterial strains 
were grown in LB media and Yeast strains were grown in YPD. Growth curves for 
most organisms were established using a plate reader and converted to 
spectrophotometer OD units. Simultaneously, using a haemocytometer, the cell 
numbers were established at varying cell OD600 densities to allow conversion 
between optical densities and cell numbers. This would later enable the potential link 
between toxicity observed and amount of radiation per cell.  
Growth curves were conducted for all the organisms, with measurements made 
every 30 minutes (Figure 24A-D). 





As can be seen in the above figure, all the growth curves showed a classic lag phase 
followed by a log phase that plateaus in a stationary phase. The growth curve for S. 
aureus did not reach complete stationary phase as the growth curve was terminated 
when the log phase was reaching its end. This was based on previous observations 
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Figure 24 Growth characteristics of model organisms 
The basic growth characteristics for all model organisms, save S. aureus, were established using 
a plate reader set to measure the absorption at OD600every 30 minutes. A growth characteristic for 
S. aureus was found by manual measurements every 30 minutes for the first hour and hereafter 
every hour for 5 hours. Bacterial strains were grown in LB media whereas yeast strains were grown 































































(data not included). Furthermore, the beginning of the log phase had been 
established, which was the point required for the toxicity experiments. 
The growth curves allowed the establishment at what point the cells for the 
experiments needed to be harvested for the toxicity experiments. To both maximise 
cell fitness and to ensure optimal colony numbers, the beginning of the log phase 
was chosen.  This meant an OD600=0.1 for E. coli and S. aureus and an OD600=1 for 
C. albicans and S. cerevisiae as established by the results from the growth 
characteristics obtained. 
Following the establishment of the growth characteristics, the cell density had to be 
correlated to a cell number. This was done by counting cell numbers using a 
haemocytometer, at various cell densities. Cell numbers were hereafter plotted 
against the OD600 value at which they were collected. This was done for all the 
organisms and the results can be seen in the Figure 25A-D. The correlation between 
cell numbers and OD600appeared as expected to be linear. This allowed for a 
conversion between observed OD readings and the numbers of cells used in 
subsequent experiments (Table 10). 





By using the newly acquired conversion factors, and the knowledge that 100 μL of 
cell culture would be used for the experiments, the number of cells in each 
experiment could be calculated (Table 10). Prior to experiments the cell culture was 
diluted 1:1000 to ensure enough even spreading on the plates, leading to well 
defined colonies easing counting and thereby collection of data.  
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Figure 25 Relationship between OD600 and cell number 
Cell numbers at various culture densities were established using a haemocytometer. This was done 








































































































OD600 vs. cell number 
(S. cerevisiae BY4741)




Organism Number of cells 
per OD600 unit 
OD600 unit 
utilised 
Number of cells utilised 
in experiment 
E. coli K-12 3*108 0.1 3*103 
S. aureus  NCIMB 
8625 
6*108 0.1 6*103 
C. albicans 
sc5314 
2*107 1 2*103 
S. cerevisiae 
BY4741 
5*107 1 5*103 
Table 10 Number of cells utilised in experimental procedures 
For each of the model organisms a linear regression was made and the link between OD600 and cell 
numbers was established. In order to attempt to use the same number of cells per experiment 
regardless of organism and in order to utilise cells in the beginning of their respective growth curves, 
it was decided to use bacterial strains at OD600=0.1 and yeast strains at OD600=1. This also correlated 
with a comparable number of cells per experiment. The number obtained in the final column, is based 
on 100 μL of cells, the volume used in the experiments, taken out at their respective OD600 value and 
diluted 1:1000.  
 
4.3 Optimisation and validation of cytotoxicity assays using 
hydrogen peroxide as primary toxic agent 
Following the establishment of the growth characteristics of the organisms it was 
important to not only establish the base-line sensitivity of the organisms to DNA 
damage but also develop the protocol for the toxicity experiments. 
Initially, the correct dilutions of the organisms were established. Based on the results 
found for Table 10, this was done by harvesting the cells at the beginning of their 
respective log-phases and hereafter performing a round of serial dilutions of each 
organism. These were then plated in triplicate to find the dilution factor resulting in 
the highest number of colonies that produced an even and countable spread on the 




plates.  It was found that a 1x10-4 dilution of the cells gave the most reliable number 
(data not included). This dilution factor was the same for all organisms. 
The next step was to establish a protocol for the toxicity assays and investigate the 
baseline toxicity of the model organisms. For this the well-established DNA 
damaging agent hydrogen peroxide was chosen. Hydrogen peroxide is not only a 
good model chemical for DNA damage, it has ease of use and finally it also forms 
reactive oxygen species similar to ionising radiation (Henle and Linn, 1997). For this 
reason it was an excellent candidate for the development of the experimental setup 
and would also be useful to establish baseline susceptibility of each organism to 
DNA damage. 
The cells were harvested and diluted in the appropriate media. They were hereafter 
subjected to a range of concentrations of hydrogen peroxide ranging from 0.5 mM 
to 70 mM depending on the susceptibility of the organisms. To generate a full toxicity 
curve and thereby give a complete view of the effects of hydrogen peroxide on the 
organisms, the dose of hydrogen peroxide was increased until no colonies appeared. 
This was adapted accordingly over a range of experiments (data not included). All 
experiments were carried out in triplicate. The final results of the hydrogen peroxide 
experiments can be seen in Figure 26A-D. 





The baseline susceptibility of the model organisms to hydrogen peroxide varied 
between species. Both E. coli and S. cerevisiae only required exposure to 10 mM 
hydrogen peroxide for no colonies to appear. Interestingly, the two pathogenic 
strains, S. aureus and C. albicans appeared to be more resilient to the effects of 
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Figure 26 Effects of hydrogen peroxide on survival rate of model organism 
Analysis of the effect of 0.5 mM-10 mM hydrogen peroxide on E. coli survival. Overall survival rate 









































































hydrogen peroxide, which may have implications for later interpretation of results. 
The results were further validated by previous published results showing the same 
degree of susceptibility to hydrogen peroxide for both C. albicans and S. cerevisiae 
(Jamieson, 1996). 
All figures show consistent dose-response curves for all organisms. This shows that 
the establishment of the protocol for toxicity evaluation was successful and could be 
utilised for later experiments. 
The IC50 values were calculated from the trend lines for each curve. The results are 
visible in Table 11. 
 
All organisms showed susceptibility to the damaging effects of hydrogen peroxide, 
however C. albicans did show a significantly lower susceptibility than the other 
organisms requiring up to nearly 50 times the concentration to eradicate 50%. 
This set of experiments not only developed a successful method for toxicology 
studies in the model organisms used in this project, it also gave information about 
the innate susceptibility of the organisms to DNA damaging agents, acquired to aid 
later interpretation of radio toxicological results. Following the establishment of a 
Organism IC50 
E. coli  0.4 mM 
S. aureus 1.5 mM 
C. albicans 23.1 mM 
S. cerevisiae 0.6 mM 
Table 11 IC50 values of hydrogen peroxide  
 




successful protocol for toxicity studies, the next step was to evaluate the toxic effects 
of the targeting agent UBI 29-41 on the model organisms. 
 
4.4 Innate toxicity of UBI 29-41 
After baseline toxicity of the model organisms used had been established, the innate 
toxicity of the targeting agent had to be assessed using the methods developed from 
the hydrogen peroxide experiments.  
The establishment of the innate toxicity of UBI 29-41 was especially important as 
antimicrobial peptides, such as Ubiquicidine, have sterilising effects, and the innate 
toxicity could interfere with later analysis of the results from the radio toxicological 
assays. Furthermore, observation of innate toxicity would provide a confirmation that 
the UBI 29-41 was functional and had not deteriorated in any fashion that could 
compromise binding. 
The experiments were conducted as explained in section 2.2.7- 2.2.8 on all of the 
model organisms described earlier to evaluate if any difference in toxicity would be 
observed due to variance in susceptibility. Each organism was grown to the desired 
OD600, where after they were diluted 1:1000 and subsequently subjected to two 
concentrations of UBI 29-41: 50 μM and 100 μM. These concentrations were 
selected as being close to the concentration to be evaluated later in a labelled 
version of the peptide (20 µM). The organisms were subjected to the antimicrobial 
peptide for 1 hour at room temperature. The organisms were then plated and grown 
at the appropriate temperature for 1-2 days until colonies appeared and the number 
of colonies was counted manually. All plates were done in triplicate. The toxicity of 




the antimicrobial peptides was established by counting the number of colonies in the 
control group (which was not subjected to antimicrobial peptides), with the survival 
rate calculated by counting how many colonies appeared in UBI 29-41 exposed 
plates and dividing this by the number found in the control group. The toxicological 
effects of UBI 29-41 are summarised in Figure 27. 
The innate toxic effects of UBI 29-41 are quite apparent in the bacterial strains E. 
coli and S. aureus, whereas there seems to be a higher degree of resistance in the 
yeast strains C. albicans and S. cerevisiae. C. albicans displayed an intermediate 
level of susceptibility whereas S. cerevisiae showed very low susceptibility. Taking 
the mechanism in which antimicrobial peptides work into consideration, including 
membrane destabilization, perforation and bacteriolysis which are all dependent on 
 
Figure 27 Analysis of the innate toxicity of UBI 29-41 
The above figure summarises the experiments analysing the innate toxic effects of UBI 29-41. 
The most susceptible organisms were the bacterial strains. C. albicans had an intermediate 
susceptibility to the toxic effects of UBI 29-41 and S. cerevisiae showed very little decrease in 


































reaching a critical threshold, the smaller size of bacteria compared to yeast could 
mean that this threshold could be reached at lower concentrations (Brouwer et al., 
2008). 
This experiment, and the observation that UBI 29-41 leads to no more than a 20-
30% decrease in survival rate at levels at 50 μM than the concentration to be later 
evaluated in radiological experiments allowed an analysis of the impact of targeted 
radio iodine in subsequent experiments. 
 
4.5 Toxicity of non-radioactive non-labelled activated iodine 
As iodine itself has been used as a means to sterilise infections, it was necessary to 
evaluate the toxicity of iodine itself (Block, 2001). Furthermore, the labelling 
technique required the presence of Tris Iodination buffer which would be incubated 
with organisms along the labelled peptide. By activating the non-radioactive by the 
same means as 125I for UBI 29-41 labelling, both factors could be evaluated 
simultaneously for any effects on microbial survival.  
The experiments were conducted as for the hydrogen peroxide (section 2.2.7) with 
the hydrogen peroxide being replaced by iodine activated by the Iodogen compound 
in Tris Iodination buffer. Two concentrations were evaluated, 0.5 mM and 1 mM. All 
experiments were done in triplicate. 





No significant decrease in survival rate was seen in most of the model organisms, 
indicating that neither Tris Iodination buffer nor iodine itself had any effect on the 
survival rate at the levels investigated. (Figure 28). 
However, the concentrations of "cold" iodine evaluated are much larger than the 
concentration of "hot" iodine to be evaluated later. This means that the likelihood of 
iodine to have an effect on the survival rate in later experiments is low. 
 
Figure 28 Overview of toxicity of non-radioactive iodine in labelling buffer 
This figure summarises the toxicological studies of activated free non-radioactive iodine in Tris 
Iodination buffer on the four model organisms included in the project: E. coli, S. aureus, C. 
albicans and S. cerevisiae. Two doses were evaluated: 0.5 mM and 1 mM and the survival rates 
were compared to organisms grown without iodine and Iodination buffer. No difference in survival 
rate was observed in any of the organisms ruling out the intrinsic antimicrobial effect of iodine and 
any effect of iodination buffer in later toxicological studies. All experiments were performed in 




























4.6 Toxicity of 125I-labelled UBI 29-41 and non-targeted 125I 
Following the establishment of the innate toxic effects of UBI 29-41 as well as the 
effects of buffer and non-radioactive iodine alone, the next step was to label UBI 29-
41 with 125I according to the protocols optimised in chapter 3. In order to establish 
the toxic effects of the targeted Auger electrons it had to be compared to the effects 
of non-targeted 125I (125I not conjugated to UBI 29-41). 
The non-targeted 125I was generated by activating the 125I in the same fashion as 
when labelling peptide (section 2.2.2), without adding UBI 29-41. This ensured that 
the only variable was the targeting agent. Two experimental doses per tube were 
evaluated, 1 MBq and 5 MBq, with actual doses established using a dose calibrator. 
These values were included as the x-axis values. The error bars were included to 
show the variability of the data formed by triplicate of organisms plated from the 
same tube. All model organisms were, following the one hour exposure to either 
radio-labelled UBI 29-41 or free activated iodine, washed with growth media and 
plated in triplicate. All work was done in a flow hood behind lead fortified glass. The 
results can be seen in Figure 29, Figure 30, Figure 31 and Figure 32. 







Figure 29 Comparative overview of the radio toxicological effects of 125I labelled 
UBI 29-41 and free activated 125I in E. coli 
Overview of the toxic effects of either targeted (125I-UBI 29-41) or non-targeted (free iodine) 
125I on E. coli survival rate. Several doses were analysed. No significant difference was 





























Figure 30 Analysis of the effects of UBI 29-41 targeted Auger electrons compared to 
non-targeted in S. aureus. 
S. aureus was exposed to increasing levels of both targeted (125I-UBI 29-41) and non-
targeted (free Iodine) Auger emitting isotope 125I No toxic effect of targeting the Auger 































Figure 31 Evaluation of the radio toxicological effects of UBI 29-41 targeted 125I 
compared to non-targeted activated 125I. 
Overview of the radio toxicological effects of UBI 29-41 targeted versus non-targeted 125I on 
attenuated Candida albicans. No significant difference between the targeted and non-



























Figure 32 Analysis of the radio toxicological effects of targeted 125I compared to non-
targeted 125I on S. cerevisiae BY4741 
Overview of the toxic effects targeted (125I-UBI 29-41) and non-targeted (free iodine) 125I on 
S. cerevisiae survival rate. No significant difference was observed between the two groups 






























The results of these analyses provide no evidence of toxic difference between the 
free 125I and the UBI 29-41 targeted 125I in any of the model organisms. In the S. 
cerevisiae radio toxicity experiments there is one point at around 2.7 MBq that 
appear to show a high degree of toxicity, however this effect was not observed at 
higher doses and is therefore considered and outlier. As no such effect was seen in 
any of the other cell lines and was not replicated in this one, it was concluded that 
the point was an experimental outlier. 
To further validate that no variance between the slopes were statistically significant, 
the two populations were compared using multiple linear regression analysis. A 
summary of the results can be seen in Table 12.  
 
Organism p-value 
E. coli K-12 0.78 
S. aureus NCIMB 8625 0.47 
C. albicans sc5314 0.69 
S. cerevisiae BY4741 0.54 
Table 12 P-values from multiple linear analysis of the two populations of 
free 125I and targeted 125I 
 
This confirms that there is no statistical significant variance in the slope between 125I-
UBI 29-41 and free 125I. 
 




4.7 Binding analysis 
To establish whether the observed lack of toxicity was due to inefficient targeting 
and binding of 125I to the microorganisms, a binding analysis was conducted.  
Following incubation of S. cerevisiae and E. coli with both free activated radioiodine 
and UBI 29-41 targeted 125I, the exact dose applied to cells was established using a 
dose calibrator as a frame of reference. The cells were hereafter pelleted by 
centrifugation and resuspended in 900 μL of appropriate media. The cells were 
pelleted again, the supernatant was removed and the cells were resuspended in new 
media. This was conducted 3 times where after the final resuspended pellet was 
transferred to a new tube to prevent radiation bound to the initial Eppendorf tube 
from influencing the results. Cells were counted and the level of 125I bound to the 
pellet was measured by dose calibrator and expressed in Bq/cell.  
As can be seen in Figure 33 there appears to be no difference between the free 
iodine and 125I-UBI 29-41, either before or after the washes, for either organism. A 
higher degree of radiation associated with cells subjected to 125I-UBI 29-41 could 
have been expected if targeting was successful.  
These results have several possible implications: 1) binding was compromised or so 
weak in interaction that the washing dissociated the UBI 29-41 from the cells 2) the 
radiation associated with the cells was so low that it could not be distinguished from 
background; and finally, 3) the concentration of labelled peptide used in the 
experiments was too low to allow sufficient binding to cells. 







Figure 33 Binding efficiency of 125I-UBI 29-41 compared to free iodine on S. cerevisiae and E. 
coli at the two analysed theoretical doses 
S. cerevisiae and E. coli were subjected to the two doses 1 MBq and 5 MBq radioiodine- either 
targeted or non-targeted. The actual doses were established using a dose calibrator. Measurements 
were performed both just prior to washing and after washing. The majority of the radiation appears 
to have been removed following washing for both free iodine and 125I-UBI 29-41. Furthermore, no 
difference in radiation associated with the cells was observed in either free iodine or125I-UBI 29-41 
indicating that there was either too low concentration of peptide or that binding of UBI 29-41 had 


















Bq per cell on S. cerevisiae before 




















Bq per cell on S. cerevisiae before 



















Bq per cell on E. coli before and 





















Bq per cell on E. coli before and 
after washing (5000 kBq)
Free iodine
125I-UBI 29-41




Based on these results, there is no conclusive evidence as to whether125I could be 
used as a therapeutic agent in the settings tested in this study. The results in this 
project indicate that under the circumstances tested here, there is no toxicity 
associated with 125I-UBI 29-41; however as will be outlined below, many parameters 
could be tested to further investigate the therapeutic potential of Auger electrons. 
 
4.8 Discussion 
This chapter aimed to establish a system for evaluating the toxicity of radio labelled 
UBI 29-41 on four model organisms. The growth curves for these organisms were 
successfully produced, and the innate levels of toxicity of UBI 29-41 was measured 
including the innate toxicity of the iodination buffer and experimental conditions as 
well as iodine itself. No significant additional effects of the radio labelled peptide 
were observed when compared to free 125I. 
Prior to any radio toxicity experiments, the clonogenic assays for the determination 
of effects of various compounds on survival rate of model organisms, was 
established. Simultaneously, the baseline susceptibility of the organisms was 
established using hydrogen peroxide (H2O2) as this is a well-known DNA damaging 
agent. Although hydrogen peroxide is not directly DNA damaging it is harmful 
indirectly via the Fenton reaction (Henle and Linn, 1997). This made hydrogen 
peroxide a suitable candidate for the establishment of baseline susceptibility. 
Interestingly, it was found that the two pathogenic strains, S. aureus and C. albicans 
showed higher degree of resistance to the effects of hydrogen peroxide compared 
to E. coli and S. cerevisiae. The findings were further backed by previously published 




results in C. albicans by Jamieson et al. when compared to S. cerevisiae (1996). 
Jamieson hypothesised that this resistance could be explained by the fact that C. 
albicans is a pathogenic strain and is therefore more likely to encounter the 
phagocytic cells of the immune system, which are prone to generate large quantities 
of ROS as a means to destroy invading microorganisms (Jamieson et al., 1996: 
Janeway et al., 2005). It is therefore more likely to have generated an efficient SOS 
response system to deal with DNA damage compared to the non-pathogenic strain. 
As S. aureus is an opportunistic strain it could be hypothesised to have generated 
the same resistance. Based on these results it is likely to expect the same tendencies 
in the later radio toxicity experiments. 
The UBI 29-41 innate toxicity assays were included to establish the toxic effects of 
the targeting agent and to be able to subtract the effects of the targeting agent of 
any toxic effects seen. The results showed that the bacterial strains were generally 
much more susceptible than the yeast strains to the toxic effects of UBI 29-41. As 
one of the modes of function of antimicrobial peptides is the creation of pores in 
microbial membranes when the concentration reaches a certain threshold, it could 
be hypothesised that the reason for the increased susceptibility of the bacterial 
strains is down to size difference. As the bacterial surface area is much smaller than 
that of the yeast strains, it is reasonable to think that the critical membrane 
concentration for pore formation is reached faster for bacterial strains (Tyson et al., 
1979; Grossman et al., 1982; Loferer-Krößbacher et al., 1998; Brogden, 2005). 
However, it is possible that other factors could play a role in susceptibility to 
antimicrobial peptides including the difference in cell wall. Despite the cell wall being 




negatively charged in both microbial systems, the chemical components differ 
greatly, where bacterial cell wall is compose of peptidoglycan and yeast is composed 
primarily of polysaccharides (Madigan et al., 2003). The most likely explanation, 
however, is the size difference, although other factors may have an impact on the 
displayed difference in susceptibility. 
One of the main aims of the project was to determine the radio toxicological effects 
of Auger electrons. Auger electrons have previously been evaluated as potential new 
therapeutic agents for cancer therapy (Xu et al., 2002; Bodei et al., 2003; Kassis, 
2003; Brady et al., 2013; Paillas et al., 2013). As the surface markers for cancers 
differs with varying degree from normal human cells, the effects of targeting are 
limited. This is one of the great challenges with cancer targeting. Secondly, the size 
of mammalian cells (~2000 μm3) is much greater when compared to bacterial cells 
(~1 μm3), or even yeast (~40 μm3) (Tyson et al., 1979; Grossman et al., 1982; 
Loferer-Krößbacher et al., 1998; web 4). As Auger electrons have a very limited 
range, the requirement for cancer therapy is internalisation in order to get close 
enough proximity to the target DNA to induce DSBs. This is potentially less of an 
issue with bacterial cells due to their restricted size. 
The overall results obtained showed very little indication of any toxic effects of 125I 
regardless of the presence of UBI 29-41. Furthermore, as the slopes of the survival 
rate were zero it is very likely that UBI 29-41 did not show any toxic effects, as this 
would have given some degree of reduced survivability of the organisms. As 
mentioned previously there are several potential reasons to why no toxicity was seen 
when based on the binding studies: 1) binding was compromised or so weak that 




washing dissociated UBI 29-41 from the cells. This lack of binding seems unlikely to 
be due to suboptimal pH. UBI 29-41 binds via electrostatic interactions due to the 
high number of positively charged amino acids. The sequence 
is TGRAKRRMQYNRR, which illustrates that nearly 50% of the peptide comprises 
positively charged amino acids (red letters) (Welling et al., 2002; Akhtar et al., 
2005).UBI 29-41 was stored in an acidic buffer, (5% acetic acid, pH4) whereas the 
Tris iodination buffer was neutral (pH 7.5) (Welling et al., 2002). The addition of acidic 
buffer containing UBI 29-41 would therefore only slightly acidify the buffer. 
Furthermore, as the pI of UBI 29-41 is 12.18 (calculated using expasy.org) a pH of 
7.5 will not have had any effect on the targeting ability, which therefore can be ruled 
out as a cause of lost binding.  
Another possibility of assessing the targeting effects of UBI 29-41 other than the 
binding experiment could be to label the peptide with a fluorophore and visualise in 
a fluorescence microscope or perhaps flow cytometry, however the small size of the 
microorganisms might be a hindrance. An issue with this might be that the labelling 
process of UBI 29-41 with a fluorophore might alter the binding of the peptide. 
Furthermore, the chemical requirements themselves might alter the chemical 
properties of the peptide itself. All this might make it incomparable to the iodine 
labelling.  
However, iodine might have had an effect on the targeting as well. An easy way to 
elucidate the effect labelling had on the targeting ability of UBI 29-41 would be the 
repetition of the innate UBI 29-41 toxicity experiments with "cold" labelled UBI 29-




41. This would have to be done using the same concentrations of UBI 29-41 as in 
the previous experiments.   
Finally, the concentration of labelled peptide was too low to allow sufficient binding, 
which potentially could have been circumvented by longer incubation time. The 
organisms were only incubated with the toxic agents for one hour prior to plating to 
reduce organism growth. Additionally, due to the very small concentration of UBI 29-
41 it is plausible that the labelled antimicrobial peptide did not have the time to reach 
its full potential in binding capacity. Furthermore, the decay rate of 125Ihas to be taken 
into consideration as only a very small percentage of the isotopes within this 
timeframe will decay and eject any Auger electrons to cause DSB. Although it was 
desirable to leave the targeted 125I attached to the cells after plating, this would only 
still be two additional days out of a half-life of 60 days. However, in order for these 
studies to make sense the Bq/cell ratio has to be addressed. The preliminary studies 
included in this chapter showed a very low association of radiation with the cells; ~5 
Bq/cell for the 1 MBq experiment and ~10 Bq/cell for the 5 MBq experiment in the 
case of S. cerevisiae, which is very low, practically background, and appears to be 
insufficient to cause cell death. E. coli showed no binding to cells following washing; 
however this could be due to the low resolution of the dose calibrator. As binding 
appears to be a significant issue it would be interesting to investigate the radiation 
associated with a peptide that has a potential better binding affinity than UBI 29-41 
to microorganisms. As an antimicrobial peptide was chosen in the first place due to 
its non-specific binding, the best approach would likely be to analyse a range of 
antimicrobial peptides for a better binding profile. Using more targeted molecules 




such as antibodies, despite binding with better affinity, have greater specificity and 
would very likely prevent a comparative study of various microorganisms as done 
here. 
Another option could be the exchange 125I for a higher energy emitter such as 123I. 
Although this would potentially suffer the same fate as 125I if binding was the limiting 
factor, it would be interesting to see if a higher energy isotope would be able to cause 
enough damage in the limited time frame. Another advantage of utilising 123I would 
be the shorter half-life which would allow for better utilisation of the decay rate within 
the time frame of the experiments. It would also be of interest to analyse the same 
conditions, isotope and doses, but for a longer period. The problem with a longer 
incubation time however, could include issues with cell fitness. Two options to 
address could be the following: 1) either the cells would have to be incubated at the 
correct temperature to improve the conditions of the cells, however the cells would 
then be dividing. Considering this, it could potentially be worthwhile to have 
investigated the growth of the organisms in the presence of free iodine as well as 
125I-UBI 29-41 to monitor the effects on the growth of the organisms over a longer 
period of time. This would also be a better simulation of the physiological conditions 
under which the potential therapy would be executed in vivo. 2) Alternatively the cells 
could be incubated for longer under the same conditions as the protocols used for 
the executed radio toxicity experiments, although this could potentially compromise 
the viability of the cells, potentially masking any effects induced by the radiation, so 
careful controls would be needed. 




Although no effect was seen in the toxicity assays in this project, the effects of the 
Auger electrons might not have been large enough to cause any detrimental effect 
in any of the organisms. This does not necessarily mean that no radiological effect 
took place. There are several ways available for the detection of DSBs in 
microorganisms. A straightforward method could be the detection of SOS-response 
genes in the organisms by quantitative reverse transcriptase polymerase chain 
reaction (qRT-PCR). As the SOS response is activated by a DSB, any up regulation 
would be an indication of damage to the DNA implying that the range was not too 
great for Auger electrons to reach. These genes could include RecA for bacteria and 
either Rad51 or Rad54 for yeast (Clever et al., 1997; Cox, 2007). RecA is a highly 
conserved protein involved in the initial steps in regulation of recombinational DNA 
repair mechanisms and homologous recombination in prokaryotes. Furthermore, it 
is found in virtually all bacteria (Roca and Cox 1990; Cox, 2007). Rad51 and Rad54 
are both involved in the recombinational DNA repair in yeast, where Rad51 is the 
RecA homologue and Rad54 is homologue to the Swi2p/Snf2p family of DNA 
stimulated ATPases (Clever et al., 1997). Although they are both highly conserved 
in eukaryotes, a rad54mutation made S. cerevisiae particularly susceptible to 
ionising radiation (Walmsley et al., 1997). Furthermore, Rad54 transcription has 
been found to be up-regulated when S. cerevisiae was subjected to DNA damaging 
agents making this a particularly interesting candidate for DNA damage monitoring. 
Another example of a method for detecting genotoxicity is the utilisation of strains of 
microorganisms that have been found or modified to alter their phenotype when 
subjected to genotoxic compounds. Such organisms include the Salmonella (Ames) 




test strain or the SOS Chromotest for bacterial strains and the GreenScreen 
genotoxicity assay for yeast strains (Quillardet et al., 1982; Mortelmans and Zeiger, 
2000; Cahill et al., 2004). The Salmonella Ames test works by the reversion of 
Histidine dependent strains back to Histidine independent clones upon subjection to 
DNA damage. This allows the direct evaluation of the effects of ionising radiation 
(Mortelmans and Zeiger, 2000). The SOS Chromotest is a colorimetric assay based 
on the insertion of lacZ under the control of sfiA, a gene involved in the SOS 
response allowing the visualisation of induction of an SOS response, indicating 
genotoxicity (Quillardet et al., 1982). Finally, the GreenScreen yeast based system 
is a colorimetric system based on green fluorescent protein (GFP) under the control 
of the RAD54 promoter. This will upon DNA damage induce an expression of Green 
Fluorescent Protein (GFP) making DNA damage observable (Walmsley et al., 1997; 
Cahill et al., 2004).  
These simple systems may be able to provide information regarding the efficiency 
of the radioactive isotopes to induce DNA damage and thereby potentially give an 
insight into whether the dimensions of the microbial cells are still above the range 
threshold. Furthermore, they could potentially clarify whether the lack in mortality 
may be due to an efficient SOS response. These tests would therefore give important 
information on whether an isotope emitting higher energy Auger electrons would be 
a beneficial route.  
Given that no toxicity was seen under the conditions tested there are some obvious 
changes that could have been made had time not been an issue, as well as the 
limitations to the storage of solid waste. The first change would be the exchange of 




125I with 123I due to the identical labelling techniques. This would allow testing of 
higher energy Auger electrons. A second range of experiments could revolve around 
the issue of proximity. Several studies have shown that in order for Auger electrons 
to meet their full potential they have to be closely linked to DNA, indicating that range 
is the main issue when dealing with Auger electrons (Krisch and Ley, 1974; 
Feinendegen, 1975; Adelstein et al., 2003; Buchegger et al., 2006). It is for this 
reason likely due to proximity issues that no toxicity was seen. This could potentially 
be alleviated by changing the isotope to one of longer range. As Auger electrons are 
particularly short range perhaps the exchange for an α or β emitter, which have 
previously been shown to be efficient in for example sterilising biofilms. However, 
the range is as mentioned also a disadvantage here as this leads to crossfire effects 
potentially damaging the surrounding tissue. 
However, the targeting agent utilised, UBI 29-41, being an antimicrobial peptide has 
intrinsic porine forming abilities. By increasing the UBI 29-41 concentration, or 
possibly give a dose of non-labelled UBI 29-41 prior to radio toxicity experiments, 
this might cause some porine formation allowing the internalisation of the radio 
labelled peptide and thereby closer proximity to the DNA. There are, however, 
several complexity factors to be considered in this scenario, the first being the innate 
toxicity of UBI 29-41. For this reason the baseline toxicity had to initially be 
established. This would therefore result in four simultaneously conducted 
experiments to be made: Free iodine alone, free iodine alone with the preliminary 
dose of UBI 29-41, preliminary dose of UBI 29-41 alone and finally the preliminary 
dose of UBI 29-41 with targeted 125I-UBI 29-41.  




As an alternative targeting agent it could be interesting to see the effects of labelling 
a known antibiotic (Chattopadhyay et al., 2010). As existing antibiotics require 
internalisation to function this would mean that the radioactive isotope would be 
internalised as well which would reduce the range to the target DNA.  
 
4.9 Conclusion 
The data in this chapter provide a baseline for the further investigation of radio 
toxicity in a range of model organisms. Despite the results seen in the comparisons 
of targeted versus non-targeted 125I here, these experiments provide some 
groundwork for the future experiments as outlined above. Indeed, for most 
therapeutic settings more targeted molecules are required for the delivery of toxic 








5 Design of anti-LAM scFv 
5.1 5.1 Introduction 
UBI 29-41has many advantages for testing labelling optimisation and toxicity in a 
range of species; for example its unspecific nature of binding allowing it to bind to a 
wide range of microorganisms as previously assessed. However, this unspecific 
nature also limits its value in most therapeutic settings as previously mentioned. For 
this reason designing and expressing a second targeting agent that could introduce 
more specificity to radionuclide delivery was a priority.  
Antibodies are renowned for their versatility and generally strong antigen-binding 
capacity making them good agents for targeted therapeutic and diagnostic agents. 
The particular part of the antibody of interest is the variable domain, also referred to 
as the antigen-recognising part, or the complementary determining region, which 
encompasses the antigen binding part of the antibody. This part needed to be 
isolated so as to create a targeting agent that would have many advantages in both 
therapeutic and diagnostic settings over the native antibody (section 1.4.3.3). 
The target chosen for the scFv was Lipoarabinomannan (LAM) as it is present on 
the widely distributed pathogen, M. tuberculosis, which is in need of new therapeutic 
and diagnostic tools. Furthermore, a hybridoma cell line, CS-35, expressing an anti-
LAM IgG3 antibody already existed, easing the design process. 
The hybridoma would allow extraction of mRNA from the cell line, and amplification 
of the variable heavy and light chain domains with framework-specific primers. This 
would allow the sequencing and identification of the correct variable domains which 
could subsequently be used for the design of the anti-LAM scFv.  




5.1.1 Specific aims 
1) To test the viability of a hybridoma cell line, CS-35, and confirm that it expressed 
anti-LAM 
2) To extract and purify mRNA from (1) and generate cDNAs 
3) To use existing primer sets against variable regions in the IgG, to produce 
products for cloning 
4) To validate products by sub cloning and sequencing 
5) To use the sequence obtained to design an anti-LAM scFv expressing coda 















5.2 Hybridoma CS-35 anti-LAM IgG3 expression 
The first part of the design process required the verification that the hybridoma cell 
line, which had been frozen for a prolonged period, was still viable and able to 
express the desired antibody. 
The hybridoma cell line CS-35 was grown in DMEM with foetal calf serum at 37°C 
and 5% CO2. In order to verify the expression of anti-LAM IgG3 antibodies from 
which the anti-LAM scFv would be designed, cell culture supernatant was analysed 
for IgG3 content.  
The hybridoma cell lines were allowed to grow until confluent, where after the 
medium was harvested and analysed using SDS-PAGE. 
In order to analyse whether there was any antibody expression, the gel was analysed 
on a western blot due to the increased sensitivity using a polyclonal rabbit anti-
mouse antibody HRP conjugate for analysis. Western blots uses antibody 
technology to visualise specific proteins in a protein gel that would otherwise be 
indiscriminate and show all proteins present. By having the primary or secondary 
antibody modified with an enzyme, most commonly horse radish peroxidase (HRP), 
and the addition of a chemiluminescent agent, a luminescent product is produced in 
the vicinity of the protein of interest in proportion to the concentration of the protein 
and this can be visualised using photographic film.  
As can be seen in Figure 34, there are dark bands at ~150 kDa, which is the 
expected size for an IgG3 antibody and more importantly, this band is not present in 
fresh media, confirming antibody expression. 






5.3 Purification of mRNA from CS-35 anti-LAM IgG3 hybridoma 
Following the successful verification of the antibody expression the next step was to 
initiate the scFv design process by purifying the mRNA from the hybridoma cell line, 
which would include the mRNA for the light and heavy chains of the anti-LAM IgG3. 
From this, the variable domain would be later isolated. As later primers would be 
used to amplify the variable regions, it was not necessary at this stage to specifically 
purify the mRNA of the desired transcripts. The mRNA was therefore purified as a 
bulk by utilising poly-dT coated magnetic agarose beads that would anneal anything 
with a poly-A tail. By using a magnet the beads would be attached to the tube wall 
allowing wash of the lysate and thereby a pure mRNA sample. 
 
Figure 34 Hybridoma CS-35 anti-LAM IgG3 antibody expression analysis using western blot 
analysis. 
Western blot analysis of the scFv expression in hybridoma supernatant at increasing concentrations. 
Bands with increasing strength was visible with a size of ~150 kDa consistent with the expected size 
Lanes: (1) 1 μL media (2) 10 μL media (3) 20 μL media (4) 1 μL CS-35 supernatant (5) 5 μL CS-35 








Due to the very unstable nature of mRNA, the purification was done in an RNase 
free environment and the purified product was immediately converted to cDNA using 
the First Strand cDNA synthesis kit (Novagen), when mRNA purification had been 
verified. This would ease downstream protocol execution. 
 
Figure 35  Agarose gel mRNA purification analysis 
Analysis of mRNA purified from the CS-35 hybridoma cell line 
expressing the anti-LAM IgG3 antibody.  A smear is visible in 
the lane containing the mRNA sample confirming that mRNA 
purification was successful. Due to the unstable nature of 









The CS-35 anti-LAM IgG3 hybridoma cell line was grown until confluent, where after 
the cells were harvested and lysed. The lysate was then passed over poly-dT coated 
magnetic agarose beads and the resulting eluate was analysed on an agarose gel 
and compared to an mRNA positive control. As can be seen in Figure 35, there is a 
visible, however faint, band in the first lane representing the positive control. The 
second lane represents the purified mRNA and a clear smear is visible indicating 











5.4 Primer test 
Based on the previously validated expression of antibodies the next step was 
commenced. This included the primer test screening for viable variable heavy and 
light chain domains for the scFv design. Following the conversion of the mRNA to 
cDNA, the next step was to isolate the variable heavy and light chain domains for 
later in silico assembly into the anti-LAM scFv. 
For this murine primer sets from an antibody primer set kit were used. These primers 
were designed to anneal to the framework region in the variable domains of mouse 
antibodies (the anti-LAM IgG3 being derived from a murine hybridoma cell line), 
allowing the amplification of the antigen binding epitopes of the antibody.  
(Rademacher et al., 2007). 
All the primer sets for the murine monoclonal antibody variable domains were tested. 
According to the Ig primer set kit (Novagen) used, the expected band size of variable 
chain amplifications is situated around 500 bp for both heavy and light chain variable 
domains. As can be seen in Figure 36 many primer pairs showed amplifications of 
cDNA fragments. Furthermore, some primer pairs showed unspecific binding and 
amplification. 
The gene segments chosen to continue in the study were MuIgVH5’-B, MuIgκVL5’-
B, MuIgκVL5’-C, MuIgκVL5’-D, MuIgκVL5’-E, MuIgκVL5’-F and MuIgκVL5’-G. 





Some primer pairs (MuIgVH5’-C, MuIgVH5’-E and MuIgκVL5’-A) showed noticeable 
amplifications of up to multiple gene segments of a size <500 bp and were therefore 
not included in the further analysis. Some of these could also be due to primer 
dimerisation, given the high concentration of primers used. 
The ~500 bp PCR products were gel purified and amplified using Taq polymerase. 
Due to the use of Taq polymerase the variable regions were amplified with 5’-
overhangs, which removed the requirement for a preliminary digestion to be inserted 
 
Figure 36 Heavy and light chain variable domain amplification. 
The mouse Ig primer set kit for the amplification of the variable heavy and light chain domains 
was tested on the cDNA converted mRNA purified from the CS-35 anti-LAM IgG3 hybridoma cell 
line. A single heavy chain domain gave a clear 500 bp product (lane 3) and several of the light 
chain primer pairs resulted in a ~500 bp product.  (1) 1 kb ladder (2) MuIgVH5’-A (3) MuIgVH5’-B 
(4) MuIgVH5’-C (5) MuIgVH5’-D (6) MuIgVH5’-E (7) MuIgVH5’-F (8) MuIgκVL5’-A (9) MuIgκVL5’-B 
(10) MuIgκVL5’-C (11) MuIgκVL5’-D (12) MuIgκVL5’-E (13) MuIgκVL5’-F (14) MuIgκVL5’-G (15) 








into the pGEM-T Easy vector. The orientation of the insert can be controlled when 
required via choice of appropriate restriction enzymes. However, as the only 
requirement from the clones was the sequence of the insert, the direction in which 
the gene segment was inserted was inconsequential. Following the insertion into the 
pGEM-T Easy vector, the product was sent for sequencing using M13 primers, both 
forward and reverse, for sequencing analysis. 
 
5.5 ScFv in silico design process 
5.5.1 Sequencing data analysis 
The sequencing data quality was initially analysed using Chromas and the most 
reliable part of the sequencing data was isolated. This included the removal of the 
first 15-20 bp and removing any base pairs (bp) beyond 850-900 bp as the quality of 
the sequencing data beyond this point generally became unreliable. As the length of 
the inserted variable domain was only approximately 500 bp this segment would 
most likely contain the entire insert. Both forward and reverse primers were 
analysed, and a consensus sequence created to avoid single base mutations from 
ambiguities in the traces. This could potentially lead to incorrect amino acids, which 
could have detrimental effect on the binding affinity.  
The forward and reverse sequences were annealed using BioEdit and the insert was 
identified by blasting the sequence against the vector sequence. This allowed the 
isolation of the variable domains for further in silico combination of the variable 
domains for the final steps of the basic scFv design. 
 




5.5.2 Translation and identification of correct VH and VL domains 
The vector sequence was translated in all reading frames using the expasy.org 
translational tool. Translation was required in all reading frames as insertion 
orientation was random as described previously. The reading frames that gave the 
longest translational product were considered to be correct, and the translated 
products were analysed for semi-conserved regions present in variable domains. 
One example hereof was the existence of two cysteines in the amino acid sequence. 
Following identification of the cysteines the sequences were analysed using a 
compilation of published variable domain sequences for reference (Kabat et al., 
1991). This book gives an overview of all sequenced antibody variable regions and 
allowed this to be a point of reference for the identification of the framework regions 
of the variable domains. Since the framework regions are slightly more conserved 
than the variable domains, the correct variable heavy and light chain segments could 
be identified.   
Following this process for all the above mentioned positive primer test amplifications, 
it was found that MuIgVH5’-B indeed was the heavy chain variable fragment and that 
MuIgκVL5’-F was the light chain variable fragment. The rest of the sequences 
showed only few resemblances with light chain variable domains and were therefore 
not carried on in the design process. As many hybridomas also express aberrant 
light chains it is not surprising to find them here as well (Carroll et al., 1988). 
These results therefore indicate that only one heavy chain and one light chain are 
translated.  This is in consensus with the hybridoma cell line expressing monoclonal 




antibodies, in which there would be expected only one functional variable heavy and 
one light chain domain expressed. 
 
5.5.3 In silico assembly of the anti-LAM scFv 
Once identified, the nucleotide sequence was trimmed so that the sequence when 
translated would be in the first forward frame. This was required for insertion into the 
P. pink vector, which needs the inserted product to be in the correct frame.  
The next step in the design process was the linking of the variable domains. Many 
linkers have been tested, however, the most utilised linker is the poly-glycine linker, 
(section 1.4.3.3) and this seemed a reasonable choice to use in the first instance. 
The shorter the linker, the greater the chance of the scFv forming unwanted dimers. 
Linkers shorter than 12 residues compromises proper folding of the scFv and force 
it to form multimers with other scFv molecules (Todorovska et al., 2001. Previous 
studies with 4 repeats of the poly-glycine motif, (GGGGS)4, had still shown some 
degree of dimerisation (Emberson et al., 2005), so 5 repeats were included. The 
linker was created by alternating the codon sequences for glycine and serine to 
minimise loop-out deletions and the creation of secondary structures in the RNA and 
DNA (Trinh et al., 2004) 
There are two possible conformations in which to design the scFv:  VH-linker-VL or 
VL-linker-VH. Some studies indicate that there are some expression rate differences 
between the two; the former has shown higher expression rates, whereas the latter 
has shown higher binding affinity (Desplancq et al., 1994; Weisser and Hall, 2009). 
Furthermore, the VL-linker-VH conformation has shown to have a preference for 




multimer formation compared to the VH-linker-VL conformation (Dolezal et al., 2000; 
Todorovska et al., 2001).  
 
The most commonly used conformation is therefore the VH-linker-VL conformation 
as high expression levels were of interest and it was decided that the VH-linker-VL 
was the conformation to be analysed first. The baseline nucleotide sequence of the 
scFv without modifications can be seen in Figure 37. 
 
 
Figure 37 Initial nucleotide sequence of the assembled anti-LAM scFv 
The nucleotide sequence for the anti-LAM scFv designed from the CS-35 anti-LAM IgG3 
hybridoma cell line. The sequences for the heavy chain (red) and the light chain (blue) were 
obtained from purified PCR amplifications of the variable domains. The polyglycine linker (pink) 








5.5.4 Modifications and optimisation of the anti-LAM scFv sequence 
5.5.4.1 His-tag addition 
With the baseline sequence of the anti-LAM scFv identified, it needed modifications 
for later purification. As the scFv was to be inserted into the pPinkα-HC vector, which 
would result in the secretion of the scFv into the supernatant of the culture, a means 
of purifying the scFv was required. For this reason a (His)6-tag was added in the C-
terminus. This would not only enable the scFv to be purified using a simple Ni2+-
column, but would also allow easy identification using anti-His antibodies for 
screening using dot-blots and western blot analysis systems. 
Not only is the His-tag advantageous for the purification process it could potentially 
also be useful labelling anchor for site-specific 99mTc and 188Re labelling (Tavaré et 
al., 2009; Badar et al., 2014). 
The final amino acid sequence of the expressed scFv can be seen in Figure 38. The 
top figure depicts the variable heavy and light chain domains in red and blue, 
respectively. The poly-glycine linker is depicted as pink and the His-tag is the yellow 
sequence at the C-terminus, a commonly used site. The bottom figure depicts the 
same scFv sequence, however here the framework regions are depicted as red and 
the CDR regions of the heavy and the light chains are shown in green. 






5.5.4.2 Restriction site modifications 
The internalisation process into the pPinkα-HC vector is the result of a fairly 
elaborate combination of restriction sites to optimise sequence alignment between 
the vector and the scFv (Figure 39).  
One of the primary reasons for choosing the pPinkα-HC was to allow the expression 
of the scFv into the supernatant of the culture, significantly easing the process of 
purification. This is, as mentioned in section 1.5.4.1, allowed by the α-mating factor 
signal sequence which is situated just before the insertion site. To ensure 




Figure 38 Overview of the final anti-LAM scFv amino acid sequence 
The final sequence of the anti-LAM scFv generated in silico from the sequencing data from the 
amplified heavy and light chain domains of the CS 35 anti-LAM IgG3 hybridoma cell line.  
(A) The red section refers to the heavy chain domain, the pink region is the poly-glycine linker, 
the dark blue refers to the light chain domain and the yellow domain is C-terminal the hexa-
histidine tag. (B)Visualisation of the framework regions (red), the CDR regions (green), the linker 








and the signal sequence is required. For this reason, an MlyI site was inserted in the 
5’end of the nucleotide sequence. MlyI is a blunt end restriction enzyme that 
recognises the following sequence: 
5’-  G A G T C (N)5↓ 
3’-  C T C A G (N)5↑ 
 
The way it cuts the insert allows the removal of all traces of the restriction site and 
in combination with a StuI digest of the pPinkα-HC vector allows the generation of 
only 3 nucleotides between the signal sequence and the scFv sequence. More 
importantly, three nucleotides also prevent any frame shifting, which would prevent 
the expression of a functional product.  
 
 
Figure 39 Insertion analysis and modification requirements of the scFv insert. 
Due to the requirement of proximity of the α-mating factor signal sequence to the gene of interest 
and more importantly the in-frame insertion of the product a unique combination of restriction sites 
were required. An MlyI site in the 5' end of the scFv gene would allow the removal of the entire 
cleavage site. Combined with a StuI cleavage of the vector would result in only the inclusion of 3 
bp between the α-mating factor signal sequence and the anti-LAM scFv. 3 bp furthermore ensure 
in-frame translation. Due to the nature of the blunt-end digest in the 5' end, a non-blunt end 









As MlyI is a blunt-end restriction enzyme a non-bunt end restriction enzyme had to 
be chosen for the 3’-end digest as to ensure the correct insertion orientation of the 
scFv sequence; a blunt-end insertion could result in an inverted insertion. For this 
reason a KpnI site was inserted into the 3’ end of the nucleotide sequence, based 
on the recommendation of the manufacturer. 
Following the insertion of the sites into the scFv sequence it was checked for 
restriction sites. It was found that two additional internal MlyI sites were present. As 
this would be detrimental to the insertion process the sequence was manually 
modified to remove the restriction site while retaining codon identity. The sequence 
was translated in silico to ensure that the translated product was unchanged. 
The final modification to the nucleotide sequence was the addition of two stop 
codons. As the variable domains are only sections of a translated product they do 
not intrinsically contain stop codons, which had to be added manually. It was chosen 
to add two stop codons as this has previously been found to be more efficient in 
stopping translation than a single stop codon, which occasionally can be overlooked. 
The final modified nucleotide sequence can be seen in Figure 40. 
As the host was to be Pichia pastoris the nucleotide sequence was generated from 
the peptide sequence based on the genetic code optimised for Pichia pastoris. The 
table used can be found in appendix 1. Finally, the in silico designed nucleotide 
sequence for the anti-LAM scFv was sent to Geneart for generation of the anti-LAM 
scFv pPinkα-HC plasmid. 
 







The aim of this chapter was the development of a novel, more targeted agent for the 
delivery of either therapeutic or diagnostic radioactive isotopes to help in the fight 
against infectious diseases, in this case tuberculosis. 
Due to the extremely versatile nature of antibodies, an antibody fragment, an scFv, 
was designed with an anti-LAM IgG3 as template. LAM, being one of the prominent 
survival and virulence factors of M. tuberculosis, was a natural first choice. As scFvs 
have a very short circulation time means that they are very well suited for imaging 
purposes. Furthermore, this also prevents the exposure of patients to prolonged 
exposure to radiation. However, the ~3.6 hours half-life would still allow the target 
microorganisms to be subjected to therapeutic radiation. 
 
Figure 40 Nucleotide sequence overview of the final modified product 
Final modifications to the nucleotide sequence including the addition of the correct restriction sites 








To ease the designing process a hybridoma cell line, CS-35, expressing an anti-LAM 
antibody, already existed. 
Following mRNA purification and cDNA conversion, the library was analysed for the 
existence of variable heavy and light chain domains using primer sets specifically 
designed to anneal to the framework regions of the variable domains. The framework 
regions are less variable than the complementary determining regions of the variable 
domain, allowing the design of a limited, albeit numerous, primer sets. 
The amplification was a success and multiple bands were amplified to the estimated 
size of ~500 bp (Figure 36). Despite the success, in some of lanes multiple bands 
were visible, all shorter than the expected 500 bp. The most likely reason for this can 
be found at the bottom of the gel. In all lanes, except the negative control without 
primers, a large concentrated smear is seen, indicating that the concentration of 
primers utilised higher than required and has likely resulted in primer dimerisation 
and/or non-specific binding and amplification.  
There were technically 2 lanes containing amplified heavy chain variable regions, 
MuIgVH5'-B and MuIgVH5'-E, however the latter was not the expected 500 bp and 
was therefore not further investigated. Furthermore, sequencing of MuIgVH5'-B 
revealed correct consensus sequences for variable heavy chain domains and was 
therefore concluded to be the heavy chain variable domain of the anti-LAM antibody. 
With regards to the light chain variable domain several primer sets resulted in 
amplification:  MuIgκVL5'-B, MuIgκVL5'-C, MuIgκVL5'-D, MuIgκVL5'-E, MuIgκVL5'-F 
and MuIgκVL5'-G. Some amplifications were more profound than others, but they 
were all sequenced and analysed, revealing that MuIgκVL5'-F was the only fragment 




containing identification segments for variable light chain. The rest of the light chain 
domains did not, following sequencing, show any elements that would identify them 
as variable light chain domains. It was therefore concluded that they were aberrant 
light chain domains, as mentioned in section 1.4.3.3, and were therefore not further 
included in the design process. This eventually led to having one light chain and one 
heavy chain domain, which would end up in the final scFv design. 
The heavy and light chain variable domains were in silico joined in a VH- linker- VL 
conformation. There is no consensus when joining the variable domains whether it 
should be with the heavy chain domain first or last, however, there are some studies 
that have shown that the conformation decided for in this project tends to have a 
better expression rate over the VL-linker-VH conformation (Desplancq et al., 1994; 
Weisser and Hall, 2009).  
The linker chosen was the classical poly glycine linker composed of repeats of four 
glycine residues followed by a single serine. An advantages of using this as a linker 
is that it introduces enough flexibility to allow proper folding of the scFv. The reason 
for choosing 5 repeats is that, as mentioned in section 1.4.3.3, the shorter the link, 
the higher degree of multimerisation of the scFv there is, and we were interested in 
single scFv molecules. The linker length has sometimes been used as a means to 
create multimers and multispecific scFv. We were however interested in analysing 
the properties of the monomeric peptide including binding affinity. 
One of the disadvantages of the linker is its high hydrophilicity, which results in it 
being very solvent exposed. This furthermore increases the chance of encounters 
with proteases, which have better cleavage conditions due to the increased 




exposure. Other linker designs have been evaluated, however these have mostly 
been involved in linker length (Alfthan et al., 1995; Albrecht et al., 2006). 
Furthermore, they are all, however, composed of hydrophilic and small amino acids 
in order to introduce the right degree of flexibility required. It is also important to 
choose the correct residues based on their tendencies to form secondary structures. 
The more likely they are to form α-helices or β-sheets the more likely they are to 
introduce rigidity to the linker and would have a negative impact on the correct folding 
of the scFv and possibly increase the chance of multimerisation. Again, monomeric 
scFvs were the area of interest in the first instance and for this reason the decision 
was made to go for the conventional polyglycine linker despite the potential 
degradation disadvantages. 
Due to the non-structural nature of the linkers does make them potential interesting 
targets for the insertion of sites for site-specific radio nuclide labelling. This would 
not only easy labelling analysis but would also be beneficial in keeping the radio 
nuclides away from the binding site thereby potentially disrupting binding. However, 
the modifications have to be non-disruptive to the chemical properties of the linker 
including flexibility and hydrophilicity to ensure correct assembly of the variable 
domains. 
The system for expression was chosen to be P. pink for several reasons. It has 
shown high protein expression levels, it is capable of post-translational modifications 
as disulphide bonds, of which two are present in the scFv, and glycosylations and 
this particular system allowed the secretion of the expressed protein into the 
supernatant for easy purification (Cereghino and Cregg, 2000). However, there are 




some issues that could validate the expression in other systems. Preliminary 
analysis of the peptide sequence did not show any signs of glycosylation sites, and 
this could validate the expression in an E. coli system as E. coli has previously been 
shown to be able to mount a very high yield (Weisser and Hall, 2009). As a high yield 
is optimal for later identification and binding studies and the fact that no glycosylation 
sites were visible this could have been a valid choice. However, as the scFvs do 
contain disulphide bonds, scFvs expressed in E. coli would have to be artificially 
established. Although previous studies have indicated that the disulphide bonds in 
intrinsically stable scFvs are not necessarily essential for correct folding, it was not 
apparent what effect the loss of the disulphide bond would have on the designed 
scFv (Wörn and Plückthun, 1998).  Using a eukaryotic system was therefore optimal. 
Furthermore, the P. pink system offered an easy way of manipulating expression 
initiation with the addition of methanol. This would ease the monitoring of expression 
and establishment of optimal supernatant harvest points. Furthermore, P. pink 
offered an easy selection method with the ade2 knock-out allowing selection on 
adenine-free media.  
Mammalian systems were not considered as an expression system as protein yield 
is generally very low (Braren et al., 2007; Leong and Chen, 2008). Furthermore, it is 
in theory not required given the relative simplicity of the scFv relative to the intact 
monoclonal antibody. 
Now the anti-LAM scFv had been designed, the next step was to express the protein 
in the P. pink expression system and later analyse the protein for post-translational 
modifications and more importantly the binding affinity to LAM. 




The above mentioned design of anti-LAM scFv was entirely based on the 
assumption that the antibody expressed from the CS-35 hybridoma cell line indeed 
would bind to LAM.  
As this would later function as a positive control for the designed anti-LAM scFv 
binding affinity, it would be prudent to initially analyse the basic binding capacity of 
the antibody. This could be done by performing a sandwich western blot running 
solubilised LAM on a gel and utilising the anti-LAM antibody as primary antibody, 
followed by an anti-mouse HRP conjugated antibody for visualisation. This would 
validate whether the antibody does bind and would function as a base for 
comparison. However, this binding analysis would be of a qualitative form rather than 
quantitative.  
Further analysis would include establishment of binding affinity, however, this would 
be in concert with the anti-LAM scFv in order to establish the effects on binding 
affinity by isolating the variable domains from the conserved regions of the antibody. 
However, it is not only the isolation of the variable domains from the rest of the 
monoclonal antibody that has an impact on the binding affinity of the scFv. Research 
has indicated that in some cases a C-terminal His-tag interferes with the antigen 
recognising site of the scFv, thereby having a negative impact on the binding affinity. 
By incorporating the His-tag in the N-terminal reduced this impact (Goel et al., 2000; 
Arnau et al., 2006). This is something that could be considered in the case that 
binding affinity of the purified molecule was found to be very low. 
This, however, will be explored in the following chapter. 
 




6 Analysis and optimisation of anti-LAM scFv 
expression 
6.1 Introduction 
In the previous chapter, an anti-LAM scFv was designed in silico based on the CS-
35 anti-LAM IgG cDNA sequences produced from a hybridoma cell line. This design 
was sent to Geneart for cloning into the P. pink vector, and once the vector was 
received, the next step was to get it expressed and analyse the protein product. 
The expression cell line chosen for its ease of use and generally high expression 
rates was P. pink, a genetically modified subtype of P. pastoris (Cereghino and 
Cregg, 2000). Furthermore, being a yeast expression system it has the capacity to 
add post-translational modifications and therefore better mimic mammalian 
expression compared to bacterial systems. As it was not known what the level of 
post-translational modifications of the scFv would be, choosing a bacterial system 
over a yeast system for higher expression might have had detrimental effect on the 
final product expressed. One of the further advantages of the P. pastoris system, 
including P. pink, is the versatility. Many parameters can be modified in order to 
attempt optimisation of expression.  
The initial aim of expression was to get enough levels to both analyse via HPLC-MS 
to validate the expression of the correct protein. The second objective was to ensure 
high enough levels to be able to analyse the binding specificity and efficiency of the 
generated scFv. As most scFvs lose some of the binding affinity of the mother 
molecule, it was interesting to compare the binding to the original anti-LAM IgG3 
from which it was isolated. 




6.1.1 Specific aims 
1) To amplify the plasmid in E. coli, and transform the amplified plasmid into the 
Pichia pink expression vector 
2) To qualitatively assess the level of expression in transformed colonies to select 
clones for further analysis 
3) To assess levels of degradation of the protein, and identify strategies for 
minimising its impact 
4) To adjust the growth conditions and inhibition of proteolytic degradation to 
optimise the amount of retrieved product for downstream analysis 
5) To use the products from (4) to validate that the expressed protein is anti-LAM 














6.2 Transformation of Pichia pink strains 1-4 with pPinkα-HC 
containing anti-LAM scFv 
Following the return of the pPinkα-HC vector from Geneart, containing the anti-LAM 
scFv gene, the construct was internalised via electroporation, as elaborated in 
section 2.2.25, into the competent XL1-Blue E. coli cell line in order to amplify the 
plasmid for later transformation of P. pink and to obtain a stock of easily obtainable 
plasmid for potential downstream applications. P. pink was transformed using 
electroporation, which was the recommended mode of transformation by Invitrogen 
as described in section 2.2.25.  
The transformed strains were plated onto three Pichia Adenine Dropout (PAD) plates 
and one YPD plate. As PAD plates are deficient in adenine, only transformed cells 
containing the vector will be able to grow. The negative control, consisting of non-
transformed P. pink, was plated on one PAD plate. Furthermore, two positive 
controls of P. pink viability were included; one pre-transformation to ensure the 
viability of the cells before electroporation and one post-transformation to confirm 
that the cells have not lost viability during the electroporation process. Both were 
grown on traditional YPD agar. Transformed strains would show up as larger 
white colonies on the PAD plates compared to the small red untransformed colonies. 
The plates for grown for 4 days at 30°C enclosed in a lightly wound plastic bag to 
prevent loss of humidity. 
As can be seen in Figure 41, the negative control on PAD shows no growth, 
indicating no P. pink growth without transformation with pPinkα-HC vector, and also 
that no contamination had taken place. Non-transformed P. pink was also analysed 




on YPD plates prior to transformation to confirm the viability of the cells. As can be 
seen in Figure 41B and Figure 41C the plates are confluent which indicates fully 
viable cells both before (B) and after (C) electroporation. The last 3 plates show the 
growth of single white colonies on PAD plates representing successfully transformed 
clones amongst small pink colonies of non-transformed P. pink. Three plates were 
grown to increase the chance of finding successfully transformed clones. 
 
 
Figure 41 Transformation evaluation of P. pink. 
Transformation analysis of P. pink with anti-LAM scFvpPink α-HC vector including controls. (A) 
PAD + Non-transformed P. pink. This was a negative control showing that the non-transformed 
P. pink was incapable of growing and furthermore  confirmed that no contamination had taken 
place  (B) YPD + Non-transformed P. pink. This worked as a positive control showing that the P. 
pink was viable prior to electroporation   (C) YPD + transformed P. pink. This was a second 
positive control showing that the P. pink was still viable following electroporation (D- F) PAD + 
Transformed P. pink. White colonies (big) signify successful transformation, where small pink 











Each white colony was hereafter isolated and analysed for anti-LAM scFv production 
in a small-scale screening. 
 
6.3 Analysis of scFv expression from P. pink anti-LAM scFv 
clones 
Following transformation of P. pink the white colonies were isolated on new PAD 
plates and catalogued for later ease of retrieval. In order to analyse the isolated 
clones for those expressing anti-LAM scFv, 5 mL of BMGY was inoculated with a 
sample picked from a clone and grown until an OD600 of 60 was reached. The culture 
was hereafter pelleted and resuspended in BMMY media to a final OD600 of 160-180 
and grown for 48 hours. One sample of 400 µL was taken of the BMGY prior to 
switch to BMMY as a negative control, just after switch to BMMY, again as a negative 
control and finally after every 24 hours. Methanol was replenished once after 24 
hours to a final concentration of 0.5%. This was done for all colonies evaluated. 
The supernatant from the clones were then evaluated for scFv production via dot-
blot analysis using an anti-hexa-His HRP-conjugated antibody for visualisation. This 
antibody would detect the His-tag designed into the scFv in the previous chapter. 
The positive control used was an anti-CD33scFv constructed by a former 
postdoctoral research associate, Louise Emberson (Emberson et al., 2002). The 
small volumes of the mini scale cultures made it logistically possible to analyse 
multiple colonies simultaneously and allowed a more efficient screening for an anti-
LAM scFv producing transformant. 




Dot blots use the same visualisation technology as western blots with the difference 
that the proteins are not transferred to a nitrocellulose membrane from a 
polyacrylamide gel, but rather transferred directly by loading the supernatant 
containing protein to a dot blot chamber and applying vacuum, which allows the 
supernatant to traverse the membrane leaving the peptide bound in the membrane 
in defined dots. Dot blots have the advantage over western blots that they can load 
up to several hundred µL compared to approximately 20 µL for western blots. 
Furthermore, they allow the screening of many clones simultaneously, where 
western blots are again fairly limited. This makes dot-blots especially suitable for the 
initial screening of colonies. In the dot blots in the present study 200 μL of samples 
were loaded in each well apart from positive controls, where 10 μL were loaded 
unless otherwise specified.  
As can be seen in Figure 42, very weak dots are visible after 24 hours. The signal 
was faint, but demonstrated the first indications of protein expression. 45 clones 
were subsequently analysed for protein expression using this experimental 
procedure (data not included). 
 





The 6 clones showing highest degree of expression after the first round of screening 
were analysed once more to verify their protein expression, and to compare the 
expression levels directly to enable selection of the clone with highest protein 
expression. The results of this screening are shown in Figure 43. 
 
 
Figure 42 Initial screening of anti-LAM scFv expressing P. pink clones 
Screening analysis of transformed P. pink clones for clones expressing His-tagged proteins. The 
top figure gives an overview of the loading profile of the dot-blot. The bottom figure shows the 
resulting dot-blot. Very faint dots are visible after 24 hours of expression in BMMY media (red 
square). Especially clones 4 and 5 showed protein expression. This was however gone after 48 














Clones 5 and 6 that previously showed protein expression did not show signs of any 
expression in the second round of analysis despite static parameters. Again, as in 
Figure 42, protein was undetectable after 48 hours suggesting degradation. Four 
clones were, however, positive for protein expression: 4, 7, 16 and 17. In particular 
clone 17 showed the highest degree of consistency in protein expression level when 
compared to the initial screening results. It furthermore seemed to show a higher 




Figure 43 Second screening of high expressing clones. 
6 clones that previously indicated expression were analysed again to identify the clone with 
highest and most stable protein expression. Clones 4, 5, 7, 16, 17 and 18 were re-analysed in 
mini scale cultures and visualised using dot-blot.  
(A) Overview of the loading profile of the dot-blot. (B) Dot-blot showing samples from the 6 clones 
taken at T= 0 and hereafter every 24 hours for 48 hours in total. Four clones, 4, 7, 16 and 17 
showed expression after 24 hours. Only clone 17 showed expression after 48 hours. The rings 












One problem encountered with the initial rounds of dot-blot and western blot analysis 
was the degree of background staining, an example of which can be seen in Figure 
43. However, optimisation of washing conditions gradually decreased the 
background staining, which is demonstrated in later dot-blots. 
Despite the promising results of protein expression from the screening analysis it 
has to be noted that 200 mL of supernatant was added to each well. For this reason 
purification was required in an attempt to maximise the concentration for later 
downstream analysis. In order to do this, the first step was to up-scale the cultures 
to increase the number of cells expressing protein, thereby hopefully increasing the 
end concentration of protein for later analysis.  
 
6.4 Large-scale production and purification of anti-LAM scFv  
The first step towards identifying the protein was the acquisition of a higher 
concentration of product on which analysis could be performed. This primarily 
required a large-scale production and then purification of the protein. This was 
accomplished using a Ni2+ column to capture the protein using the His-tag designed 
into the scFv in the previous chapter. 
Cultures from P. pink anti-LAM scFv clone 17, selected for its apparent high 
expression levels, were grown as previously described with the following 
difference:  the volume of the starter glycerol-containing BMGY culture was 
increased to 300 mL, resulting in a methanol-induced anti-LAM scFv expressing 
BMMY culture of approximately 100 mL. The culture was grown at 25°C for 24 hours 
and harvested by centrifugation at 5000 rpm. The anti-LAM scFv was immediately 




purified from the supernatant using a His Trap Ni2+ column as described in section 
2.2.29. The Ni2+ of the purification column is able to interact with the imidazole ring 
of histidine in the His-tag. As 6 histidines are present in direct succession the binding 
affinity is very efficient. The Ni2+ column however, interacts with all encountered 
imidazole rings resulting in low-affinity binding of non-specific proteins as well. By 
washing the column with a low concentration imidazole the non-specific proteins 
bound will be eluded quickly as the low imidazole concentration more easily 
outcompetes the single histidine binding facilitated compared to the stronger affinity 
of the His-tag. This therefore not only helps increase the concentration of the desired 
product but also increase the purity. 
The anti-LAM scFv was grown accordingly onwards unless otherwise specified. 
The first step in protein purification was the optimisation of the imidazole 
concentration required to optimally elute the scFv. Too high a concentration may not 
only elute scFv multimers but could also interfere with later HPLC-MS analysis. Too 
low a concentration might cause the protein to be not eluted at all. Furthermore, the 
analysis would also elucidate at what fraction the protein is eluted which would ease 
later purifications by skipping the need for a dot-blot analysis step prior to down-
stream analysis. 





At first a wash buffer with an imidazole concentration of 100 mM was implemented 
as a means to wash any low- affinity bound proteins out and only leave the scFv 
bound to the Ni2+ column. Following the 100 mM imidazole wash, a variety of elution 
buffers containing from 150 mM imidazole to 500 mM imidazole were washed 
through the column and collected at 10x1 mL elutions, which were then analysed 
using dot-blot analysis. 
As can be seen in Figure 44, no dots were visible in the elution profile save the first 
dot in 150 mM imidazole concentration. Furthermore, a dot is visible in the wash, 
 
 
Figure 44 Initial protein purification optimisation on HisTrapTM Ni2+ column 
Initial analysis of protein purification at various imidazole concentrations using dot-blot analysis. 
Initial imidazole concentration of wash buffer was 100 mM. Supernatant (SN) prior to loading to 
column was analysed for protein content to analyse the degree of purification, the flow through 
(FT) was additionally included to analyse the degree of protein binding and wash (W) was also 
included to analyse any potential premature elution.2 dots are visible in the diagram: one in the 













indicating that a His-tagged protein is eluted in the wash buffer. This suggests that 
the His-tagged protein eluted in the first mL of 150 mM imidazole elution buffer is the 
left-over protein that had not quite been eluted in the wash buffer. To prevent 
premature elution, the concentration of imidazole was lowered to 25 mM. The 
purification was performed as previously with the exception that the 100 mM 
imidazole wash buffer now was utilised as an elution buffer. The protein samples 
were acquired as previously and the samples were again analysed using a dot-blot. 
As can be seen in Figure 45, the dot blot analysis of the elution profile changed. 
There was no longer any protein being eluted in the wash, which was further 
confirmed by the disappearance of protein in the first sample. The scFv was now 
being eluted in the 3rd and 4th sample (100 mM imidazole). This is consistent with 
the theory that the first couple of samples would contain primarily 25 mM imidazole 
wash buffer and thereby be too low an imidazole concentration to elute any scFv.  
The optimised imidazole concentrations in both wash buffer and elution buffers were 
used henceforth in scFv purification. 
 






6.5 Size analysis of eluted protein 
A disadvantage of dot-blot analysis is the lack of size information. This demanded 
the analysis of the purified protein in a gel-separation based system. For this western 
blot analysis was chosen due to the sensitivity compared to Coomassie stained 
SDS-PAGE gels. This was important as SDS-PAGE gel wells have a more limited 
loading capacity than dot-blot wells (20 μL vs. 200 μL), and protein expression levels 
were already known to be low. 
A new batch of scFv was purified according to the optimised conditions, with the 
exception that the only elution buffers used were 100 mM imidazole and 500 mM 
 
 
Figure 45 Optimised elution profile of anti-LAM scFv. 
A) Schematic overview of the loading profile of the dot-blot analysing the second elution profile of 
anti-LAM scFv. B) Dot-blot analysis of optimised elution profile. Two dots were visible at 100 mM 
imidazole concentration at the third and fourth 1 mL sample (red box). 200 μL were loaded and 10 















imidazole. 500 mM imidazole was included to wash out any residual protein from the 
column.  
The modified purification protocol showed an increased protein concentration 
(Figure 46B) compared to previous results and further size analysis could now be 
conducted. The elutions displaying the highest concentration of protein (100 mM 
imidazole elution samples 3-7were analysed on a western blot using an anti-his HRP 
conjugated antibody for visualisation (as described in section 2.2.32). 
As can be seen in Figure 46C, there appears to be a band in the first lane, 
corresponding to the 3rd elution sample at 100 mM imidazole. More importantly, the 
positioning of the band shows a size of roughly 30 kDa. The theoretical molecular 
weight of the designed anti-LAM scFv without post-translational modifications was 
calculated to be approximately 27 kDa. Therefore, the band in the western blot most 
likely represents the scFv. No bands were apparent in the remaining lanes. This 
indicates that scFv concentration is below the limit of visualisation. 
 





Despite evidence of a protein of equivalent size detected by an anti-His antibody, 
additional HPLC-MS analysis was required for absolute confirmation that this was 
the anti-LAM scFv. This required a higher scFv concentration to be detectable by the 
HPLC-MS. Optimisation of the P. pink scFv expression was therefore required. 
However a major roadblock was the degradation that had been previously indicated 




Figure 46 Dot blot and western blot size analysis of purified protein 
A) Schematic overview of the loading profile of the dot blot over elution profile of purified 
expressed protein. B) Dot blot of elution profile of nickel purified cell culture supernatant. 200 μL 
was loaded from each sample and a 10 μL positive control was used. 
C) Lane 1: 3rd elution sample at 100 mM imidazole from (B), lane 2: 4th elution sample at 100 
mM imidazole from B 3: 5th elution sample at 100 mM imidazole from (B), 4: 6th elution sample 
at 100 mM imidazole from (B), 5: 7th elution sample at 100 mM imidazole from (B). 20 μL was 













6.6 Degradation analysis of the expressed anti-LAM scFv  
It became apparent that the problem with obtaining high protein levels was largely 
down to protein degradation from the disappearance of dots after 24 hours. 
As mentioned previously, this started becoming apparent in the small-scale 
screening process, however the exact level of degradation was still unknown. As 
dot-blot and western blots were reliant on the anti-His antibody for detection it was 
unknown whether the reduced detection levels were due to whole protein 
degradation, or whether it solely was due to the proteolytic cleavage of the His-tag 
from the scFv. A fast degradation of the His-tag could also have important 
implications for the purification of the protein as the lack of a His-tag would render 
the scFv uncapturable by the Ni2+ column. 
To visualise the extent of the degradation of the purified protein a new batch was 
expressed and purified, as described previously, and can be seen in Figure 47A and 
Figure 47B. The samples 3-8 eluted at 100 mM imidazole and the 3rd and 4th sample 
eluted at 500 mM imidazole showed the highest levels of protein concentrations and 
were chosen for further degradation evaluation. They were run on an SDS-PAGE 
gels and Coomassie stained to give a preliminary indication of the extent of scFv 
degradation.  
As can be seen in Figure 47C there were no bands visible in either of the loaded 
wells at the expected ~27 kDa. There were however thick smears at the bottom of 
all the wells  suggesting degradation. One encouraging observations was that 
although there was no non-degraded protein seen in the Coomassie stained gel, it 




revealed that if proteolytic degradation could be prevented there would be enough 
protein for further analysis. 
 
 
As Coomassie staining has limited sensitivity the 4th sample from the 100 
imidazole elution (containing the highest concentration of protein) was further 
analysed on a silver stained gel (Figure 48A) and a western blot (Figure 48B) as 




Figure 47 Degradation profile of the presumed anti-LAM scFv. 
A) Schematic overview of the loading profile of the dot-blot for protein purification overview B) 
Dot-blot of HisTrap purified protein at 100 mM and 500 mM imidazole concentration.  Supernatant, 
flow through and wash was included as previously. 200 μL of each sample was loaded as well as 
a 10 μL positive control C) Coomassie stained gels of the elutions from the dot-blot containing the 
highest levels of protein. 100 mM is the imidazole concentration and the number in brackets 














The silver stain analysis (Figure 48A) revealed that not all the protein was degraded 
and showed a band of ~27 kDa which correlated with the size of the band found in 
Figure 46C. It still showed a large smear at the bottom of the gel consistent with the 
Coomassie stained gel, again indicating degradation.  
The western blot, which is anticipated to have roughly the same level of sensitivity 
as the silver stain, was run simultaneously to the silver stain. Interestingly, no band 
was visible at ~27 kDa as in the silver stained gel. This further indicates rapid 
degradation of the His-tag, allowing purification on the Ni2+ column but not 
visualisation on a western blot. Optimally this could be analysed by mass 
spectrometry however the concentration of the scFv was too low to be detectable by 
standard polyacrylamide gel. 
 
Figure 48 Simultaneous degradation analysis of the purified protein on both silver stain 
and western blot. 
A) Silver stain analysis of the second lane of figure 41 C as this had the highest protein 
concentration of the elutions. A band just above 25 kDa is visible which is consistent with the 
theoretical value of ~27 kDa for the anti-LAM scFv. B) Western blot identical to the silver stain 
and run simultaneously. No band is visible in the first lane indicating proteolytic cleavage of the 
His-tag. Both gels were loaded with 20 μL of elution sample 4 at 100 mM from figure 41 and 3 μL 













Therefore, degradation appeared to be one of the major issues relating to expression 
of an intact scFv and for this reason this needed to be addressed if high protein 
concentration levels were to be achieved. For this two routes were proposed: either 
by the increase of initial protein concentration giving a larger batch to work with 
before degradation occurs, or by trying to inhibit the proteolytic degradation 
altogether. 
As it was important to get a higher protein concentration at the same time, the initial 
focus was to attempt to increase the protein yield by optimising the growth and 
expression conditions. 
 
6.7 Optimisation of growth conditions and oxygen levels for 
optimisation of anti-LAM scFv production 
The first step for protein optimisation was growing the cultures in baffled flasks as 
opposed to regular conical flasks in order to increase aeration. Using the baffled 
flask the same culture volume (100 mL) was grown under the same conditions as 
previously described. In order to investigate the effects of increased aeration of the 
media, a sample (100 mL) from the same BMGY starter culture, which had been 
increased to 600 mL, was grown under the same conditions, but in a conventional 
non-baffled flask. 
As can be seen in Figure 49, expressing protein in the baffled flasks seem to have 
a negative impact on the anti-LAM scFv expression levels. Furthermore, the 
difference in expression levels was apparent.  





To analyse whether flask morphology had any impact on the expression profile of 
the scFv, the elution samples that appeared to contain the highest levels of protein 
were analysed on a silver stained gel. These included the 4th elution sample 
collected at 100 mM imidazole from the non-baffled flask, the 3rd elution sample at 
500 mM imidazole from the non-baffled flask and the 4th elution sample at 100 mM 
imidazole from the baffled flask. 
There appeared to be no observable difference in either dimerisation or degradation 
of the protein. However, in the lane containing the 3rd elution sample at 500 mM 
 
 
Figure 49 Analysis of the effect on protein expression between a baffled and regular 
conical flask 
A) Schematic overview of the loading profile of the dot-blot in (B). B) Dot blot analysis of the 
purified protein from two cultures grown either in baffled flasks or conevntional flasks. Both 
elutions were done at both 100 mM imidazole and 500 mM imidazole concentration. 200  C) 
Silver stain analysis of the elutions with highest protein concentrations from the dot-blot analysis 
1) Ladder 2) 4th elution sample from non-baffled flask100 mM imidazole 3) 3rd elution sample 














imidazole from the non-baffled flask, there appeared to be very little monomeric 
protein. This indicates that dimerised protein requires higher level of imidazole 
concentration for elution due to the presence of two His-tags.  
.To further investigate the effects of oxygen levels in the scFv expression, the same 
culture volumes of 100 mL were grown in a small 100 mL flask and a big 500 mL 
flask, respectively. The size of the small flask was chosen to minimise the air pocket 
that would be available, intentionally reducing the aeration of the media. The cultures 
were otherwise grown as previously described. Optimally, this aeration would have 
been monitored had the equipment been available. 
The media was harvested as normal and the scFv purified as described previously 
and analysed using dot-blot again after standard procedure. As can be seen in 
Figure 50B, there appears to be an overall much higher protein concentration in the 
larger flask when compared to the small flask. 





In order to analyse whether the oxygen levels might have an impact on the stability 
or the dimerisation of the scFv, a silver stain analysis was conducted on the samples 
showing protein expression. These included samples 3-5 eluted at 100 mM 
imidazole from the large flask, samples 3-5 eluted at 500 mM imidazole from the 
large flask and 3rd and 4th sample eluted at 500 mM imidazole from the small flask. 
The silver stain was otherwise performed as previously described (section 2.2.34). 
 
 
Figure 50 Expression and size analysis of constant volume (100 mL) cultures grown in 
large flasks (500 mL) and small flasks (100 mL) 
A) Schematic overview of the loading profile of the dot-blot B) Dot-blot analysis of the elution 
profile of the Ni2+ column purified protein. 200 μL was loaded of each sample and 10 μL was 
used as a positive control. The expression rate appears much higher in the large flask compared 
to in the small flask  C) A silver stain analysis of the following elutions from the dot blot 20 μL 
was loaded of each sample and 3 μL was used as a positive control: 1) Ladder 2) 3rd elution 
sample from large flask, 100 mM imidazole 3) 4th elution sample from large flask, 100 mM 
imidazole 4) 5th elution sample from large flask, 100 mM imidazole 5) 3rd elution sample from 
large flask, 500 mM imidazole 6) 4th elution sample from large flask, 500 mM imidazole 7) 5th 
elution sample from large flask, 500 mM imidazole 8) 3rd elution sample from small flask, 500 













As can be seen in Figure 50C there are no differences seen between the lanes, apart 
from the expected fluctuations in intensity due to the difference in protein 
concentrations in the analysed elution samples. 
As increasing the scFv expression appeared to be problematic and the Coomassie 
staining showed a decent, but degraded protein concentration, the efforts were 
changed to prevent scFv degradation rather than improve initial yield. 
 
6.8 Inhibition of proteolytic degradation of anti-LAM scFv using 
casein in both complex and minimal media 
One way of preventing the degradation of a desired protein is the addition of 
inconsequential bulk proteins such as casein to act as an alternative source on which 
the proteases can act. This would thereby in theory decrease the amount of 
proteases available to degrade the expressed protein. Casein was for this reason 
added to the expression media. 
Furthermore, the complexity of the media has in some cases been found to have an 
impact on the degradation levels of the expressed protein. Minimal media (YNBM) 
can potentially prevent the expression of proteases and thereby inhibit the proteolytic 
degradation of the expressed protein. However, this normally also has a negative 
impact on the yield. Despite this, if the switch to minimal media could increase the 
stability of the protein it was considered worth investigating. 
The starter cultures were set up as previously described in BMGY media and 
resuspended in either complex media (BMMY) or minimal media (YNBM). The 
cultures were then split into two flasks each of 50 mL final volume. Casein was added 




to one BMMY culture and one YNBM culture and all the cultures were hereafter 
grown as previously described and scFv was purified from the supernatant as before. 
The samples were finally analysed by dot-blot and silver stain. 
 
As can be seen in Figure 51B, growth in YNBM minimal media had a detrimental 
effect on the protein expression levels as anticipated. Casein had no effect on the 
protein levels in either YNBM or BMMY media. Interestingly however, in BMMY 
 
 
Figure 51 Degradation analysis of expression in complex (BMMY) and minimal (YNBM) 
media with or without casein 
A) Schematic overview of the loading profile of the dot-blot. B) Dot blot analysis of the elution 
profile of the eluted purified protein. Protein expression generally appeared higher in complex 
media compared to minimal media as expected. Interestingly, the elution profile seemed to shift 
from high imidazole to low imidazole concentration elution when casein was added. C) Silver 
stain analysis of the elutions with highest protein concentration. 1) Ladder 2) BMMY (-cas) 100 
mM (4) 3) BMMY (-cas) 500 mM (3) 4) BMMY (+ cas) 100 mM (4) 5) BMMY (+ cas) 500 mM (4) 














media, the addition of casein shifted the elution (of the scFv towards the primarily 
100 mM imidazole elution (BMMY + casein) as opposed to the primary elution at 500 
mM imidazole (BMMY - casein).  
The following samples, chosen from the dot blot, were hereafter analysed using 
silver staining (Figure 51C): 4th elution from BMMY (- casein) at 100 mM imidazole, 
3rd elution from BMMY (- casein) at 500 mM imidazole, 4th elution from BMMY (+ 
casein) at 100 mM imidazole, 4th elution from BMMY (+ casein) at 500 mM 
imidazole, 4th elution from YNBM (- casein) at 500 mM imidazole and finally 4th 
elution from YNBM (+ casein) at 500 mM imidazole.  
When analysed on a silver stained gel these elution samples did not show the same 
increased dimerisation profile as previously, which could have explained the 
increased imidazole concentration requirement. 
Growth on the regular complex BMMY media appeared to have a more positive 
effect on the protein expression. The addition of casein seemed to have a shifting 
effect on the elution profile of the expressed protein. Without casein, a higher 
concentration of imidazole was required for full elution than with casein.  
When the BMMY elutions were analysed on a silver stained gel there appeared to 
be a dark smear in the first elutions at 100 mM, both with and without casein. This 
had not occurred in either of the previously silver stained elutions. However, this 
could be due to leftover media in the Ni2+ column as a result of inadequate washing. 
Bands similar to the other lanes were still visible under the smear overall indicating 
that neither growth on minimal media nor the addition of casein had the desired effect 
on the protein concentration. Furthermore, casein did not seem to have any effect 




on the protein degradation as the separation profile was identical to that without 
casein. 
This indicated that growth on complex media without casein, which was the protocol 
up to this point, was the most successful so far. However, other parameters could 
still be changed in an attempt to decrease proteolytic degradation, such as variations 
in temperature and the addition of protease inhibitors. 
 
6.9 Inhibition of proteolytic degradation by addition of protease 
inhibitors at various temperatures 
As the addition of casein did not have any effect on the stability of the scFv, protease 
inhibitors were added to the media in a last attempt to decrease the proteolytic 
degradation of the expressed scFv. However, the addition of protease inhibitors 
generally has a negative impact on the growth of P. pink and for that reason it was 
hypothesised that the addition would decrease protein production due to reduced 
fitness of the cells, despite the potential increased stability of the product. Despite 
this drawback, it was worth investigating. 
Furthermore, it was interesting to analyse the effects of reducing the incubation 
temperature as this might have an impact on the proteolytic activity of the proteases 
degrading the expressed protein. As P. pink is a relatively versatile organism, 
previous studies have shown that it is capable of growth at 20°C. 
The anti-LAM producing P. pink strain clone 17 was therefore grown, in the presence 
and absence of protease inhibitors at both 20°C and 25°C in BMMY without casein 
in large non-baffled flasks in expression cultures of 50 mL. Two cultures were grown 




at 20°C and two were grown at 25°C. Additionally, a protease table was added to 
one culture grown at each temperature. The cells were grown for 24 hours and the 
supernatant was harvested and purified as before. 
 
As can be seen in Figure 52B there was a slight increase in protein expression at 
20°C with protease inhibitors. When comparing the temperatures alone, 20°C 
seemed to have a very small increase in expression when compared to 25°C, 
however this could be due to variations in purification efficiencies. 
 
 
Figure 52 Analysis of effect of temperature and protease inhibitors on expression and 
degradation of expressed protein. 
A) Schematic overview of the loading profile of the dot blot B) Dot blot analysis of the elution 
profile of the expressed protein under various conditions: 20°C or 25°C and with or without 
protease inhibitors (+/- prot.inh.). C) Silver stain analysis of the elutions containing the highest 
concentration of protein from (B). 20 μL was loaded of each sample and a 3 μL positive control 
1) Ladder 2) 3rd elution sample from 20°C (- prot.inh.) 100 mM imidazole 3) 3rd elution sample 
from 20°C (+ prot.inh.) 100 mM imidazole 4) 3rd elution sample from 25°C (- prot.inh.) 100 mM 













The following elution samples were further analysed on silver stain to evaluate 
degradation and dimerisation patterns (Figure 52C): 3rd elution from culture grown 
at 20°C (- protease inhibitors) at 100 mM imidazole, 3rd elution from culture grown 
at 20°C (+ protease inhibitors) at 100 mM imidazole, 3rd elution from culture grown 
at 25°C (- protease inhibitors) at 100 mM imidazole, 3rd elution from culture grown 
at 25°C (+ protease inhibitors) at 100 mM imidazole. The silver stain was conducted 
as previously. 
There was found to be no difference between the elutions indicating that the 
protease inhibitors had no effect on preventing proteolytic degradation of the protein. 
When analysing using silver stain to see if either of the parameters had any effect 
on the dimerisation of the product, there was again no noteworthy difference seen. 
The general consensus from the optimisation assays was that very little helped in 
reducing dimerisation or decreased degradation. Despite this, here were still many 
possibilities for optimisation of scFv expression and degradation prevention as will 
be discussed below, however time became the limiting factor. 
 
6.10  Discussion 
The aim of this chapter was the transformation of Pichia pink with the pPinkα-HC 
vector containing the designed anti-LAM scFv from chapter 5. 
Following the transformation of the P. pink strain, the white transformed colonies 
were screened for both protein expression and optimal time point for harvesting of 
the media. As the vector in which the scFv was inserted contained the α mating 




factor signal sequence from S. cerevisiae, the expressed scFv would be released 
into the supernatant, easing the acquisition of the protein. 
As the screening of the clones progressed, it became readily apparent that most 
clones in fact did show some degree of expression, but the degree varied greatly. 
This can due to some extent be associated with the number of vectors were 
internalised during the transformation of the individual clones. However, there are 
some problems associated with the increased protein expression. First, if the vector 
content is too high this could result in an overproduction of protein and result in the 
formation of inclusion bodies and the result would be congested cells (Love et al., 
2012). This would not only require lysis of the cells but most likely also denaturation 
and renaturation of the purified protein in order to retrieve the protein of interest. This 
would not only have an effect on the protein yield but would also complicate the 
harvesting process. Furthermore, the formation of inclusion bodies would be a rate-
limiting step thereby inhibiting large-scale protein production and could furthermore 
lead to toxic levels to the cells reducing fitness and as a result reducing the 
expression levels (Love et al., 2012).  
Several conditions were analysed, including variance in temperature and oxygen 
levels, in an attempt to not only increase scFv production but also reduce proteolytic 
degradation. Reducing cultivation temperature has in previous studies showed to 
have a substantial positive impact on the Fab expression in a Pichia pastoris system 
(Dragosits et al., 2009). The reduction of temperature in this study from 25°C to 20°C 
did not have any effect on either the expression levels or the degradation rate of the 
expressed protein (Figure 52B). 




Another attempt included the reduction of oxygen levels as it was observed that 
during the initial screening in 50 mL falcon tubes, where there was expected low 
oxygenation compared to baffled flasks, protein expression was generally 
acceptable. However, when expression was moved to baffled flasks a reduction in 
protein expression was observed (data not included). A comparative study was set 
up to analyse the same culture in either baffled or non-baffled flasks. The results 
showed an increased expression in the non-baffled flasks indicating that high protein 
expression required lower oxygen contents, contradicting the fact that methanol 
metabolism requires oxygen (Jahic et al., 2002).  However, other studies have 
shown the same effect of higher protein concentrations at lower oxygen levels 
(Charoenrat et al., 2005; Baumann et al., 2007; Baumann et al., 2010).  
This effect could also potentially be the effect of increased stress on the cells in 
baffled flasks compared to regular conical flasks. This could increase lysis and could 
furthermore increase the proteolytic degradation, indirectly resulting in a lower yield. 
So perhaps the expression levels are comparable, but the product in the baffled 
flasks is degraded more rapidly. 
Another possibility for the lack of scFv expression might simply be that it sometimes 
just isn't expressed or the expression rate goes down due to unmonitored changes 
in growth conditions. For this reason it could be interesting to analyse the scFv 
expression on mRNA level using qRT-PCR. This could not only elucidate whether 
the lack of scFv is due to degradation or lack of expression but could also validate 
the effects the various growth conditions has on the expression rate. P. pink is known 
for the very varied protein expression levels even under static conditions (Miller et 




al., 2005). Transcriptional analysis could shed some light on the expressional 
pathway of the scFv. 
A second problem became apparent as expression experiments progressed, which 
was degradation. This not only complicated basic identification but also made 
downstream analysis very elusive.  Due to the nature of the His-tag, which was 
designed into the final scFv for ease of purification and identification, it was 
unfortunately also one of the most exposed epitopes of the scFv. This could 
potentially have made it very susceptible to protease cleavage, which would not only 
complicate purification, but would prevent detection by HRP-conjugated anti-His 
antibodies. 
There are many potential reasons behind protein degradation and potential 
remedies. The most likely reason is due to protease activity. Proteases are vital 
components of any organism, from virus to mammalian cells. They are key players 
in protein maturation, degradation of outdated proteins for recycling and even for self 
defence against foreign bodies. As a consequence there is a great variety of 
proteases each with varying specificity, abundance and efficiency. As most of these 
activities are found within the cells, this is where the large majority of proteases are 
found. They can however be released into the extracellular space upon cell stress 
and cell lysis for which reason it is of great importance that the cells of the expression 
system are as much in optimal conditions as can be achieved. The problem with P. 
pink as an expression system is the activation of expression using methanol. 
Although P. pink is a methylotrophic organism it only tolerates methanol at low levels, 
not exceeding much more than 3% of the media (PichiaPinkTM Expression System 




manual, Invitrogen). This along with the experience that growth did not occur 
following the shift to methanol-containing media (data not shown) indicates that the 
cells were growing under sub-optimal conditions. This could lead to cell lysis and the 
release of proteases into the media leading to degradation of the anti-LAM scFv.  
One of the options for the inhibition of degradation by proteases is the utilisation of 
either of three P. pink knock-out mutant strains. As mentioned above, these strains 
include knock-outs for the prb1 gene encoding proteinase B, the pep4 gene 
encoding proteinase A or both (Gleeson et al., 1998). As proteinase A is involved in 
the activation of proteinase B it could have been of particular interest to investigate 
this mutant as a potential substitute for the utilised "wt" P. pink strain. The problem 
with the mutant strains is however, that previous studies have shown that stability of 
the cells has been compromised by the mutations making them more fragile 
requiring extra care with not only storage but during fermentation as well  (Gleeson 
et al., 1998) . The original P. pink strain was for this reason chosen for preliminary 
studies. However, it could be interesting to see if the mutants could have a positive 
effect on the stability of the protein in future experiments. General analysis of the 
peptide sequence and the susceptibility to proteases definitely indicates that 
proteolytic degradation might be the culprit of the low protein yield. 
Another option, which was investigated was the use of protease inhibitors. In addition 
to them seemingly having little effect on the degradation levels of the expressed 
protein, protease inhibitors are furthermore generally fairly expensive and are not 
suitable for large-scale production of proteins in a small lab unless the advantages 
outweigh the disadvantages.  




As briefly mentioned, a quick in silico proteolytic digest of the product indicated that 
it contains many proteolytic cleavage sites. As especially endoproteases have 
specific recognition sequences, an attempt could have been made to modify the 
sequence of the anti-LAM scFv to eradicate some of the cleavage sites. This 
however, would not be without potential consequences. Even modifications in the 
framework regions of the scFv could have an altering effect on the overall structure 
of the antigen recognising site. For this reason it could be argued that the most 
logical structural feature to attempt to modify is the His-tag. As this site is protruding 
from the protein it is more susceptible to proteolytic cleavage, but also easier to 
modify without affecting the structure of the scFv. Furthermore, without the His-tag 
it is, as mentioned, not only impossible to easily purify but also prevents the use of 
anti-His antibodies for western blot and dot-blot analysis. There is in fact some 
indication that some of the low detection levels of the expressed scFv when 
comparing western blots with their respective silver stains might be due to the loss 
of the His-tag. In a few instances there are very thin bands visible around the 
expected size in the silver stained gels without it being present in the western blot, 
,despite being executed simultaneously. This problem could potentially be 
circumvented by using an anti-mouse variable domain antibody modified with HRP.  
The proteolytic cleavage of the His-tag could also have further implications for the 
purification itself. If the His-tag is cleaved off prematurely it does not allow purification 
using Ni2+ column. So even if high concentrations of protein are expressed, if the 
His-tag is not present acquiring the protein becomes a problem.   




Another sensitive structural motif that is susceptible to proteolytic cleavage is the 
linker region. The linker chosen was the poly glycine linker (GGGGS)5 due to the 
flexible and hydrophilic nature which would not only enable the correct folding of the 
scFv but the length would also prevent multimerisation (Alfthan et al., 1995). 
However, the protruding nature of the linker suffers the same disadvantages as the 
His-tag such as increased susceptibility to proteases due to the increased exposure 
(Alfthan et al., 1995). It could therefore be argued that other linker regions could be 
tested for improved stability. Furthermore, although linkers of shorter length have 
shown an increased degree of multimerisation, this effect does not appear to be 
significant before the length of the linker decreases to below 11 residues (Albrecht 
et al., 2006). As the length of the linker inserted in this project was 25 residues it 
could be argued that a decrease in length might have a positive impact on the 
stability by potentially decreasing the exposure to proteases. 
Additional modifications of the structure could also involve analysing the effect 
utilising a VL-linker-VH conformation as opposed to the VH-linker-VL conformation 
evaluated in this study. Although it is unlikely to have an effect on the protease 
degradation of the peptide, it could have an impact on the expression levels of the 
scFv. Although the conformation utilised in this study is the one that has previously 
been shown to have the highest levels of expression (Desplancq et al., 1994; 
Weisser and Hall, 2009). Furthermore, studies have shown that the VL-VH 
conformation had a negative impact on antigen binding activity, whereas the VH-VL 
conformation retained 73% of parental antigen binding activity (Albrecht et al., 2006).  
With this in mind, it could still be a factor worth investigating. 




One of the problems with the P. pink expression system was its instability in 
expression rates (Miller et al., 2005). For this reason, it could be interesting to 
transfer the expression of the anti-LAM scFv to E. coli to not only see if higher 
expression rates could be achieved, but also if this could have a positive effect on 
the stability of the product (Miller et al., 2005). As the expression rate in E. coli is 
higher than in P. pink, the protein would be able to be purified quicker and analysed 
before succumbing to proteolytic degradation (Miller et al., 2005). 
Subsequent to the identification and production optimisation of the scFv, the most 
important factor was to establish the binding affinity of the scFv, which was not 
accomplished due to low protein concentrations. Although the IgG3, from which the 
scFv was in silico isolated, did show binding towards LAM, there is no guarantee 
that this binding affinity is directly transferred to the scFv. In fact, most scFvs show 
a decreased affinity towards the antigen compared to the parental molecule 
(Albrecht et al., 2006). This can to a large extent be attributed to the loss of the 
conserved regions, which despite having no direct impact on the complementary 
determining regions, do offer structural support, which when lacking could result in 
a slightly modified binding pocket.  Furthermore, in the scFv the two variable 
domains are linked by a flexible linker that offers no more support for the molecule, 
than to keep the domains in such close proximity that aggregation would occur due 
to electrostatic interactions and hydrophobic patches.  
The initial establishment of anti-LAM activity would be established by running a 
sandwich western of the LAM using the scFv as primary antibody. This would be 
visualised using the anti-His antibody previously utilised. 




If binding was found positive, the next step would be to establish the affinity of the 
scFv. This would be established using BIAcore, which allows the establishment of 
the binding constant using Surface Plasmon Resonance technology (SPR). SPR 
uses flow technology to analyse the binding affinity of molecules in solution to 
immobilised antigens. A detector analyses the reflection angle of the immobilised 
antigen. Hereafter a flow of antibodies in solution is run over the antigens and upon 
binding the reflection angle changes and this is detected. By comparing the change 
in reflection associated with binding and following dissociation by running clear 
storage solution and analysing the reversion of reflection pattern, the binding 
constant of the analysed molecule can be detected. The binding constant of the 
designed anti-LAM scFv would be compared to the parental antibody that would 
function as a positive control. This way it would be possible to also quantitatively 
assess the effect on binding affinity by isolating the antigen binding part from the rest 
of the antibody. 
There is the possibility of affinity maturation of the scFv, should the affinity have been 
compromised by being separated from the parental molecule. This can be done 
using phage display technologies (Renaut et al., 2012). This would not only allow 
the potential rescue of lost binding affinity but even an improvement of the KD 
towards the antigen, LAM.  
Following the establishment of the binding affinity, it would have been advantageous 
to repeat the experiments from chapter 3 and 4, but with UBI 29-41 exchanged for 
the anti-LAM scFv in order to establish the value of the anti-LAM scFv as a diagnostic 
or therapeutic targeting agent. Furthermore, as can be seen in Figure 53. There are 




14 tyrosine residues in the anti-LAM scFv compared to the single tyrosine in UBI 29-
41, making it potentially more useful as a therapeutic targeting agent as it can deliver 
a greater dose per targeting agent.  
 
Overall, although the expressed protein could not be unequivocally demonstrated to 
be the anti-LAM scFv, there are several lines of evidence from the experiments in 
this chapter that suggest the correct protein was expressed. Namely, Figure 46 and 
the silver stains obtained from expression optimisation assays all showing a protein 
of the right size that also has a tendency to dimerise. Despite some work remaining 
to optimise the expression levels and reduce degradation, this chapter managed to 
meet most of its aims, and provides much of the groundwork for future efforts in 

















7 General Discussion 
The overall aim of this project was to develop novel diagnostic and/or therapeutic 
agents to help in the fight of troublesome pathogens.  
 
7.1 125I as a therapeutic agent 
The first half of the project revolved around the establishment of Auger electrons as 
new potential therapeutic agent. While there was no increase in mortality in any of 
the model organisms using either 1 MBq or 5 MBq125I there are several factors that 
could explain this: 
1. The targeting compromised the delivery either by being too low a 
concentration or by having reduced binding 
2. The LET of the isotope utilised was not high enough to cause substantial DNA 
damage. 
3. The range of Auger electrons is too short to reach DNA to cause any DSB 
In order to properly evaluate the potential future of Auger electrons as therapeutic 
agents these problems need to be addressed. 
Firstly, the issue with lacking toxicity seen could be due to the targeting agent 
compromising the delivery of the Auger emitting isotope to the target 
microorganisms. This could be due to the concentration of UBI 29-41 being too low 
to mount a response by not delivering a high enough dose of 125I, which would be 
seen as a decreased survival rate. By testing a variety of increasing concentrations 




of UBI 29-41 to the activated 125I it would be possible to evaluate whether the lack of 
mortality was due to inadequate peptide concentration. 
Preliminary evaluations of peptide binding, using a simple binding experiment in 
which the microorganisms subjected to 125I-UBI were washed in media and radiation 
associated with the cells, was subsequently established. Although only conducted 
on two organisms a single time each due to time and materials restraints, it showed 
negligible binding to cells following three round of washing. The Bq/cell were 
identical to the free iodine control, indicating that there was little to no specific binding 
beyond that of free activated iodine. Furthermore, the generation of positive iodine 
ions as a result of the Iodogen reagent could have caused the free iodine to bind to 
the negatively charged surface of S. cerevisiae which could have masked the binding 
of the peptide. Interestingly, the peptide did show ability to bind and cause cell death 
in previous experiments, indicating a fully functional peptide. Whether the Tris 
Iodination buffer had any effect on the binding ability is unknown. It is unlikely that 
the Iodogen reagent has had any effect on the chemical properties of the peptide as 
this was immobilised in the glass vial and the peptide was iodinated in a separate 
tube. A cold-labelled version of UBI 29-41 was prepared in order to see if the labelling 
process in itself could have had an effect on the binding capacity of the polypeptide. 
In initial studies, no difference in toxicity was observed when compared to the non-
labelled peptide (data not shown), however this was not fully explored and is 
therefore not included as this is considered inconclusive.  
Another aspect of the binding studies that could have been manipulated was the 
duration to which the organisms were exposed to the radiation prior to washing and 




plating. This was only one hour which may have been too short to elicit toxic effects. 
Extending incubation time would allow UBI 29-41 enough time to bind properly to 
the cells, but also to increase the number of decays each organism would be 
subjected to. As the half-life of 125I is 60 days, one hour or even two days (if including 
the growth on the plates in which some radiation was still present) is a very minor 
percentage of the half-life, meaning that most of the 125I was not allowed time to 
decay. A larger study investigating various incubation times would have been 
worthwhile to execute to analyse if a greater effect could be attained. This could give 
some primary indications to the efficiency of targeting of UBI 29-41, which due to the 
short range of Auger electrons is vital for any genotoxicity to be seen.  
Secondly, the Auger electron emitting isotope analysed in this project was 125I. 
Despite being of shorter range compared to other isotopes, such as the more 
energetic123I, it had other qualities like a long T1/2 (~60 days) compared to the half-
life of 123I, 13.2 hours (O'Donoghue and Wheldon, 1996; Kassis, 2011). This made 
125I a good candidate to optimise toxicity experiments with. Furthermore, the labelling 
method would likely allow easy exchange with longer range isotopes such as 123I. 
For this reason one of the next steps in evaluating the effects of Auger electrons 
would be the exchange of 125I with 123I although the labelling procedure would very 
likely have to be further optimised for 123I. 
Due to the higher energy of the Auger electrons and thereby longer range, it might 
be possible to reach the DNA and cause damage. 
This leads to the final proposal: that the reason that no toxicity seen is because the 
distance to the microbial DNA from the membranes is still too great.  To evaluate 




this there are two immediate possibilities: The first is the analysis of genotoxicity 
using genetically modified organisms developed to visualise DNA damaging events. 
Many commercial microbial strains are available that are capable of visualising 
genotoxicity such as the Salmonella Ames test or the SOS Chromotest for bacterial 
strains and the GreenScreen genotoxicity assay for yeast based systems (Quillardet 
et al., 1982; Mortelmans and Zeiger, 2000; Cahill et al., 2004). As mentioned in 
section 4.7 these tests were able to visualise DSB, for example by reversion of 
histidine-dependence clones to histidine-independence, or by the detection of 
upregulation of SOS response genes by the incorporation of a lacZ under the control 
of sfiA, an SOS response gene. This could allow an insight into whether range is an 
issue, or dose being an issue. 
Secondly, DNA damage in particular can also be assessed using qRT-PCR to 
measure SOS response genes in the model organisms subjected to Auger electrons. 
These could include RecA monitoring for bacterial strains and Rad51 for yeast 
strains (Clever et al., 1997; Walmsley et al., 1997; Cox, 2007). By evaluating the 
upregulation of the SOS-response it could give an indication if any DNA damage is 
occurring and that the lack of mortality seen could be due to a well-established SOS 
response. If no upregulation of the SOS-response genes alongside a binding 
analysis is seen this could indicate that the range is indeed too large for the Auger 
electrons to reach the DNA and cause any DSB.  
One issue with antimicrobial peptides in general is the lack of specific binding 
(Walker et al., 2007). This can be useful for unspecific imaging purposes in cases 
where it is unknown if the cause of an inflammation or fever is caused by an infection, 




however when it comes to therapy it is more beneficial to have a targeting agent with 
a higher specificity. One main issue with antimicrobial peptides is the non-target 
tissue accumulation (Akhtar et al., 2005; Meléndez-Alafort et al., 2005; Brouwer et 
al., 2006; Brouwer et al., 2008). If the peptides have been labelled with therapeutic 
isotopes, these isotopes are accumulated in non-target areas of the body, potentially 
damaging non-target tissue, commonly kidneys, liver intestines and bladder. 
Furthermore, diluting the targeting agent across non-target tissues would also 
require the administration of higher total dose of therapeutic agents, again leading 
to increased toxic dose accumulated in non-target tissues (Torchilin, 2000). This 
further strengthened the requirement for a stability analysis which did indeed show 
deconjugation of 125I from UBI 29-41. This could have been very problematic in in 
vivo settings causing further systemic spreading of the radiation. 
However, for this project, UBI 29-41 was a good targeting candidate due to the non-
specific nature of antimicrobial peptides. This allowed the analysis of the toxic effects 
of Auger electrons on a variety of micro-organisms. This was primarily possible due 
to the controlled environment in which UBI 29-41 was utilised. Furthermore, the 
nature of the peptide (13 aa) with a single tyrosine residue made labelling 
optimisation straightforward. The use of the Iodogen labelling method made it easy 
for the exchange of 125I with isotopes of higher LET such as 123I. This would be 
interesting to, again, analyse in controlled in vitro settings, however, UBI 29-41 
appears to have its greatest value as an imaging agent of infectious diseases due to 
the non-target bio distribution with accumulation in liver, intestines, kidneys and 
bladder (Akhtar et al., 2004; Akhtar et al., 2005). Nonetheless, UBI 29-41 still holds 




value as a non-specific targeting agent for in vitro studies and would be useful for 
the later evaluation of higher energy isotopes.   
 
7.2 ScFv construction and expression 
Due to the unspecific targeting of UBI 29-41, the second part of the project revolved 
around the development and expression of an anti-LAM scFv. ScFvs hold an 
advantage over antimicrobial peptides in other aspects than specificity; scFvs are 
more adaptable to meet physiological requirements, such as the addition of parts of 
the Fc regions to increase circulation time (Milenic et al., 2004; Weisser and Hall, 
2009) and it is possible, by modification of linker regions, to create multispecific 
targeting agents (Holliger et al., 1993; Illiades et al., 1997; Todorovska et al., 2001; 
Dolezal et al., 2003; Weisser and Hall, 2009). 
The variable domains of the parental anti-LAM IgG3 molecule were successfully 
isolated and in silico linked by a flexible linker, inserted into a secretion vector and 
transformed into strain 1 of Pichia pink containing no protease knock outs.  
Although expression was appeared to be successful, there was a great problem with 
degradation. Consequently, any future attempts to express the scFv would need to 
address this, perhaps firstly by investigating the level of degradation in any of the 
existing protease knock-out P. pink strains mentioned in section 1.5.4.1.1.  
Although the concentrations of scFv never reached levels to perform glycosylation 
analysis it is likely that the scFv is not glycosylated; glycosylations primarily reside 
in the Fc region of the antibody (Youings et al., 1996; Ahmad et al., 2012). It may 
then be possible to increase the yield by expressing the anti-LAM scFv in a bacterial 




system. However both post translational modification and folding would have to be 
interrogated prior to transfer as previously addressed.  
The anti-LAM scFv developed in this project, could have significant diagnostic value. 
As LAM is released into urine it could greatly aid in the diagnosis of tuberculosis, 
especially in children and immune-compromised individuals, in which diagnosis is 
very difficult due to lack of immune response to the Mantoux tuberculin skin test and 
therefore often associated with false-negatives (Ducatti et al., 2006; Jassal and 
Bishai, 2009; Minion et al., 2011). As this further does not require in vivo 
administration to patients, the murine ancestry of the scFv is no longer of importance, 
only binding affinity. 
Although M. tuberculosis is predominantly an intracellular bacterium, research has 
indicated that even during latent phase, there are some active extracellular bacilli 
present (Lewis, 2010; Gegenbacher and Kaufmann, 2012). This increases during 
the active phase which may open up for potential new ways of not only diagnosing 
for tuberculosis, but also to diagnose the extent of tuberculosis infection and 
localisation if the scFv could be modified to allow in vivo administration (Lewis,2010; 
Gegenbacher and Kaufmann, 2012).  
With regards to therapeutics, one of the big disadvantages of M. tuberculosis is it 
being a primarily intracellular bacteria. Although research has indicated that even in 
latent phase, the bacteria are to some extent found in the extracellular space of the 
granulomas, there will be bacteria also found in the phagosomes of macrophages 
(Lewis, 2010; Gegenbacher and Kaufmann, 2012). Even when these phagocytic 
cells are overcome by the infection and initiate necrosis, the bacteria will most likely 




be taken up by a newly recruited macrophage, going directly from one intracellular 
space to another. For this reason, the designed scFv would have to be internalised 
into the infected cells and into the phagosome they reside in if an Auger emitting 
isotope is to be used. This could be overcome by mimicking the work by Cornelissen 
et al. (2011). By modifying an immune conjugate directed towards phosphorylated 
histone 2A variant H2AX (γH2AX) with the HIV-derived cell penetrating peptide Tat, 
the immune conjugate was allowed nuclear localisation (Cornelissen et al., 2011). 
This opens up for the possibilities of internalising the therapeutic isotopes to the 
intracellular bacteria. One problem that remains is the lack of surface markers 
distinguishing infected from non-infected cells. 
However, proteins with  iodination of tyrosine residues have a tendency to be 
dehalogenised and metabolised when internalised, indicating that internalisation 
might not be optimal with the labelling techniques analysed in this project (Mattes et 
al., 1997; Milenic et al., 2004; Wu and Senter, 2005). A potential way to overcome 
this step is the utilisation of either an α- or β- emitter, such as 131I (Wu and Senter, 
2005). This way the scFv could be directed to the site of infection by the few 
extracellular bacteria present and the range of the radioactive particles would 
potentially allow the sterilisation of the bacteria from outside the phagocytic cells 
and/or induce apoptosis of the infected cells, allowing release of the bacteria from 
the intracellular pockets. However, this would potentially have damaging effects on 
the surrounding tissue due to crossfire-effects (Milenic et al., 2004). This could have 
fatal consequences in the late stages of infection for lung tissue already very 
damaged.  




Another issue with tuberculosis is the generation of caseous granulomas, which 
raises the question as to the efficiency of transporting the therapeutic agent to the 
sites of infection. Although neo-vascularisation is observed in the latent stages, 
which would ease the access of the therapeutic agent to the site of infection, active 
cavitary tuberculosis has shown loss of vascularisation of the infected nodules, 
which could complicate the delivery of the nuclides if delivered at the wrong stages 
of disease development (Ulrichs et al., 2005). 
M. tuberculosis is for this reason a generally problematic organism to eradicate and 
other targets could be deemed more favourable to initially treat such as extracellular 
pathogens. An example of which, could be S. aureus of which new types of multi 
resistant strains are continuously found (Enright et al., 2002; Alanis, 2005; 
Collingnon et al., 2009; Tübbicke et al., 2012). Due to the extracellular nature, S. 
aureus would be easily accessible to the targeted Auger emitting isotopes. One of 
the advantages of Auger electrons, if they could be found to be toxic to 
microorganisms if bound to the cells in an extracellular fashion, would be the reduced 
generated resistance.  The problem with the existing antibiotics is that for each of 
them there is at least one mechanism of resistance that has been developed (Alanis, 
2005). Furthermore, due to limited funding and time-limits, as a new therapeutic 
compound takes between 10-14 years to develop, most new antimicrobial 
compounds that have come out recently have been slight structural changes to 
already existing antibiotic chemicals and therefore rapidly generate new resistance 
(Alanis, 2005). Auger electrons and the generation of DSB in microbial DNA would 
be a new and potential useful technique to which microorganisms would have 




problems generating resistance towards. The only way this would be accomplished 
would be the increased efficiency of the SOS response. However, obviously if an 
scFv is to be used as a targeting agent, the specificity has to be altered. 
 
8 Conclusion 
There were four aims to this thesis. UBI 29-41 was successfully labelled and it was 
concluded that the levels of Iodine recommended by the manufacturer was 
consistent with found data. The protocol for labelling was further optimised for the 
experimental setup needed for the evaluation of radiotoxic effects of Auger electrons. 
The evaluations of the toxic effect of Auger electrons were largely inconclusive. 
Under the conditions evaluated in this project no toxic effect was observed when 
compared with non-targeted 125I in any of the four model organisms. However, the 
experimental setup allows easy manipulation for the evaluation of the radiological 
effects of other isotopes. 
To introduce more specificity we wanted to design an scFv from an anti-LAM IgG3. 
The variable domains were successfully isolated, identified and the scFv was in silico 
assembled. 
The pPinkα-HC vector containing the designed anti-LAM scFv was transformed into 
P. pink and a product of the expected size was successfully expressed.  
The results presented in this thesis will therefore aid in the development of new 
antibiotics for infectious diseases. 
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